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Consumers have begun to take a more proactive approach to their healthcare by accessing
pharmaceutical companies Websites to obtain health and drug information, support
groups, rebates, coupons, as well as free drug trials. In exchange for these benefits,
companies require consumers to voluntarily disclose information. However, research has
shown that consumers continue to be concerned about how their information is managed,
used, and distributed by companies, especially if accessed via the Web. To date, there
has been limited empirical research to examine the actual online practices of companies
when it comes to privacy, especially those of pharmaceutical companies. Using Delphi
expert panel process, the components of a benchmarking index were identified to
examine the documented and actual online practices of 100 Website registrations with
pharmaceutical companies. The evolution for the development of an index to measure
the personal information privacy violations of pharmaceutical companies is presented.
Second, empirical evidence is provided regarding the magnitude of voluntary adherence
to the Fair Information Practices (FIPs) by pharmaceutical companies based upon the
personal information privacy violations. The results revealed that companies with
headquarters in Europe had fewer personal information privacy violations than those in
Asia, UK, and the US. Moreover, the results indicate that fewer personal information
privacy violations occur for chronic conditions than for non-chronic conditions, as well
as fewer violations occur with Website registrations for updates than for discounts.
Finally, both Europe and UK demonstrated more overall adherence to FIPs than the US
and Asia. This suggests that self-regulation may not be sufficient, while more
enforcement may be necessary to decrease personal information privacy violations.
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Chapter 1
Introduction

Background
The technological advancement of the Internet has revolutionized the way
companies interact with consumers by enabling the ability to collect, store, transfer, sell,
and analyze consumer information (Jaisingh, Barron, Mehta, & Chaturvedi, 2008; Kim &
Byramjee, 2014; Lanier & Saini, 2008; Rapp, Hill, Gaines, & Wilson, 2009; Xu, 2009).
Companies are able to leverage the Internet to establish relationships with consumers
through the selling of products and services or to be a source for information. However,
in order to establish this relationship and engage in target marketing, companies must
collect information either by voluntary or involuntary methods (Christiansen, 2011). “A
user’s voluntary sharing of such information” (Christiansen, 2011, p. 509) is considered
voluntary disclosure and one of the methods of collecting information. Another method
of voluntary disclosure is by providing information on blogs or social networking sites
(Christiansen, 2011). Christiansen (2011) also noted that involuntary methods are
malicious and “involve the use of technology to collect data and track movements by
Internet users without their knowledge and/or permission” (p. 511). Examples of
involuntary methods include cookies, deep packet inspection, and scraping. Cookies are
used to track consumer activities such as Internet viewing history (Christiansen, 2011).
Contrary to one’s belief, according to Vega (2010), cookies can re-establish themselves
even if the file has been deleted. Deep packet inspection is used to monitor all consumer
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online activity by reading and analyzing packets of information across the Internet
(Stecklow & Sonne, 2010). Christiansen (2011) noted that:
Scraping, a particularly worrisome method of data collection, involves gathering
personal details shared on forum discussions and social media sites in order to
expand and flesh-out personal profiles of specific people, even when sites are for
members only or are intended to be confidential (p. 511).
The company manages the storage, access, and distribution after the information
is collected (Milne, Rohm, & Bahl, 2004). As a result, the information becomes at risk
for secondary use, unauthorized access, and sharing with third parties (Milne et al.,
2004). Hoffman, Novak, and Peralta (1999) defined secondary use as “the use of
personal information for other purposes, subsequent to the transaction where the
information was originally collected” (p. 131). In the same context, Hoffman et al.
(1999) noted that online practice of information sharing (OPIS) is “manifested by
consumers’ concern that Web providers are selling their personal information to third
parties without their knowledge or permission” (p. 131). Because of these risks,
consumers are exposed to threats, such as identity theft and unsolicited marketing, which
contribute to an elevation of consumer personal information privacy concerns (Federal
Trade Commission [FTC], 2000; Zorotheos & Kafeza, 2009). As a result, consumers are
hesitant to provide personal information on the Internet (Nam, Song, Lee, & Park, 2006).
Likewise, Lanier and Saini (2008) noted that, while consumers appreciate the
convenience and benefits of various technological advancements, they are concerned
about how the voluntary and involuntary information collection practices impact their
privacy. Therefore, consumers take prudent actions, such as decreasing Internet use,
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fabricating or falsifying their information, and refusing to disclose information about
themselves (Cromer, 2010; Poddar, Mosteller, & Ellen, 2009; Yang & Wang, 2009). In
this respect, Meinert, Peterson, Criswell, and Crossland (2006) noted that e-commerce
suffered an approximate $15 billion in unrealized revenue due to lack of consumer trust
regarding companies’ ability to protect or use their personal information in an ethical
manner. In an effort to alleviate consumer concerns, companies post privacy seals and
privacy policies on their Website to provide awareness of their information handling
practices (Pollach, 2007). Jafarr and Abdullat (2009) defined the documented practices
of the privacy policy (DPPP) as a “written, published statement that articulates the policy
position of an organization on how it handles the personally identifiable information that
it gathers and uses in the normal course of business” (p. 126). Regardless of privacy
seals and DPPP, consumers expect companies to have an ethical responsibility to engage
in practices that maintain information integrity and protect consumer information from
unauthorized disclosure, access, use, or loss (Kelly & Rowland, 2000; Peltier, Milne, &
Phelps, 2009). Geva (2008) noted that society expectations of companies regarding
corporate social responsibility (CSR) are four fold: “economic (‘make profit’), legal
(‘obey the law’), ethical (‘be ethical’), and philanthropic (‘be a good corporate citizen’)”
(p. 7). Mohr, Webb, and Harris (2001) defined CSR as “a company’s commitment to
minimizing or eliminating any harmful effects and maximizing its long run beneficial
impact on society” (p. 47). Moreover, customers’ expectations are heightened for
financial, medical, and health information (Gupta, Iyer, & Weisskirch, 2010; Yang &
Wang 2009). Therefore, given the significant rise in the use of healthcare Websites
(Davis, 2012; Kim & King, 2009) and the sensitivity of consumers’ information privacy,
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pharmaceutical companies’ Websites are the focus of this research study. The purpose of
this research study was to investigate the documented practices of the privacy policy and
the actual online practices of information sharing and consumer control that are
contributing to the proliferation of personal information privacy violations (PIPV).
This research study developed a benchmarking instrument that assessed and
compared the documented and actual online practices implemented by pharmaceutical
Websites. Using multiple hierarchical measures, a single composite index was derived
that represents an assessment of PIPV. The Personal Information Privacy Violations
Index (PIPVI) benchmarking instrument was used to compare the practices implemented
from 100 Website registrations of pharmaceutical companies that market chronic and
non-chronic prescription medications directly to consumers. These two sub-categories of
the pharmaceutical markets were selected, as both appear to have a significant market
share and appear to collect personal information. A breach of such personal information
can cause substantial embarrassment or even harm to consumers. For example, revealing
the names of elected officials who are taking medications for a mental or other disorder
can certainly be harmful to their reputation, possibly threatening their ability to stay in
office. The remainder of this paper is organized to describe the problem statement,
dissertation goals, and research questions any hypotheses that this research study
addressed. Next, a literature review of the independent and dependent variables, along
with the methodology are presented, followed by the barriers and issues, as well as the
approach for this research study. Afterwards, the results, conclusions, study limitations,
and recommendations for future research are presented. Finally, the appendix includes
the PIPVI benchmark instrument that was used to record the data for each pharmaceutical
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Website and the PIPVI expert panel instrument that was used to elicit responses from the
expert panel.

Problem Statement
The research problem that this research study addressed is the proliferation of
online privacy violations by companies (Anton, Earp, & Young, 2010; 2013; Kim &
Byramjee, 2014; Li, Sarathy, & Xu, 2011; Nam et al., 2006; Nhan, Kinkade, & Burns,
2009; Peltier et al., 2009). Westin (1976) noted that information privacy is defined as,
“the right of individuals, groups, or institutions, to determine for themselves when, how,
and to what extent information about them is communicated to others” (p. 7). Jafar and
Abdullat (2009) noted that “the personal information privacy of an individual is violated
when electronic personal information that was entrusted to third parties is electronically
shared or crossed referenced with other parties without the consent of the individual” (p.
126). Specifically, consumers continue to be concerned with unsolicited email, identity
theft, and negligent information loss through the selling and unauthorized use of their
information when using the Internet (Anton et al., 2010; Lanier & Saini, 2008; Pollach,
2007). Therefore, prior to disclosing information, consumers engage in a risk-benefit
analysis to evaluate if the benefit of the transaction surpasses the risk of information
disclosure (Xie, Teo, & Wan, 2006; Xu, 2009; Yang & Wang, 2009). For example, when
conducting online banking transactions, consumers will voluntarily disclose information,
but information sharing by the bank to third parties is unacceptable. This behavior is
consistent with the value and stimulus propositions of the Social Exchange Theory
(SET). The value proposition noted that “the more valuable to a person is the result of
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his action, the more likely he is to perform the action” (Emerson, 1976, p. 340). The
stimulus proposition noted that:
If in the past the occurrence of a particular stimulus, or set of stimuli, has been the
occasion on which a person's action has been rewarded, then the more similar the
present stimuli are to the past ones, the more likely the person is to perform the
action, or some similar action now. (Emerson, 1976, p. 339)
In other words, Emerson (1967) noted that if the consumers perceived that the expected
benefit would prevail over the risk of information disclosure, they would voluntarily
disclose information. Likewise, if consumers have previously disclosed information and
received the reward without perceptions of PIPV, they will be more willing to disclose
information in similar conditions (Emerson, 1976). However, Nam et al. (2006) noted
that “media scrutiny of Internet fraud, hacking, and identity theft has heightened people’s
awareness of the risks of conducting transactions on the Internet” (p. 212).
Identity theft and other personal information privacy violations in the United
States (US) have continued to rise and receive media attention. As a result of a breach in
2010, the federal regulators issued its largest HIPPA penalty that totaled $4.8 million due
to an incident involving unsecured patient data for 6,800 patients (McGhee, 2014). FTC
(2013) reported that in 2012, identity theft was the top consumer complaint, with 369,212
incidents. Likewise, the Privacy Rights Clearinghouse (2013) reported that since 2005,
932,729,111 records have been breached containing personal information from 4,478
reported incidents. Meanwhile, the Internet Crime Complaint Center (IC3) (2014) noted
that over three million incidents have been reported since 2000. It is important to note
that the IC3 reported that the first million complaints occurred over seven years, with the
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next million occurring in 3.5 years, indicating a significant escalation in cyber crimes
each year. The IC3 (2010) indicated that a substantial number of complaints are due to
loss of personally identifiable information (PII). Culnan and Armstrong (1999) defined
PII as “information identifiable to an individual” (p. 105). PII is represented by
information such as name, postal address, email address, phone or fax number, Social
Security Number (SSN), or credit card number (FTC, 2000). Similarly, non-PII is
defined as “information that, taken alone, cannot be used to identify or locate an
individual” (FTC, 2000, p. 170). Age, gender, income, and education level are examples
of non-PII. The aforementioned incidents are significant indicators of the growth and
occurrence of personal information privacy violations occurring through the use of the
Internet and are key contributors to the escalation of consumer concerns (Lanier & Saini,
2008; Zorotheos & Kafeza, 2009).
The online practices of consumer control (OPCC) are also important to consumers
(Liu, Marchewka, Lu, & Yu, 2005). In this context, Hoffman et al. (1999) defined
consumer control as “the consumer’s ability to control the dissemination of information
related to or provided during such transactions or behaviors to those who were not
present” (p. 131). Liu et al. (2005) noted that consumers expect to maintain some level
of control over how their information is used and distributed. However, the above
incidents give rise to consumer concern regarding the inability to control their
information. Consumers’ concerns regarding the loss of control are substantiated by
Clarke, Flaherty, and Zugelder (2005), who noted that 16% of major email marketers’
OPCC did not comply with the opt-out requirements established by the FTC. By not
honoring consumers’ requests to opt-out of further communications, consumers will
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continue to receive unsolicited emails, also known as spam, and perceive that their
personal information privacy has been violated. Ahmed and Oppenheim (2006) noted
that the Mail Abuse Prevention System defined spam as:
An email is “spam” IF: (1) the recipient’s personal identity and context are
irrelevant because the message is equally applicable to many other potential
recipients; AND (2) the recipient has not verifiably granted deliberate, explicit,
and still-revocable permission for it to be sent; AND (3) the transmission and
reception of the message appears to the recipient to give a disproportionate benefit
to the sender. (p. 157)
In fact, Bhuleskar, Sherlekar, and Pandit (2009) reported that 45% of emails represent
spam and approximately 14.5 billion spam emails are distributed on a daily basis with
consumers receiving an estimated annual spam of 2,500 emails.
Given the consistent rise in personal information privacy violations over the
years, the FTC has made consumer protection a critical aspect of its mission (FTC, n.d).
The FTC has the statutory authority and responsibility for prohibiting unfair and
deceptive practices by holding companies accountable for privacy practices regarding
information collection, use, and security (Earp & Baumer, 2003). Mohr, Webb, and
Harris (2001) noted that companies continue to be confronted with pressure to maintain
profitability and govern themselves in a socially responsible manner. Geva (2006) stated
that “the greatest problem of ethical conduct in business, lies in compliance” (p. 7). Geva
(2008) further noted that “it is the financial interest of businesses to comply with the law,
to engage in ethical behavior, and to exercise philanthropy” (p. 14). In response to the
reoccurrence of information breaches in the US, the FTC established and adopted laws
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and regulations to protect consumers online. First, the Fair Information Practices (FIPs)
are “global principles that fairly balance the need for business to collect and use personal
information with the legitimate privacy interests of consumers to be able to exercise
control over the disclosure and subsequent uses of their personal information” (Milne, &
Culnan, 2002, p. 345). FIPs are generally contained in a Website’s DPPP. Next, the
Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 (CANSPAM Act) is “a law that sets rules for commercial email, establishes requirements for
commercial messages, gives recipients the right to have you stop emailing them, and
spells out tough penalties for violations” (FTC, 2009, para. 1). As a result, some
companies enable consumers to opt-in or opt-out of email communications. However,
enforcement of FIPS and CAN-SPAM Act occur through self-regulation (FTC, 2000;
Lanier & Saini, 2008; Nemati & Dyke, 2009; Xu, 2009). According to Xu (2009), “selfregulation involves the setting of standards by an industry group or certifying agency and
the voluntary adherence to the set of standards by members or associates” (p. 24). In
other words, companies are responsible for voluntarily compliance with these laws and
regulations (Nemati & Dyke, 2009; Storey, Kane, & Schwaig, 2009). Geva (2006) noted
that “a compliance problem is primarily one of ability and willingness (p. 137). Despite
the existence of a Website’s DPPP and other US laws and regulations, the FTC (2013)
noted that it continues to address cases of personal information privacy violations in the
US with multi-million dollar settlements.
Although consumers’ concerns are increasingly rising, Internet use is also on the
rise, which implies that consumers are being more meticulous about interaction with
particular Websites (Cromer, 2010). For instance, Nam et al. (2006) noted that the use of
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the Internet as an informational source has surpassed the purchasing of products. In this
respect, as consumers begin to take a more proactive approach to their healthcare, the use
of the Internet to obtain medical drug information is also on the rise (Davis, 2012). Davis
(2012) indicated that the Internet is the second most used source for prescription drug
information after healthcare physicians. However, Davis (2012) further noted that
consumers prefer pharmaceutical companies’ Websites as a primary source of
information. Kim and King (2009) noted that consumers’ access of pharmaceutical
companies’ Websites tripled from 2000 to 2003. Joseph, Spake, and Finney (2008)
supported this proliferation and also noted that less than 10% of consumers indicated
physicians should be the primary source for pharmaceutical information. This is evident
by consumer use of pharmaceutical companies’ Websites to access health and drug
information, support groups, free drug samples, and rebates (Sheehan, 2005). It is
important to note that to acquire those benefits, consumers are required to disclose
personal information. Equally important, consumers are more cautious about disclosing
personal information with health Websites due to the sensitivity of information that may
be required and the risk of companies developing inferences using information collected.
For example, Bansal, Zahedi, and Gefen (2010) noted that employers or insurance
agencies could use personal health information to discriminate against consumers.
Therefore, it is important for consumers to understand the documented and online
practices of the company (Milne, Rohm, & Bahl, 2004; Van Dyke, 2007). Thus,
additional research of the online information practices of Websites was warranted to
understand the practices that are contributing to the proliferation of personal information
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privacy violations (Kim & Byramjee, 2014; Lanier & Saini, 2008; Schwaig, Kane, &
Storey, 2005).

Dissertation Goals
The main goal of this research study was to develop the Personal Information
Privacy Violation Index (PIPVI) benchmarking instrument that can be used to assess the
DPPP, OPIS, OPCC, and compute the PIPVI while using it to compare 100 Website
registrations of pharmaceutical companies that market chronic and non-chronic
prescription medications. For example, Palmer (2012) noted that contraceptives are an
$8 billion annual drug market. In addition, Chordas (2011) stated that “in 2009, more
than 90 million prescriptions for contraceptives were dispensed” (p. 64). Likewise, a
report by Global Industry Analysts, Inc. (GIA) (2010) noted that consumers experiencing
allergies are constantly rising, and by 2015, this market is expected to surpass $14.7
billion. Hoy and Park (2014) and Davis (2012) noted that consumers use the Internet as a
source for medical information in addition to their physician. Kim and King (2009) also
asserted that, “internet sources are more important for prescription drugs than for nonprescription drugs” (p. 5). Likewise, consumers use of the Internet as a source for
prescription drugs increased from 45.7 million in 2004 to 116 million in 2012 (Hoy &
Park, 2014). Moreover, Hoy and Park (2014) noted that pharmaceutical companies are
predicted to spend $1.86 billion by 2015 on online advertising. Based upon the growth
projections for prescription medications and the projected expenditure in online
advertising, it is expected that consumer use of pharmaceutical Websites will continue to
rise. Therefore, it is important to understand the documented and actual online
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information practices of pharmaceutical companies to gain insight into how information
is used that is collected through their Websites. With the use of actual counting of
violations, as opposed to perception-based survey, the expectation was that this research
study would provide insight into the practices that are contributing to PIPV. Given the
heightened concerns of consumers regarding personal information privacy, the results of
this research study provided consumers with empirical evidence of how information is
managed and used by pharmaceutical companies. In addition, consumers will be able to
assess the magnitude of information sharing and ability (or lack thereof) to control their
information. A high magnitude of personal information privacy violations could
negatively impact consumers’ trust, concerns, and interactions with the Websites, which
could continue to constrain the growth of e-commerce. Because enforcement of the FIPs
occurs through self-regulation, the results of this research study provided evidence
regarding the magnitude of voluntary adherence to the FIPs by pharmaceutical
companies. This evidence can assist advocacy groups and regulators with understanding
the effectiveness of self-regulation. Furthermore, it can aid in determining if more
stringent laws and regulations or enforcement are necessary. In addition, companies can
use the PIPVI benchmarking instrument to perform a self-assessment of their Website
documented and online practices, while seeing how these differ or change over time.
The need for this research was demonstrated by the work of Schwaig et al. (2005),
who examined the DPPP for Fortune 500 companies and their adherence to the FIPs.
Their results indicated that only 3% of the DPPP included all notices of the FIPs, while
31% contained at least one item for each notice. In comparison to the FTC (2000), which
noted that 32% of the sites examined partially implemented four of the FIPs, there has
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been minimal improvement over the years. Schwaig et al. (2005) contended that
companies considered the existence of the DPPP more important than the content or
enforcement. They argued that some companies use the DPPP as disguises for their
limited practices, and further research is warranted to determine the gap between the
DPPP and the actual online information practices. O’Connor (2007) examined the DPPP,
OPIS, and OPCC of hotel Websites. O’Connor (2007) further indicated that none of the
hotel Websites fully complied with the FIPS. Even though O’Connor (2007) also
assessed OPIS and OPCC, only overall percentages of the online practices were provided.
Therefore, this research study will extend O’Connor’s (2007) study with a different
population and provide an extended focus on the volume of third-party emails received.
This dissertation builds on the previous research by Schwaig et al. (2005),
Sheehan (2005), and White (2010). Sheehan (2005) examined the Websites of 94
branded-drug companies’ types of information collected, planned use, and
communication of the DPPP. First, Sheehan’s (2005) results indicated that 94% of the
Websites displayed privacy notices. Second, even though approximately 80% to 90% of
the Websites complied with the FIPs for notice, less than 30% complied with access,
choice, and security. Third, the types of information consumers were expected to
disclose represented over 50% demographic, 40% medical, and 33% other information.
Finally, Sheehan (2005) contended that the evaluation of the DPPP represented claims
and does not constitute the actual practices implemented. Sheehan (2005) was limited to
the DPPP and did not assess the online practices. Similar to Sheehan (2005), this
research study assessed the documented practices of the privacy policy against the FIPs
and the PII collected by the Websites. However, this research study overcame Sheehan’s
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(2005) limitation by assessing the DPPP, OPIS, and the OPCC to provide a holistic view
of how pharmaceutical companies are using the information collected through their
Websites.
The first specific goal of this research study was to develop and assess the
experts’ approved components and weights for the DPPP implemented by pharmaceutical
companies using the Delphi expert methodology. The second specific goal of this
research study was to develop and assess the experts’ approved components and weights
for the OPIS implemented by pharmaceutical companies using the Delphi expert
methodology. The third specific goal of this research study was to develop and assess the
experts’ approved components and weights for the OPCC implemented by
pharmaceutical companies using the Delphi expert methodology. The fourth specific
goal of this research study was to develop the components of the single, integrated
measure of PIPVI and assess the DPPP, OPIS, and the OPCC implemented by
pharmaceutical companies using the Delphi expert methodology. The fifth specific goal
was to assess and compare the DPPPM of pharmaceutical companies whose headquarters
are based in the United States versus Europe, Asia, or United Kingdom. The sixth
specific goal was to assess and compare the OPISM, OPCCM, and PIPVI for 100
Website registrations of pharmaceutical companies that a) market chronic versus nonchronic prescription medications, b) market registrations for prescription medication
discounts versus updates, c) their headquarters are based in United States versus Europe,
Asia, or United Kingdom. The seventh specific goal was to assess and compare the
differences for 100 Website registrations between the documented and actual online
practices of consumer control for choice and access of pharmaceutical companies that a)
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market chronic versus non-chronic prescription medications, b) market registrations for
prescription medication discounts versus updates, c) their headquarters are based in
United States, versus Europe, Asia, or United Kingdom. The eighth specific goal of this
research study is to assess and compare the OPISM, OPCCM, and PIPVI between
pharmaceutical companies that collect a limited amount of PII and those that collect a
high amount of PII. The last and ninth goal is to measure if there are any significant
differences in the pharmaceutical companies’ DPPPM, OPISM, OPCCM, and PIPVI
based on their size, reported annual revenues, and years in existence. Figure 1 represents
the conceptual model for the PIPVI.

Figure 1: Conceptual Model for the Personal Information Privacy Violations
Index (PIPVI)
Research Questions and Hypotheses
The main research question (RQ) that this research study addressed was: are there
any significant differences in the PIPVI, DPPPM, OPISM, and the OPCCM between
pharmaceutical companies that market chronic and non-chronic prescription medications
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directly to consumers? This entailed using the PIPVI benchmarking instrument to assess
the DPPPM, OPISM, OPCCM, and PIPVI scores for pharmaceutical companies’
Websites that market prescription medications directly to consumers. Afterwards, the
DPPPM, OPISM, and OPCCM scores were used to derive the PIPVI for each sample and
then used to compare the groups of pharmaceutical companies’ Websites.
The first seven research questions are focused on the examination of the
documented and the actual online information practices of pharmaceutical companies as
well as their adherence to U.S. laws and regulations. To date, there have been several
studies that examined how well a company’s documented DPPP adhered to the FIPs
(FTC, 1998, 2000; Milne, & Culnan, 2002; Pollach, 2007; Schwaig et al., 2005; Storey et
al., 2009). Schwaig et al. (2005) and Sheehan (2005) noted that the DPPP do not
guarantee the actual practices. Therefore, this research study addressed the gap in the
literature by assessing the DPPP, OPIS, and OPCC over a five-month period with a focus
on pharmaceutical companies’ Websites that market chronic and non-chronic prescription
medications directly to consumers.
RQ1a: What are the experts’ approved components of the DPPP implemented by
pharmaceutical companies using a Delphi expert methodology?
RQ1b: What are the experts’ approved weights of the DPPP’s components
implemented by pharmaceutical companies using a Delphi expert
methodology?
RQ2a: What are the experts’ approved components of the OPIS implemented by
pharmaceutical companies using a Delphi expert methodology?
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RQ2b: What are the experts’ approved weights of the OPIS’s components
implemented by pharmaceutical companies using a Delphi expert
methodology?
RQ3a: What are the experts’ approved components of the OPCC implemented by
pharmaceutical companies using a Delphi expert methodology?
RQ3b: What are the experts’ approved weights of the OPCC’s components
implemented by pharmaceutical companies using a Delphi expert
methodology?
RQ4: What are the experts’ approved weights of the single, integrated hierarchical
measure of PIPVI’s components of DPPP, OPIS, and the OPCC
implemented by pharmaceutical companies using a Delphi expert
methodology?
RQ5: Are there any statistical significance mean differences for DPPM between
pharmaceutical companies that headquarters are based in United States
versus Europe, Asia, or United Kingdom?
RQ6: Are there any statistical significance mean differences for OPISM, OPCCM,
and PIPVI between pharmaceutical companies that a) market chronic versus
non-chronic prescription medications, b) market registrations for
prescription medication discounts versus updates, c) their headquarters are
based in United States, versus Europe, Asia, or United Kingdom?
RQ7: Are there any significant differences between the documented and the
actual online practices for choice, and access of pharmaceutical companies
that a) market chronic versus non-chronic prescription medications, b)
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market registrations for prescription medication discounts versus updates, c)
their headquarters are based in United States, versus Europe, Asia, or United
Kingdom?
The next research question addressed the quantity of PII collected by
pharmaceutical companies. Sheehan (2005) noted that pharmaceutical companies’
Websites collect PII or anonymous information through mechanisms such as site
registrations and questionnaires in exchange for information, rebates, and free trials. The
type of information collected influences the consumer’s level of privacy concern and
interaction with the Website (Li et al., 2011; Sheehan, 2005; Xu, 2009; Yang & Wang,
2009). In this respect, Sheehan (2005) argued that consumers are most concerned about
disclosing financial and health information. According to Zimmer et al. (2010),
“consumers have become increasingly protective of the information they disclose” (p.
395) because they continue to be concerned about information management by
companies. Therefore, this research study examined the PII collected by pharmaceutical
companies’ Websites to gain insight into what PII consumers are expected to disclose.
RQ8: Are there any statistical significance mean differences for OPISM, OPCCM
and PIPVI between pharmaceutical companies that collect a limited amount
of PII and those that collect a high amount of PII?
Last, the three null hypotheses used the demographic information collected for
each pharmaceutical company to assess if there are significant differences in the
pharmaceutical company's DPPPM, OPISM, OPCCM, and PIPVI based on its size,
annual revenues, and years in existence.
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H1: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will
not be significantly different when controlling for company size.
H2: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will
not be significantly different when controlling for annual revenue.
H3: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will
not be significantly different when controlling for years in existence.

Relevance and Significance of the Study
Relevance
Due to the occurrence of online privacy violations, research in this area continues
to be relevant (Belanger & Crossler, 2011; Peltier et al., 2009). The proliferation of
online privacy violations continues to be a problem for consumers (K. Kim & Kim, 2011;
Koorzaan & Boswell, 2008; Li et al., 2011). Lee, Ahn, and Bang (2011) noted that even
though companies have implemented FIPs, personal information privacy violations
continue to rise. In addition, online identity theft has rapidly emerged as the top identity
crime, and the number of threats to consumers continues to rise year after year (RacoltaPaina & Luca, 2010). As previously noted, the FTC (2010) continues to address cases of
personal information privacy violations in the US with multi-million dollar settlements.
Because adherence to the FIPs is self-regulated, it is challenging to regulate and enforce.
Pratt and Conger (2009) noted that technological advancements have contributed to the
erosion of personal information privacy over the last 30 years. Technology maturity has
significantly decreased the challenges for companies to collect, integrate, and aggregate
consumer information (Nemati & Dyke, 2009; Pratt & Conger, 2009; Taylor, Davis, &
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Jillapalli, 2009). It is important to note that prior to the Internet, this capability was
practically impossible (Pratt & Conger, 2009), except through a manual effort. For
example, prior to the Internet, consumers may have completed a post card in a
physician’s office, clinic, or hospital, which became at risk for unauthorized use or
information sharing by the staff or mail handlers if reply was sent by mail.
A poll by CBS News and The New York Times reported that 83% of 1,167
Americans interviewed expressed negative views of companies’ information collection
practices (Roberts, 2009). Once consumers disclose information, they have relinquished
control and are unaware of how their information will be managed and used (Li et al.,
2011; Rapp et al., 2009; Reay, Dick, & Miller, 2009). Therefore, consumers will
continue to be at risk for personal information privacy violations if their information is
exposed to threats such as unauthorized access, secondary use, or sold to third parties.
Secondary use is defined as “use of information for other purposes, subsequent to the
transaction where the information was originally collected” (Hoffman et al., 1999, p.
131). Because of the consistent occurrence of personal information violations, the
growth of e-commerce is at risk (Kim & Byramjee, 2014; K. Kim & Kim, 2011; Li et al.,
2011). However, Lee et al. (2011) noted that implementation of the FIPs could mitigate
consumer concerns and increase their willingness to disclose personal information. As
Internet use of pharmaceutical companies’ Websites continues to rise, it is important to
understand the extent their privacy policy complies with the FIPs, information sharing,
and consumer control to assess their contribution to personal information privacy
violations (Sheehan, 2005). This will assist consumers with determining if
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pharmaceutical companies can be trusted with their information, given the sensitivity of
health information.
Although there are several research studies (Earp & Baumer, 2003; Gupta et al,
2010; Joinson, Reips, Buchanan, & Schofield, 2010; K. Kim & Kim, 2011; Li et al, 2011;
Phelps, Norwak, & Ferrell, 2000; Vlasic, 2006) evaluating different aspects of consumer
information privacy concerns, research that examines the actual online practices of
companies is limited. Various studies have examined specific aspects of online practices,
such as assessment of privacy policies against the FIPs, consumer control, and secondary
use (FTC, 1998, 2000; Lai & Hui, 2006; Milne & Culnan, 2002; O’Connor, 2007;
Pollach, 2007; Schwaig et al., 2005; Storey et al., 2009; White, 2010). However, there is
a gap in the literature of comprehensive empirical research examining information
privacy with an assessment of privacy policies against the FIPs, information sharing, and
consumer control in one study for a particular population. This research study addressed
that gap by conducting an assessment of these constructs for pharmaceutical companies’
Websites that provide information about prescription drugs. Websites that sell
prescription drugs were excluded from this research study.
W. J. Kim and King (2009) noted that “the pharmaceutical market is one of the
world’s leading industrial sectors with worldwide sales volume estimated as $534.8
billion in 2005” (p. 5). The pharmaceutical industry is under the regulation of the Federal
and Drug Administration (FDA) under the authority of the Federal Food, Drug and
Cosmetic Act and, therefore, must comply with more stringent guidelines than other
industries. The pharmaceutical market is comprised of both prescription and nonprescription drugs. W. J. Kim and King (2009) defined prescription drugs as drugs that
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cannot be dispensed without a prescription, while a prescription is not required for nonprescription drugs. They also noted that prescription drugs represent significant revenue
for this industry. Prior to 1997, pharmaceutical marketing was primarily directed toward
physicians. Because of the relaxation of direct-to-consumer (DTC) advertising
regulations in 1997, pharmaceutical companies expanded advertising to include DTC.
Because considerable profits have been realized from advertising, the pharmaceutical
industry has radically increased their direct-to-consumer (DTC) advertising (Joseph et al.,
2008; W. J. Kim & King, 2009). For example, pharmaceutical companies in the US have
increased DTC advertising spending for prescription drugs from $242 million in 1994 to
an estimated $4.2 billion in 2005 (W. J. Kim & King, 2009). Advertising of prescription
drugs is not limited to such media as television and radio, but also includes the Internet.
W. J. Kim and King (2009) noted that the Internet has increasingly become a popular
medium for consumers to obtain information regarding prescription drugs. The
aforementioned factors provide impetus for pharmaceutical companies’ Website being
selected as the unit of analysis.
Significance
The significance of this research study is its results provided an understanding of
the magnitude of personal information privacy violations by pharmaceutical companies.
Since the FIPs are governed by self-regulation (FTC, 2000; Lanier & Saini, 2008; Nemati
& Dyke, 2009; Xu, 2009), this research study provided evidence regarding the extent of
voluntary adherence by pharmaceutical companies. Next, this research study also
provided insight into the secondary use and third party sharing of consumer information.
Because consumers are highly concerned about information management and use, the
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results of this research study provided insight into how well pharmaceutical companies
are addressing consumer concerns.
Furthermore, other researchers can use the PIPVI benchmarking instrument to
assess Websites for new populations. This research study sought to provide a mechanism
to assess the document and actual online practices of a Website to gain a better
understanding of the practices contributing to PIPV. Those responsible for the design
and development of companies’ Websites can use this tool to conduct a self-assessment
of the Website’s documented and online practices. The use of the PIPVI can also provide
an increased awareness of the practices that are important to regulators and consumers to
assist with improving the Website’s practices. Furthermore, this evidence will assist
advocacy groups and regulators with understanding the effectiveness of self-regulation to
aide in determining if more stringent laws and regulations or enforcement are necessary.

Barriers and Issues
This research study had several potential issues with conducting this experiment.
First, an issue of concern was that the responses of the experts solicited for participation
in the expert review panel might not be constructive. Therefore, to address this concern,
the expert panel survey consisted of questions that elicited both binary and open-ended
responses. Because this research study developed the PIPVI benchmarking tool, the
reliability of this instrument was also a concern. To address this concern, a methodical
analysis of literature and evaluation by the expert panel was conducted to ensure the
intention of the instrument.

24

In addition, the data collection for this research study was an issue due to
potential revisions to the Websites or practices during the length of the study because the
data collection from the Websites occurred over a five-month period. For instance, the
privacy policy or online practice could have been revised during the five months that may
alter the results. O’Connor (2007) noted that it is common practice for companies to
provide notification of privacy policy updates. To address this issue, a copy of the
privacy policy was downloaded and assessed at the beginning and the end of the research
study. If notifications were received during data collection or analysis, the privacy policy
would have been reviewed for modifications that would significantly alter the results and
determine if the Website results should be excluded from the study or updated. However,
no notifications were received, nor changes to the privacy policy occurred. In addition,
the results represented data for a specific date range. Data received after the specified
date was excluded.
Another issue that required consideration was that because information was
collected from online transactions, aggregation of information by the Websites of
pharmaceutical companies could be an issue. To mitigate this issue, a unique email and
name was identified for each Website registration initiated on the pharmaceutical
company Website to ensure results were maintained separately. A new domain name was
purchased to set up an email account for each registration for the pharmaceutical
companies’ Websites. For example, a Website may allow separate registrations for a
newsletter and discounts. Therefore, registration for the newsletter had a different name
and email address than the registration for the discount for the same pharmaceutical
company Website.
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Because secondary use by the pharmaceutical companies was measured by
emails, the use of personal information may be understated because postal mail received
cannot be measured by pharmaceutical company, since all Website registrations used the
same postal address. Therefore, to address this concern, a unique name was used for all
Website registrations to ensure postal mail received could be aggregated appropriately.
One more issue that required consideration is that because some Website
registrations required an address, the same P.O. Box was used for all registrations.
Therefore, it may have been difficult to determine which pharmaceutical company
Website the mail originated from. To address this issue, as mentioned above, a unique
name was used for each pharmaceutical company Website registration to assist with
determining the origin of the mail.
Furthermore, the sample represents a random selection of pharmaceutical
companies’ Websites and results may not be representative of the industry as whole.
This research study was conducted using pharmaceutical companies’ Websites that
provide information about chronic and non-chronic prescription drugs in the US. The
companies may be headquartered in and outside of the US, such as in France, Germany,
Japan, Switzerland, or the UK. In an effort to get a valid cross section of pharmaceutical
companies’ Websites, the sample included 100 registrations initiated through 53
Websites across 25 pharmaceutical companies with a proportionate distribution between
US and non-US headquarters. The sample excluded pharmaceutical companies’
Websites that sell prescription drugs.
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Limitations and Delimitations
Limitations
Because this research study developed a new benchmarking instrument, one
limitation was the set of measures that was combined to form the PIPVI. Another
limitation was that the reliability and validation of the instrument relied on an expert
panel. The expert panel assigned the relative weights for the document and online
practices measures. As a result, generalization of the results from this research study was
cautioned. Further studies will be required with other populations to increase
generalizability of the results.
An additional limitation of this research study was the inability to assess the
actual security practice. The inability to observe the companies’ actual information
protection methods for transmittal and storage prohibits observation and information
collection for examination. Next, it is important to note that while the focus of this
research study is online practices, it is believed that information is being shared through
other sources, such as physician offices and pharmacies. The actual practices for OPIS
for several of the Websites could not be adequately assessed because no emails were
received during the research study. Moreover, the actual practices of OPCC regarding
the deletion of personal information could not be assessed. Most of the pharmaceutical
companies required a request for deletion to be submitted by email, phone, or mail, which
was beyond the scope of this research study. The last limitation is that the information
represented a point in time due to unpredictable modifications of privacy policies or
practices that could occur after data collection.
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Delimitations
First, a delimitation of this research study was that the experts recruited for the
panel were based upon a convenience sampling. Sekaran (2003) defined convenience
sampling as “the collection of information from members of the population who are
conveniently available to provide it” (p. 276). Experts, including professional contacts
with those associated with this project, and members in professional societies and social
media networking sites, were solicited to participate. Because of this convenience
sampling, other qualified experts may not have been contacted and therefore not included
in the expert panel.
Second, another delimitation of this research study was that the pharmaceutical
companies’ Websites included in the examination were limited to prescription drugs and
not over-the-counter drugs. A third delimitation was that the pharmaceutical companies’
Websites were limited to manufacturers that advertise pharmaceutical drugs in the US
even though their headquarters may be located in and outside the US, such as in France,
Germany, Japan, Switzerland, or the UK. A fourth delimitation was that if a postal
address is required, a P. O. Box was used instead of a street address. The P. O. Box is
preferred to mitigate receipt of a high volume of mail at the personal home address.
After completion of this research study, the P. O. Box was terminated with no forwarding
address. A fifth delimitation was that the Website registration was limited to newsletters,
updates, discounts or support programs. Last, a delimitation regarding confinement of
the Website registrations was that secondary use and email metrics may be understated
because specific triggers may not have been invoked for other transactions not included
in this research study. For example, the experiment included Website registrations for
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newsletters, discounts, or support programs, which may not trigger the same processes as
completion of a survey or quiz.

Definition of Terms
The following represent terms and definitions.
Analysis of Variance (ANOVA) - “to determine group differences when two or more
factors create these groups” (Mertler & Vannatta, 2010, p. 90)
Analysis of Covariance (ANCOVA) - “adjusts the effects of variables that are related to
the dependent variables” (Mertler & Vannatta, 2010, p. 93)
Cronbach Alpha - “a reliability coefficient that indicates how well the items in a set are
positively correlated to one another” (Sekaran, 2003, p. 307)
Construct Validity - “a determination of the significance, meaning, purpose, and use of
scores from an instrument” (Creswell, 2002, p. 184)
Consumer Control (OPCC) – “individuals could exercise control over the accuracy,
completeness, timeliness, use, distribution, and disposition of their personal information”
(Zuo et al., 2007, p. 452)
Content Validity - “the extent to which the questions on the instrument and the scores
from the questions are representative of all the possible questions that could be asked
about the content or skills” (Creswell, 2002, p. 18)
Controlling the Assault of Non-Solicited Pornography and Marketing Act (CANSPAM Act) - “a law that sets rules for commercial email, establishes requirements for
commercial messages, gives recipients the right to have you stop emailing them, and
spells out tough penalties for violations” (FTC, 2009, para. 1).
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Convenience Sampling – “the collection of information from members of the population
who are conveniently available to provide it” (Sekaran, 2003, p. 276)
Corporate Social Responsibility (CSR) - “a company’s commitment to minimizing or
eliminating any harmful effects and maximizing its long run beneficial impact on
society” (Mohr, Webb, & Harris, 2001, p. 47)
Delphi Expert Methodology – “devised in order to obtain the most reliable opinion
consensus of a group of experts by subjecting them to a series of questionnaires in depth
interspersed with controlled opinion feedback” (Dalkey & Helmer, 1963, p. 458)
Fair Information Practices (FIPs) - “global principles that fairly balance the need for
business to collect and use personal information with the legitimate privacy interests of
consumers to be able to exercise control over the disclosure and subsequent uses of their
personal information” (Milne, & Culnan, 2002, p. 345).
Federal Trade Commission (FTC) - A U.S. government organization whose mission is
“to prevent business practices that are anticompetitive or deceptive or unfair to
consumers; to enhance informed consumer choice and public understanding of the
competitive process; and to accomplish this without unduly burdening legitimate business
activity” (FTC, n.d., para. 1).
Homogeneity of Variance - “the degree of variance within each of the samples should
be about the same” (Terrell, 2012, p. 245)
Inter-rater Reliability - “two or more individuals observe an individual’s behavior and
record scores, and then the scores of the observers are compared to determine whether
they are similar” (Creswell, 2002, p. 182)
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Involuntary Disclosure - “this malicious method involves the use of technology to
collect data and track movements by Internet users without their knowledge and/or
permission” (Christiansen, 2011, p. 511)
Non-Personally Identifiable Information (Non-PII) - “information that, taken alone,
cannot be used to identify or locate an individual” (FTC, 2000, p. 169).
Online Practices of Information Sharing (OPIS) - “manifested by consumers’ concern
that Web providers are selling their personal information to third parties without their
knowledge or permission” (Hoffman et al., 1999, p. 131)
Opt-in – “consumers must give permission before marketer can use their personal
information” (Milne & Rohm, 2000, p. 238)
Opt-out - “consumers can remove their names from a list by checking a box on a form
provided by the marketer or by calling or writing the marketer” (Milne & Rohm, 2000, p.
238)
Outlier - “cases with unusual or extreme values at one or both ends of a sample
distribution” (Mertler & Vannatta, 2010, p. 27)
Personal Information Privacy Violation - “the personal information privacy of an
individual is violated when electronic personal information that was entrusted to third
parties is electronically shared or crossed referenced with other parties without the
consent of the individual” (Jafar & Abdullat, 2009, p. 126).
Personally Identifiable Information (PII) - “information that can be used to locate or
identify an individual” (FTC, 2000, p. 169).
Pre-Analysis Data Screening - “pre-analysis data preparation deals with the process of
detecting irregularities or problems with the collected data” (Levy, 2006, p. 150).
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Privacy - “the right of individuals, groups, or institutions, to determine for themselves
when, how, and to what extent information about them is communicated to others”
(Peltier et al., 2009, p. 192).
Privacy Policy (DPPP) - “a written, published statement that articulates the policy
position of an organization on how it handles the personally identifiable information that
it gathers and uses in the normal course of business” (Jafarr & Abdullat, 2009, p. 126).
Ratio Scale – “a scale that has an absolute zero origin, and hence indicates not only the
magnitude, but also the proportion of the differences” (Sekaran, 2003, p. 422)
Reliability - “individual scores from an instrument should be nearly the same or stable on
repeated administrations of the instrument, they should be free from sources of
measurement error, and they should be consistent” (Creswell, 2002, p. 180)
Response Set - “cases where respondents submitted the same score for all items” (Levy,
2006, p. 151)
Secondary Use - “use of information for other purposes, subsequent to the transaction
where the information was originally collected” (Hoffman et al., 1999, p. 131).
Self-regulation - “the setting of standards by an industry group or certifying agency and
the voluntary adherence to the set of standards by members or associates” (Xu, 2009, p.
24)
Spam - “an email is ‘spam’ IF: (1) the recipient’s personal identity and context are
irrelevant because the message is equally applicable to many other potential recipients.
AND (2) the recipient has not verifiably granted deliberate, explicit, and still-revocable
permission for it to be sent; AND (3) the transmission and reception of the message
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appears to the recipient to give a disproportionate benefit to the sender” (Ahmed &
Oppenheim, 2006, p. 157).
Validity - “draw meaningful and justifiable inferences from scores about a sample or
population” (Cresswell, 2002, p. 185)
Voluntary Disclosure - “a user’s voluntary sharing of such information” (Christiansen,
2011, p. 1).

Summary
The purpose of chapter one was to first introduce the research study.
Identification of the research problem, barriers and issues, along with the limitations to
conducting this research study, were discussed. Next, a theoretical justification for the
research study was provided. The research problem that this study addressed was that
although there are laws and regulations for consumer protection when interacting online,
there continues to be a proliferation of online privacy violations by companies. Valid
literature supporting the research problem and the need for this study was presented.
Furthermore, chapter one presented the main goal, specific goals, research
questions, and hypotheses for this research study. The main goal of this research study
was to develop the Personal PIPVI benchmarking instrument that can be used to assess
the DPPP, OPIS, OPCC, and compute PIPVI while using it to compare 100 registrations
initiated through 53 Websites of 25 pharmaceutical companies that market chronic and
non-chronic prescription medications. Prior literature that supports the main goal was
presented (Belanger & Crossler, 2011; Lee, Ahn & Bang, 2011; Li et al., 2011; K. Kim &
Kim, 2011; Peltier et al., 2009; Koorzaan & Boswell, 2008). The nine specific goals,
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along with the relevance and significance for this research study, were also discussed.
According to literature, the number of threats to consumers, such as online identity theft,
continues to rise year after year (Racolta-Paina & Luca, 2010). Because of the consistent
rise in online privacy violations such as online identity theft, research in this area
continues to be relevant (Belanger & Crossler, 2011; Peltier et al., 2009). This research
study added to the body of knowledge by providing insight into the documented and
actual online practices of pharmaceutical companies that contribute to personal
information privacy violations. In addition, this research study provided empirical
evidence on how information is managed and used by pharmaceutical companies’
Websites.
Furthermore, chapter one continued by identifying the barriers, issues, and
mitigations for this research study pertaining to the expert panel participation, data
collection, aggregation of the information, and Website registrations. The limitations and
delimitation of the research study were discussed. The chapter concluded with a
definition of terms used during the research study along with relevant acronyms.
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Chapter 2
Literature Review

Introduction
In this chapter, a literature review was presented to provide a synopsis of the
relevant literature pertaining to Website practices and to lay the theoretical foundation for
this research study. Hart (1998) noted that the literature review provided the foundation
for the research and stressed the importance of adequate knowledge of the history and
current research to identify areas of concerns, interest, and neglect. To acquire the
knowledge and understanding, a comprehensive literature search for quality peer
reviewed and secondary literature was conducted that was also used to lay the foundation
for this research study. This is a critical process and, as noted by Levy and Ellis (2006),
“in any systematic approach, if the system input is either incorrect, of low quality, or
irrelevant, the resulted output is going to be ineffective regardless of the quality of the
processing stage or, colloquially, garbage-in/garbage-out” (p. 185). This examination is
interdisciplinary in nature and, therefore, an extensive search of the Information Systems
(IS) literature domain was conducted using several databases from multiple fields
including the following: IS, business, and marketing. From this literature review process,
three important constructs were identified in the literature domain relating to personal
information violations: privacy policy, information sharing, and consumer control. A
comprehensive examination of these areas was conducted to ascertain what is already
known, research questions, approach, and theoretical foundation for this research.
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Moreover, information regarding composite indices and the Delphi expert methodology
was presented.

Personal Information Privacy Violations
Personal information privacy violations using the Internet continue to receive
media attention and continue to be a growing concern for consumers (K. Kim & Kim,
2011; Koorzaan & Boswell, 2008; Li et al., 2011). While the advancement of technology
has provided significant benefits to companies and consumers, it has also had an adverse
effect. Research has shown that information privacy remains a top concern for
consumers (Smith, Dinev, & Xu, 2011).
Personal information privacy violations can occur in multiple ways through the
information collection and management practices by companies. Companies collect
information through voluntary and involuntary methods (Christiansen, 2011). Even
though consumers are voluntarily providing information, companies are able to collect
additional information without consumer consent, using methods such as cookies and
Web bugs (Smith et al., 2011). Cookies and Web bugs are designed to capture
information about consumers, including their Web browsing activities. The information
collected from those activities can be aggregated and used to create a consumer profile.
Therefore, whether information has been collected through voluntary or involuntary
methods, the information becomes at risk for unauthorized use, management, and
distribution (Milne et al., 2004). The persistent growth of identity theft and spam are also
key indicators that companies are mismanaging consumer information. Gomez, Pinnick,
and Soltani (2009) indicated that companies such as Google®, Yahoo®, Microsoft®, and
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Facebook® share consumer information with a significant quantity of affiliates. Because
of the persistent personal information privacy violations and the heightened concerns of
consumers, Van Dyke (2007) noted the importance of understanding the online practices
of Websites. Furthermore, Smith et al. (2011) stated that there are very limited empirical
descriptive studies that address the organizational unit of analysis.
Table 1
Summary of Personal Information Privacy Violations Literature
Study

Methodology

Christiansen,
2011

Standard

Gomez et al.,
2009

Literature
review and
experiment

K. Kim & J.
Kim, 2011

Empirical
study via
experiment

Sample

Instrument or
Construct

Main Finding or
Contribution

Personal privacy
and Internet
marketing

Provides an overview
of technology and
personal privacy in
marketing along with
recommendations for
the marketing and
government industries.

50
Websites

Data handling
practices, consumer
concerns

Consumers are
concerned about
privacy and do not
support information
collection and
disclosure by Websites
without their
permission.

223
Undergraduate
students

Trusting intentions,
trusting beliefs,
perceived privacy
empowerment,
purchase decision
involvement,
disposition to trust,
privacy-protection
self-efficacy

The presence of a
well-known third party
seal on an unfamiliar
retailer website
increased trust in the
website and the seal
presence was mediated
by perceived privacy
empowerment.
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Table 1
Summary of Personal Information Privacy Violations Literature (continued)
Study

Methodology

Sample

Instrument or
Construct

Main Finding or
Contribution

Koorzaan &
Boswell, 2008

Empirical
study via
survey

230 undergraduate
students

International
personality item
pool

Personality traits
impacts concern for
information privacy.

Li et al., 2011

Empirical
study via
experiment

220
students

Emotions,
fairness levers,
general privacy
concern, situation
specific privacy
calculus, sensitivity
of information

Emotions influence
information disclosure.
During e-commerce
transactions with an
unfamiliar vendor,
information disclosure
is based upon
competing influences
of exchange benefits
along with privacy
protection belief and
privacy risk belief.

Milne et al.,
2004

Empirical
study via
survey

2468
adults,
300
students,
40 nonstudents

Online protection
behavior, attitudinal
behaviors,
demographic
antecedent

Consumers are not
taking adequate
precautions to protect
themselves against
identity theft.

Smith et al.,
2011

Literature
review and
analysis

320
privacy
articles,
128 books
and book
sections

APCO macro
model

Provides an
interdisciplinary
review of privacyrelated research and
recommendations for
future research.

Van Dyke,
2007

Empirical
study via
experiment

124
employees,
undergraduate
and

Privacy concern,
website
personalization
preference

Increased awareness of
data collection
techniques elevated
consumer privacy
concerns and reduced
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graduate
students

preference for Web
site personalization.

Privacy Policy and the Fair Information Practices
Websites’ compliance with the FIPs has been a topic of discussion for personal
information privacy when using the Internet. The FTC has been examining online
privacy violations since 1995. In 1998, the FTC issued its first FIPs report to Congress
with a recommendation for Websites to implement the FIPs (FTC, 1998). These
principles were established prior to the Web and have been recognized by government
agencies in the US, Canada, and Europe since 1973 (FTC, 2000). Park (2011) noted that
“the FIPs are global principles that balance business needs for data collection with
consumer protection” (p. 651). However, enforcement of the FIPs is through selfregulation and companies are responsible for voluntary compliance and monitoring. The
four widely accepted FIP principles are notice, choice, access, and security (FTC, 2000).
The FTC (2000, p. iii) defined these principles as:
§

Notice – Websites would be required to provide consumers clear and
conspicuous notice of their information practices, including what information
they collect, how they collect it (e.g., directly or through non-obvious means
such as cookies), how they use it, how they provide choice, access, and
security to consumers, whether they disclose the information collected to
other entities, and whether other entities are collecting information through
the site.
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§

Choice – Websites would be required to offer consumers choices as to how
their personal identifying information is used beyond the use for which the
information was provided (e.g., to consummate a transaction). Such choice
would encompass both internal secondary uses (such as marketing back to
consumers) and external secondary uses (such as disclosing data to other
entities).

§

Access – Websites would be required to offer consumers reasonable access to
the information a Website has collected about them, including a reasonable
opportunity to review information and to correct inaccuracies or delete
information.

§

Security – Websites would be required to take reasonable steps to protect the
security of the information they collect from consumers.

In 1998, the FTC examined the online practices of 1402 US commercial
Websites. While 85% of the Websites collected large amounts of information, only 14%
of the random sample disclosed some type of information regarding the Website’s
information practices and only approximately 2% provided notice in a comprehensive
privacy policy (FTC, 1998). Two years later, the FTC (2000) examined 426 US
commercial Websites and over 90% of those Websites collected PII. While there was an
increase in posting at least one privacy disclosure for these Websites, there continued to
be very limited compliance of at least one element for each principle of the FIPs. The
FTC (1998, 2000) also indicated that a significant number of companies failed to provide
the basic principle of notice and overall had not implemented the FIPs. It is important to
note that, because privacy policies are not required, some companies cannot be held
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accountable for their privacy practices until they are stated (Storey et al., 2009). For
example, it may be difficult to file a claim against a company without posted privacy
policies because they have not made any declarations regarding information collection
nor usage practices. The FTC (1998) report to Congress noted that there is a need for
companies to implement the basic principles of the FIPs, but no legislation was
recommended at that time. In addition, the FTC (1998) noted that if consumer concerns
are not addressed, “electronic commerce will not reach its full potential” (FTC, 1998, p.
43). Two years later, based upon minimal improvement in adherence to the FIPs, the
FTC’s report to Congress recommended that Websites that collect PII comply with the
following FIPs: notice, choice, access, and security (FTC, 2000).
In response to the FTC (1998), Culnan (2000) examined 361 of the most visited
US commercial Websites using the FTC (1998) as the foundation to provide support for
self-regulation and to discourage legislation. Culnan (2000) argued that the FTC sample
was not representative of Websites consumers frequently visited. The results suggested
that 65% posted some type of privacy notice, which was higher than the FTC (1998).
The Direct Marketing Association (DMA) argued that Culnan (2000) provided evidence
that companies were voluntarily adhering to the FIPs and self-regulation was an effective
approach (Culnan, 2000). To the contrary, Consumer Federation of America supported
the FTC (1998) and noted that “meaningful and effective privacy protections for
consumers are largely missing” (Culnan, 2000, p. 24). Likewise, the Center for
Democracy and Technology (CDT) (1999) also disagreed with the DMA and stated that
“privacy policies are the exception and not the rule” (p. 10). The CDT (1999) also noted
that there is very limited adherence to the complete set of FIPs. While Culnan (2000)
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noted that the DMA reported positive results regarding posting of privacy policies, the
CDT (1999) argued that the information presented in the privacy policies were not
reflective of consumer concerns. The CDT (1999) acknowledged that while some
progress is apparent, more is required to establish information privacy as the rule rather
than the exception. Years later, O’Connor’s (2007) examination of hotel Websites
continued to reveal evidence of non-adherence to the complete set of FIPs and privacy
policies continued to ignore the concerns of consumers. The FTC (1998, 2000) and
Culnan (2000) focused on a broad population of commercial Websites across multiple
industries. In contrast, this research study will focus on a specific industry. Belanger and
Crossler (2011) noted that the type of industry impacts a company’s privacy concerns and
practices because some industries may be required to adhere to certain regulations. In
addition, well-known brand names may take additional precautions regarding privacy in
an endeavor to maintain brand reputation (Belanger & Crossler, 2011).
Likewise, Storey et al. (2009) examined the privacy policies of U.S. Fortune 500
companies against the FIPs. Storey et al. (2009) believed these companies were expected
to be leaders in personal information privacy issues and were scrutinized more closely by
privacy advocates and the government. Their results indicated that a company’s
dependency on consumer information influenced the quality of the privacy policy. For
example, business to consumer, electronic commerce, informational, heavy traffic, and
large company Websites that are dependent upon consumer information are more likely
to adhere to the FIPs than those of companies that are not dependent upon consumer
information. Storey et al. (2009) stated that the results contradict consumers’ perceptions
that information dependent companies are more likely to violate consumers’ information
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privacy. However, Storey et al. ’s (2009) findings were concluded based upon the stated
practices opposed to actual practices. Pratt and Conger (2009) argued that, while the
FIPs are commendable, they could give consumers a false illusion of privacy protection.
While the privacy policy quality may be high, the statements do not guarantee actual
practices (Schwaig et al., 2005; Sheehan, 2005), as is evident by the continued growth in
personal information privacy violations (Lee et al., 2011). Lee et al. (2011) noted that,
even though companies have implemented the FIPs, personal information privacy
violations continued to rise. But there is a belief that implementation of the FIPs could
reduce consumer concerns (Beldad, Jong, & Steehouder, 2009; Culnan &Armstrong,
1999; Lee et al., 2011). Furthermore, the CDT (2011) stated that “Fair Information
Practices (FIPPS) must be the foundation of any comprehensive privacy framework” (p.
7).
Table 2
Summary of Privacy Policy and the Fair Information Practices Literature
Study

Belanger &
Crossler,
2011

Beldad et al.,
2009

Methodology

Sample

Instrument or
Construct

Literature
review and
analysis

142 journal Information
articles,
privacy
102
conference
proceedings

There is more to be
explored or explained
about Information
Privacy research.

Empirical
study via
experiment

77 Dutch
municipal
Websites

While 50% complied
with notice, they fell
short in access,
choice, and security.

Fair Information
Practices

Main Finding or
Contribution
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Table 2
Summary of Privacy Policy and the Fair Information Practices Literature (continued)
Study

Methodology

Sample

Instrument or
Construct

Main Finding or
Contribution

CDT, 1999

Literature
review and
analysis

Industry
reports

Fair information
practices, privacy

Companies are not
fully adhering to the
Fair Information
Practices.

CDT, 2011

Literature
review and
proposal

Data breach

Summarized the
framework of federal
and state data breach
and security laws, as
well as recommended
legislative proposals.

Empirical
study via
secondary
data analysis

1000 US
adults 18
years or
older

Information
privacy concerns,
procedural
fairness,
impersonal trust

Companies can
increase customer
retention by
recognizing
procedural fairness.

FTC, 1998

Empirical
study via
experiment

1400
Websites

Fair information
practices

Companies are not
adhering to
guidelines regarding
online collection and
use of consumer
information.

FTC, 2000

Empirical
study via
experiment

521
Websites

Fair Information
Practices

Industries have made
limited progress in
protecting consumer
privacy online.

Culnan &
Armstrong,
1999
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Table 2
Summary of Privacy Policy and the Fair Information Practices Literature (continued)
Study

Methodology

Lee et al.,
2011

Literature
review and
analysis

O’Connor,
2007

Empirical
study via
experiment

Park, 2011

Empirical
study via
experiment

Sample

Instrument or
Construct

Main Finding or
Contribution

Privacy
protection

Enforcement of the
Fair Information
Practices can be
beneficial from the
social welfare
perspective by
limiting the
competitionmitigation firm
incentives.

97 hotel
Websites

Fair Information
Practices

No website fully
complies with the
Fair Information
Practices.

398
Websites

Notice,
Choice

The minimal levels of
privacy provision
suggested the
deficiency of
marketplace benefits.

Personal
information
privacy

Privacy violations are
still occurring despite
legal and selfprotection policies.

Fair Information
Practices

Companies are not in
full compliance with
the Fair Information
Practices. Companies
are more concerned
about the existence
rather than the
content.

Literature
Pratt &
review and
Conger, 2009 analysis

Schwaig et
al., 2005

Empirical
study via
experiment

Fortune
500
companies’
websites
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Table 2
Summary of Privacy Policy and the Fair Information Practices Literature (continued)
Study

Methodology

Sample

Instrument or
Construct

Main Finding or
Contribution

Sheehan,
2005

Empirical
study via
experiment

94 DTC
brandeddrug
Websites

Fair Information
Practices

Websites have more
adherences to notice
and choice than
access and security of
the Fair Information
Practices. In
addition, readability
of privacy policies is
difficult to
understand

Empirical
study via
experiment

Fortune
500
companies’
Websites

Fair Information
Practices

A company’s
dependence upon
consumer
information may
influence the strength
of their privacy
policy.

Storey et al.,
2009

Information Sharing
One of the top concerns of consumers is information disclosure to third parties
without consent (Anton et al., 2010; Lanier & Saini, 2008; Pollach, 2007). Jaisingh et al.
(2008) noted that this type of information sharing represented a “collection and release of
consumer information” (p. 858) that would be considered a PIPV. As a result of
unauthorized information sharing, research has shown that consumers continue to be
concerned about information management (Pratt & Conger, 2009; Roberts, 2009; Zimmer
et al., 2010). This concern is supported by constant evidence of companies sharing
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information without consumer knowledge, which contributes to PIPV. Pratt and Conger
(2009) contended that once companies integrate and aggregate information, it would be
shared or sold.
Wu, Lau, Atkin, and Lin (2011) argued that, while companies benefit from the
sale of personal information, it could be more detrimental to consumers than illegal
information collection. For example, Wu et al. (2011) noted a 1999 incident of a
murdered female resulting from the purchase of her Social Security Number (SSN) from
the Internet for only $45. While this is an extreme case, it clearly demonstrated that
secondary use can be life-threatening and that consumers have reason for heightened
concerns. Pratt and Conger (2009) noted that once information disclosure occurs,
consumers should expect their information will be sold or shared and their privacy cannot
be restored. With technology, the ability for companies to easily integrate information
has had both a positive and negative impact on consumers’ personal information privacy.
While consumers also benefit from information disclosure, the negative impact on their
personal information privacy could outweigh the benefits (Pratt & Conger, 2009). For
example, consumers may receive information, free drug samples, or coupons in exchange
for spam from other companies with whom they did not engage, which leads to increased
risks such as identity theft, secondary use, and an increase in spam because their
information was shared or sold. Therefore, the perception of personal information
privacy violations may not be worth the exchange for information, free drug sample, or
coupon. Furthermore, Pratt and Conger (2009) noted that it is important to understand the
information sharing practices of companies.
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Identity theft continued to be the primary concern for 11 consecutive years (Lane
& Sui, 2010; Racolta-Paina & Luca, 2010; Wu et al., 2011). In 2009, there were 11.1
million cases of reported identify theft (Moore, 2010). Consumers will attempt to
mitigate this threat by falsifying information to avoid providing legitimate personal
information (O’Connor, 2007). In addition, consumers also provide a secondary email
address to mitigate receipt of spam to their primary email address. Consumers receive
2,500 spam emails annually (Bhuleskar, Sherlekar, & Pandit, 2009). Given the continued
growth of information sharing by companies, there seems to be no relief in sight. While
consumers benefit from falsifying information, there is a negative impact on the accuracy
of company information, which also has financial impacts (O’Connor, 2007; Poddar et
al., 2009). Data inaccuracy is a $600 billion annual cost due to unnecessary postage,
printing, and staff overhead (Poddar et al., 2009). Therefore, companies must find a
balance between information disclosure benefits and personal information privacy
(Christiansen, 2011).
Table 3
Summary of Information Sharing Literature
Study

Methodology

Sample

Instrument or
Construct

Main Finding or
Contribution

Anton et al.,
2010

Empirical
study via
survey

2094
Internet
users in
and
outside of
the US

Privacy concerns of
personalization,
notice/awareness,
information transfer,
information
collection,
information storage,
and
access/participation

The top concern for
both U.S. and non-U.S.
respondents was
information transfer.
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Table 3
Summary of Information Sharing Literature (continued)
Study

Methodology

Bhuleskar et
al., 2009

Literature
review and
proposal

Christiansen,
2011

Standard

Lanier &
Saini, 2008

Literature
review and
analysis

Lane & Sui,
2010

Jaisingh et al.,
(2008)

Sample

Instrument or
Construct

Main Finding or
Contribution

Spam filtering
techniques

Summarized spam
filtering techniques
and proposed a hybrid
filtering technique.

Personal privacy
and Internet
marketing

Consumer
privacy
articles
published
from 1989
to 2007 in
academic
journals

Provides an overview
of technology and
personal privacy in
marketing along with
recommendations for
the marketing and
government industries.

Conceptualization of
consumer privacy,
consumer related
privacy issues, firm
related privacy
issues

There is an opportunity
for more theoretically
driven research to
develop a model that
identifies the domain
of consumer privacy
including the
relationships,
antecedents and
consequences.

Literature
review and
synthesis

Identify theft
patterns

Identify theft crimes
are higher in the
southwestern states
and lower in the New
England and northern
plain states.

Literature
review and
synthesis

Privacy

When the benefits of
personalized products
or services are less
than the privacy loss,
companies should
consider not collecting
consumer information.
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Table 3
Summary of Information Sharing Literature (continued)
Study

Methodology

Moore, 2010

Standard

O’Connor,
2007

Empirical
study via
experiment

Poddar et al.,
2009

Pollach, 2007

Pratt &
Conger, 2009

Instrument or
Construct

Main Finding or
Contribution

Cybercrime

Summarizes
cybercrime issues and
risks to organizations
and the use of the
COSO framework to
identify risks.

97 hotel
Websites

Fair Information
Practices

No website fully
complies with the Fair
Information Practices.

Empirical
study via
interviews

21
Internet
users

Information
exchange

Consumers are
challenged with
maintaining control of
their online identities
and lacked trust of
how their information
is being managed
online.

Empirical
study via
experiment

50
commercial
Websites

Privacy concerns,
data collection, data
storage, data
sharing, unsolicited,
marketing
communications

The privacy policy
content is more
focused on mitigating
lawsuits rather than
addressing consumer’s
privacy concerns.

Personal
information privacy

Privacy violations are
still occurring despite
legal and selfprotection policies.

Literature
review and
synthesis

Sample

50

Table 3
Summary of Information Sharing Literature (continued)
Study

Methodology

Sample

Instrument or
Construct

Racolta-Paina
& Luca, 2010

Literature
review and
synthesis

Roberts, 2009

Empirical
study via
telephone
survey

1167
adults
nationwide

Privacy concerns:
right to privacy,
data collection,
threat to privacy,
federal government
regulation

Consumers are
concerned about data
collection practices,
identify theft and feel
that more regulation is
necessary from the
federal government.

Wu, Lau et
al., 2011

Literature
review and
analysis

Legal
Government,
documents institution, citizens
along with
blogs and
black
board
systems

China consumers are
less aware than U.S.
consumers that
technology can be
used to protect against
online privacy
violations.

Zimmer et al.,
2010

Empirical
study via
experiment

264
business
management
students

There is a relationship
between intent to
disclose and disclosure
behavior.

Online consumer
characteristics and
behaviors

Intent to disclose,
dyadic relationship

Main Finding or
Contribution
Describes the
importance of the
online consumer in the
21st century along with
their characteristics
and behaviors.

Consumer Control
Another top concern of consumers is loss of control (Cromer, 2010; Hough, 2009;
Poddar et al., 2009). Zuo and O’Keefe (2007) contended that “to honor individuals’
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rights over their personal information, privacy protection should ensure that individuals
could exercise control over the accuracy, completeness, timeliness, use, distribution, and
disposition of their personal information” (p. 452). Culnan and Armstrong (1999) noted
that consumers perceived they had lost the ability to control the use and distribution of
their personal information. Once consumers disclose their information, they have ceded
their rights to the company (Zuo & O’Keefe, 2007). However, consumers still expect to
maintain control of how their information will be used and distributed with the intention
of mitigating threats such as secondary use, identity theft, and spam. Belanger and
Crossler (2011, p. 1017) indicated that 85% of those surveyed expressed the need to
control information access. Culnan and Armstrong (1999) noted that consumers are less
likely to perceive their personal information privacy has been violated if they are able to
control the use of their information. Companies address this concern by providing the
ability to opt-in or opt-out of originating or third party communications. Consumer
choice is also one of the principles of the FIPs that stated that consumers should be given
the opportunity to control their information. To opt-out of communications or
information distribution “consumers can remove their names from a list by checking a
box on a form provided by the marketer or by calling or writing the marketer” (Milne &
Rohm, 2000, p. 238). The DMA prefers the opt-out approach because the consumer
consent is implicit until a request for removal is received (Clarke et al., 2005). To the
contrary, opt-in is the recommended approach by the European Union Data Directive
(Lai & Hui, 2006). This approach requires that “consumers must give permission before
marketer can use their personal information” (Milne & Rohm, 2000, p. 238). With this
approach, information cannot be sent or disclosed unless the consumer provides consent.
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This approach would be detrimental to companies who specialize in selling consumer
information because they would be relying on voluntary consent (Hough, 2009). Even
though some companies provide the ability to opt-out or opt-in, Milne and Rohm (2000)
noted that these options are often intentionally invisible on Websites. O’Connor’s (2007)
examination of hotel Websites indicated hotels lacked principles of choice, access, and
the security of information transferred to third parties. In addition, 38% of the Websites
did not provide consumers with a choice to opt-in or opt-out of third party disclosure
(O’Connor, 2007, p. 195). Furthermore, consumers’ ability to control third party
communications was 62%, compared to 49% for the originating company
communications (O’Connor, 2007, p. 195). This implied that the originating company
provided less control over consumer communications (O’Connor, 2007). In this
situation, consumers could be more at risk for personal information violations by the
originating company than by third parties. Even though consumers are concerned about
secondary use, their concern is not only applicable to external use but internal use as
well.
Ford (2005) noted that it has been estimated that “more than 13 billion spam
messages are sent per day” (p. 355), which cost U.S. companies approximately 10 billion
dollars a year. Spam can be very frustrating and trigger consumer reactions such as
distrust and ceasing further interaction with that company. Because spam was recognized
as a significant problem and efforts to control it have been ineffective, in 2003, Congress
passed the CAN-SPAM Act, which provides legislation for email regulations. It is
important to note that this law does not prohibit spam, but provides content specifications
and supports the opt-out approach (Clarke et al., 2005).
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Table 4
Summary of Consumer Control Literature
Study

Methodology

Belanger &
Literature
Crossler, 2011 review and
analysis

Clarke et al.,
2005

Literature
review and
synthesis

Cromer, 2010

Empirical
study via
secondary
data and
survey
Empirical
study via
secondary
data analysis

Culnan &
Armstrong,
1999

Sample

Instrument or
Construct

Main Finding or
Contribution

142 journal
articles, 102
conference
proceedings

Information privacy Summarizes the
current state of
information privacy
research and provides
recommendations for
future research.
CAN-SPAM Act

Summarizes the CANSPAM Act law and
the sales implications.

2,126 online
consumers,
482 online
consumers

Adaptive behavior,
Internet experience,

Consumers use selfefficacy to regulate
Internet use and
adaptive behaviors to
mitigate online risk
concerns.

1,000 U.S.
adults 18
years or
older

Information privacy
concerns,
procedural fairness,
impersonal trust

Companies can
increase customer
retention by
recognizing
procedural fairness.

risk concern

Ford, 2005

Literature
review and
analysis

CAN-SPAM Act

Summarizes the
preemption of the state
spam laws by the
CAN-SPAM Act.

Hough, 2009

Literature
review and
analysis

Loss of control

Summarizes the facets
of privacy, control
preservation, and how
technology contributes
to a loss of consumer
control.

54

Table 4
Summary of Consumer Control Literature (continued)
Study

Methodology

Sample

Lai & Hui,
2006

Empirical
study via
experiment

68 undergraduate
students

Instrument or
Construct
Frames, defaults,
privacy concern

120 undergraduate
student

Main Finding or
Contribution
Different phrasing of
consumer choice and
default preferences for
opt-in or opt-out
influences consumer
participation.

Milne &
Rohm, 2000

Empirical
study via
survey

1508
adults

Awareness of
information
capture, knowledge
of name removal
mechanisms

Consumers are
unaware of data
collection practices
and name removal
mechanisms.

O’Connor,
2007

Empirical
study via
experiment

97 hotel
Websites

Fair Information
Practices

No website fully
complies with the Fair
Information Practices.

Poddar et al.,
2009

Empirical
study via
interviews

21
Internet
users

Information
exchange

Consumers are
challenged with
maintaining control of
their online identities
and lacked trust of
how their information
is being managed
online.

Zuo &
O’Keefe,
2007

Literature
review and
analysis

Information Privacy Introduced a set of
Protection
information privacy
protection models to
reduce the information
flow to provide
consumers with
greater control of
information
disclosure.
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Social Exchange Theory
The theoretical foundation for this research draws on the social exchange theory
(SET). The context of the SET is that there is a voluntary exchange between multiple
parties. Homans (1958) noted that “persons that give much to others try to get much from
them, and persons that get much from others are under pressure to give much to them” (p.
606). This theory posits that consumers engage in a “privacy calculus” where they assess
information disclosure against the expected benefits (Emerson, 1976). During the
assessment, consumers evaluate if their information will be used ethically and if they will
not suffer negative consequences from information disclosure (Culnan & Armstrong,
1999; Xu, 2009). Yang and Wang (2009) used the SET to examine cost-benefit effects
on privacy concern and behavioral intention. Yang and Wang (2009) found that privacy
concern has a negative effect on information disclosure but a positive effect on privacy
intention. In order to make an informed decision, the consumer should have prior
knowledge of companies’ information practices (Milne & Rohm, 2000; Xu, 2009).

Table 5
Summary of Social Exchange Theory Literature
Study

Methodology

Instrument or
Construct

Main Finding or
Contribution

Homans, 1958 Theoretical

Social Behavior

Describes the concept
of social behavior as
an exchange of goods.

Emerson,
1976

Social Exchange
Theory

Provides an overview
of the Social
Exchange Theory.

Theoretical

Sample
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Table 5
Summary of Social Exchange Theory Literature (continued)
Study

Methodology

Sample

Instrument or
Construct

Main Finding or
Contribution

Culnan &
Armstrong,
1999

Empirical
study via
secondary
data analysis

1000 U.S.
adults 18
years or
older

Information privacy
concerns,
procedural fairness,
impersonal trust

Companies can
increase customer
retention by
recognizing
procedural fairness.

Milne &
Rohm, 2000

Empirical
study via
survey

1508
adults

Awareness of
information
capture, knowledge
of name removal
mechanisms

Consumers are
unaware of data
collection practices
and name removal
mechanisms.

Xu, 2009

Theoretical

Information
exchange, social
contract,
information control

Privacy concerns
influence information
disclosure behavior.

Shopping Website
ethical
performance,
perceived ethical
performance of the
site, trusting belief,
trusting intention

Consumers can
distinguish between
good and bad ethical
websites.
Perceived ethical
performance may
increase consumer
trust in the website.

Yang &Wang, Empirical
2009
study via
experiment

238
Taiwan
undergrad
uate and
graduate
students

Composite Indices
There are certain phenomena that are too multifarious to express with an
individual indicator. According to Latuszynka (2012), the reputation of composite
indices has increased over the years, and researchers have begun to use composite indices
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to measure complex phenomena with multiple dimensions. Srebotnjak (2007) wrote,
“composite indicators are designed to measure a state, trend, or process that is the scope
of policy decisions” (p. 14). Latuszynka (2012) noted that “the most common application
of composite indices are currently classifications (primarily rankings of countries
performance) and forecasting (estimating market trends)” (p. 68). Saisana, Saltelli, and
Tarantola (2005) noted that the pros of composite indices are as follows;
§

Composite indicators can be used to summarize complex or multi-dimensional
issues, in view of supporting decision-makers.

§

Composite indicators provide the big picture. They can be easier to interpret
than trying to find a trend in many separate indicators. They facilitate the task
of ranking countries on complex issues.

§

Composite indicators can help attracting public interest by providing a
summary figure with which to compare the performance across countries and
their progress over time.

§

Composite indicators could help to reduce the size of a list of indicators or to
include more information within the existing size limit. (p. 307)

Saisana et al. (2005) further noted that the cons of composite indices are as follows:
§

Composite indicators may send misleading, non-robust policy messages if
they are poorly constructed or misinterpreted. Sensitivity analysis can be used
to test composite indicators for robustness.

§

The simple "big picture" results which composite indicators show may invite
politicians to draw simplistic policy conclusions. Composite indicators should
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be used in combination with the sub-indicators to draw sophisticated policy
conclusions.
§

The construction of composite indicators involves stages where judgment has
to be made: the selection of sub-indicators, choice of model, weighting
indicators, and treatment of missing scores, etc. These judgments should be
transparent and based on sound statistical principles.

§

There could be more scope for Member States about composite indicators
than on individual indicators. The selection of sub-indicators and weights
could be the target of political challenge.

§

The composite indicators increase the quantity of data needed because data
are required for all the sub-indicators and for a statistically significant
analysis. (p. 308)

In order to derive a composite index, the following four steps are required: (a)
variables that are correlated with the phenomenon must be selected, (b) variables must be
normalized and standardized, (c) weights must be assigned to each variable, and (d)
aggregation of information (Latuszynka, 2012; Muro, Mazziotta, & Paretto, 2011).
“Indicators should be aggregated and weighted according to the underlying theoretical
framework” (OECD/JRC, 2008, p. 15). Muro et al. (2011) noted that there are three
ways to aggregate the information: arithmetic mean, factorial analysis, and power mean
or adjusted mean. The arithmetic mean approach is “that the weights of the components
are completely arbitrary” (Muro et al., 2011, p. 5). Arithmetic mean has two approaches:
simple (non-weighted) mean and weighted mean. The simple mean approach “implies
that all the weights are equal and that all components (dimensions) are perfectly suitable”
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(Muro et al., 2011, p. 5). OECD/JRC (2008) noted that this approach could “disguise the
absence of a statistical or an empirical basis, e.g. when there is insufficient knowledge of
casual relationships or a lack of consensus on the alternative” (p. 31). In addition,
OECD/JRC (2008) contended that caution should be taken when variables are grouped in
dimensions, because some groupings “could result in an unbalanced structure in the
composite index” (p. 31). Moreover, OECD/JRC (2008) argued that an element of
double counting could be introduced when highly correlated variables are combined.
With the weighted mean, “the weights are not equal, this implies that the substitutability
between components is not perfect” (Muro et al., 2011, p. 5). Next, the factorial analysis
uses a statistical technique to assign the weights, rather than the researcher (Muro et al.,
2011). OECD/JRC (2008) noted that that this approach can be used to group indicators
based upon the extent of their correlation. Muro et al. (2011) stated that the factorial
analysis has two limitations. The first limitation is that because the weights are acquired
based upon the data, they are not stable over time and space, which can make it difficult
to compare results (Muro et al., 2011). Likewise, OECD/JRC (2008) stated that with
correlated based indicators, the estimation of the weights cannot occur if there is no
correlation. The second limitation is that weights are assigned “to the original variables
on the basis of their variance and covariance” (Muro et al., 2011, p. 5). The last approach
to aggregate information is the power mean, which assigns greater weight on the lower
developed dimensions (Muro et al., 2011). Likewise, the adjusted mean “adjusts the
arithmetic mean by using a penalty coefficient or function” (Muro et al., 2011, p. 5).
This research study will create the PIPVI composite index based upon indicators
identified from a review of literature that will also be validated by an expert panel. Next,
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the weight assignment approach was used and based upon the mean response from the
expert panel. Finally, the aggregation was also conducted using the weighted mean
approach.

Table 6
Summary of Composite Indices Literature
Study

Methodology

Latuszynka,
2012

Literature
review and
analysis

Composite indices

Provides an overview of
incorporating dynamic
rankings of measured
items and using
composite indices to
measure the complex
phenomena.

Muro et al.,
2011

Literature
review and
proposal

Composite indices

Provides a proposal for a
new composite index.

OECD/JRC, standard
2008

Composite
indicators
construction guide

Provides an overview of
constructing and using
composite indicators.

Saisana et
al., 2005

Composite
indicators

Provides an overview of
composite indicators
advantages and
disadvantages along
with using uncertainty
and sensitivity analysis
to assess composite
indicators.

Composite
indicators

Composite indicators
provide a useful tool to
aggregate data for policy
considerations.

Srebotnjak,
2007

Literature
review and
synthesis

Sample Instrument or
Construct

Main Finding or
Contribution
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Delphi Expert Methodology
The Delphi expert methodology was “devised in order to obtain the most reliable
opinion consensus of a group of experts by subjecting them to a series of questionnaires
in depth interspersed with controlled opinion feedback” (Dalkey & Helmer, 1963, p.
458). Because the expert panel feedback is not elicited face to face, this eliminates direct
disagreement among the expert panel (Dalkey & Helmer, 1963; Jain, 1985). Dalkey and
Helmer (1963) noted that the Delphi expert methodology’s objective is “to obtain the
most reliable consensus of opinion of a group of experts” (p. 458). Ramim and Lichvar
(2014) indicated that “the Delphi methodology is mainly used in the situation where
accurate information is unavailable and human judgment input is crucial” (p. 127).
Sarlak and Aliahmadi (2008) further stated that “the notion is that well informed
individuals, calling on their insights and experience, are better equipped to predict the
future than theoretical approaches or extrapolation of trends” (p. 1468). McCubbrey and
Taylor (2005) contended that the Delphi expert methodology includes the following nine
steps:
1. Define the problem – what is to be forecast and how will the results be used when
available.
2. Select knowledgeable and willing participants as a panel to respond to a
questionnaire. The participants do not know one another and never meet face to
face.
3. Structure the questionnaire.
4. Select the medium to be used to contact participants.
5. Send the questionnaire (Round 1).
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6. Compute the simple average of the results.
7. Send a 2nd questionnaire (Round 2).
8. Compute the average from the 2nd round results.
Send a 3rd round questionnaire (Round 3). (p. 476)
McFadzean, Ezingeard, and Birchall (2011) stated that the Delphi expert
methodology “ensures that the data collection process is both reliable and valid because it
exposes the investigation to differing, and often divergent, opinions and seeks
convergence through structured feedback” (p. 108).

Table 7
Summary of Delphi Expert Methodology Literature
Study
Dalkey &
Helmer,
1963

Jain, 1985

Methodology
Empirical
study via
survey using
the Delphi
Expert
methodology

Standard

Sample
7 panel
experts

Instruments or
Constructs

Main Finding or
Contribution

Factors that
The Delphi export
influence judgment methodology is beneficial
in providing preliminary.
Insights even though
predictions derived by
opinion consensus
may lack reliability.
Forecasting
methods

Provides a summary
of the Delphi expert
methodology process.
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Table 7
Summary of Delphi Expert Methodology Literature (continued)
Study

Methodology

Sample

Instruments or
Constructs

Main Finding or
Contribution

McCubbrey &
Taylor, 2005

Empirical
study via
survey using
the Delphi
expert
methodology

17 panel
experts

Effects of
electronic
commerce
technology

Delphi expert
methodology was
successful in
predicting the effects
that EC-enabled
disintermediation and
reintermediation
would have on
traditional travel
agents in the US.

McFadzean et
al., 2011

Empirical
study via
interviews and
the Delphi
expert
methodology

43 senior
managers,
36
academics

Information
assurance,
information
systems,
corporate
strategy

Information assurance,
information systems,
and corporate strategy
alignment is essential
to organizational
success.

Sarlak &
Aliahmadi,
(2008)

Empirical
study via
survey using
the Delphi
expert
methodology

25 panel
experts

Trust factors

Online and virtual
universities must
recognize factors
effecting student trust.

Summary of What is Known and Unknown
A review of various aspects of personal information privacy was conducted to
provide the foundation for this research study. Through this review of the literature, the
constructs of privacy policy, information sharing, and consumer control were identified
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as they relate to personal information privacy violations. The literature review provides a
description of what is known and unknown about the constructs in this research study.
Research regarding personal information privacy extended across fields including IS,
marketing, and business.
Companies have benefited tremendously from the progression of technology by
being able to easily integrate and aggregate information to create consumer profiles for
targeting marketing (Jaisingh et al., 2008; Lanier & Saini, 2008; Rapp et al., 2009; Xu,
2009). However, this capability has also facilitated the growth of PIPV. Belanger and
Crossler (2011), as well as Vlasic (2006), stated that consumers are not aware of the
various information collection practices of companies. Due to continued media attention
regarding personal information privacy violations and consumers’ perceptions of identity
theft and spam, consumers are concerned about information management and use by
companies (Roberts, 2009; Zimmer et al., 2010).
Based upon studies by the FTC (1998, 2000) and the lack of privacy policies on
Websites, the FTC recommended that companies adhere to the FIPs. However, research
continued to illustrate that companies were still not adhering to this recommendation
(O’Connor, 2007; Sheehan, 2005; Storey et al., 2009). It is important to note that the
self-regulation instead of the legislative approach could be seen as a contributor since the
adherence and monitoring is voluntary. Storey et al. (2009) noted companies are aware
that they cannot be held accountable for privacy practices that have not been stated.
Furthermore, even though some companies have implemented privacy policies and
adhere to the FIPs, this does not guarantee the actual practices will align with the stated
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practices (Schwaig et al., 2005; Sheehan, 2005). In this respect, there is limited empirical
research that has examined the stated practices against the actual practices.
Two of the top consumer concerns are loss of information control (Cromer, 2010;
Hough, 2009; Poddar et al., 2009) and the information sharing practices of companies
(Anton et al., 2010; Lanier & Saini, 2008; Pollach, 2007). Consumers have continued to
express that they have lost control when interacting with Websites. Even though
companies have attempted to address this concern by providing opt-out and opt-in
capabilities, these options are not always easily accessible (Milne &Rohm, 2000). Most
companies implement the opt-out approach because the consumer will remain on the
email list and information can be shared until a request for removal is initiated.
Otherwise, with the opt-in approach, the company cannot send communications or share
information until the consumer provides consent. Spam statistics continued to
demonstrate that companies’ participation in information sharing remained persistent
(Bhuleskar et al., 2009; Ford, 2005). However, there are limited empirical studies that
have examined the magnitude of information sharing practices. Pratt and Conger (2009)
noted that it is essential to understand the information sharing practices of companies.
The constructs of privacy policy (O’Conner, 2007), information sharing (Jafarr &
Abdullat, 2009), and consumer control (Pollach, 2007) have been found to be
contributors of PIPV. Very limited empirical studies have been located with a
comprehensive view of these constructs in a single study. Therefore, more research is
warranted to examine privacy policies, information sharing, and consumer control to
determine their contribution to PIPV.
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To assess the constructs above, this research study will focus on pharmaceutical
companies’ Websites. Consumers have begun to take a more active role in their
healthcare and have increased their use of the Internet to obtain information. In
particular, the use of pharmaceutical websites has significantly increased over the years
(Hoy & Park, 2014; W. J. Kim & King, 2009). Because of this phenomenon, consumers
are exposed to potential personal information violations when interacting with these
Websites. These Websites offer registration for newsletters, rebates, discount cards, and
drug samples, which are all beneficial to consumers. In order to obtain these benefits,
consumers must disclose information. However, consumers concerns are heightened
when interacting with health related Websites due to the sensitivity of the information. In
addition, it is believed that potential inferences could be made based upon information
disclosed and possibly used against the consumer for other purposes, such as employment
or health care coverage decisions (Bansal et al., 2010). Therefore, assessing the privacy
policy, information sharing, and consumer control of pharmaceutical companies may
provide a better understanding of their contribution to PIPV.

Contributions of Research Study
This research study made several contributions to the information privacy domain
and body of knowledge. The main contribution of this research study was to advance the
awareness of PIPV. First, empirical evidence was provided regarding the magnitude of
voluntary adherence to the Fair Information Practices by pharmaceutical companies.
This evidence is important to regulators and associations to assist with understanding the
effectiveness of self-regulation. Second, this research study provided insight into the
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documented and actual online practices of pharmaceutical companies that contribute to
personal information privacy violations. Assessment of the documented and online
practices in one study validated whether companies are actually adhering to their
documented practices. Differences based upon condition type, registration type,
headquarters country/region, company size, annual revenue, years in service, and PII
collection was also examined. Third, companies can use the PIPVI benchmarking
instrument to perform a self-assessment of their Website documented and online
practices. Last, given the heightened concerns of consumers regarding personal
information privacy, the results of this research study provided consumers with empirical
evidence of how their information is managed and used by pharmaceutical companies. A
high magnitude of personal information privacy violations could negatively impact
consumers’ trust, concerns, and interactions with the Websites, which could continue to
constrain the growth of e-commerce.
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Chapter 3
Methodology
Overview
Research Design
This research study was conducted in three phases, as shown in Figure 2. The first
phase developed the PIPVI benchmarking instrument that was used to assess the
documented and online practices of Websites. Ellis and Levy (2009) noted that
“developmental research attempts to answer the question: How can researchers build a
‘thing’ to address the problem?” (p. 326). Developmental research should include three
critical components (Ellis & Levy, 2009). First, “establishing and validating criteria the
product must meet” (Ellis & Levy, 2009, p. 326). Reviewing and establishing the criteria
of DPPP, OPIS, and OPCC from literature on this topic met this critical component.
Second, “follow a formalized, accepted process for developing the product” (Ellis &
Levy, 2009, p. 326). This second component was met by creating a set of questions from
literature that was used to develop the PIPVI benchmarking instrument. In phase one, an
expert panel using the Delphi expert methodology evaluated the draft of the PIPVI
benchmarking instrument. For this expert panel, at least 35 individuals from academia
and practitioners in the field of information security and privacy, as well as corporate
social responsibility, were solicited to participate from professional contacts with those
associated to this project and membership in professional societies. In addition, a
message was posted to LinkedIn contacts and Information Security Groups. After
consensus was achieved through several iterations with the expert panel, the feedback
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was incorporated to create the final PIPVI benchmarking instrument. The last component
is “subjecting the product to a formalized, accepted process to determine if it satisfies the
criteria” (Ellis & Levy, 2009, p. 326). To satisfy this component, the expert panel was
requested to evaluate the documented and online practices criteria, as well as assess the
relative importance of each criterion in DPPP, OPIS, and OPCC. The relative importance
of each criterion within each measure (DPPPM, OPISM, & OPCCM), along with the
relative importance of the measures, was aggregated to develop the PIPVI.

Figure 2: Research Methodology
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In phase two of this research study, the final PIPVI benchmarking instrument was
used to collect data from pharmaceutical Websites that market chronic and non-chronic
prescription medications directly to consumers. This research study occurred over a fivemonth time period with no interventions. The time delay is necessary to observe and
collect data from the companies’ practices over a period of five months to enable the
assessment of spam, secondary use, and information sharing. O’Connor (2007) and White
(2010) used a time delay. For example, O’Connor (2007) collected data for one year to
assess secondary use of information by registering for newsletters, competitions, and
loyalty programs on 97 hotel Websites.
To assess the pharmaceutical company’s DPPP, a copy of the privacy policy was
downloaded and analyzed against the FIPs using assessments by Culnan (2000), FTC
(2000), O’Connor (2007), Schwaig et al. (2005, 2006), Sheehan (2005), and Storey et al.
(2009) as the foundation for development of the PIPVI benchmarking instrument. The
aforementioned studies used a survey instrument with a binary coding scheme that was
used in this research study to represent the presence or absence of each criterion with
levels: no (0) and yes (1). It is important to note that the questions for this research study
for these criteria were structured such that a response of yes indicated a violation.
Registration for a newsletter, update, discount, or support program was initiated
with a unique name and email address for each Website to assess the types of PII
collected, OPIS, and OPCC. It is important to note that where applicable, multiple
registrations per Website were initiated with a unique name and email address if the
Website allowed registration for different activities. For example, some Websites allowed
registrations for both updates and discounts. In addition, multiple Website registrations
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occurred with different selections for opt-in/opt-out selections for secondary use and third
party sharing, as well as the patient or caregiver. The use of a unique name and email
address for each registration maintained data integrity to facilitate accurate descriptive
metrics for each pharmaceutical company Website. Otherwise, it would have been a
potential challenge to determine accurate metrics for the origination of emails to assess
OPIS for each pharmaceutical company Website. To assess OPIS, the number of emails
received from the originating company, third parties, phone calls, and text messages were
aggregated. The Website registrations provided empirical evidence of the actual OPIS.
The assessment criteria by O’Connor (2007) assessed the consumer’s ability to
access, modify, and delete his or her information. For example, an attempt was made to
view, modify, and delete the information provided during the Website registration
process. This validation provided evidence of the actual OPCC that was used to validate
against the DPPP. Because pharmaceutical companies required a request by email,
phone, or mail to delete personal information, this validation was beyond the scope of
this research study. Similar to the assessment of the DPPP, a binary response will be
recorded for each criterion with levels: no (0) and yes (1). It is important to note that the
questions for this research study for these criteria were structured such that a response of
yes indicated a violation.
To validate the documented practices against the actual online practices, the
choice and access criteria from the DPPP and OPCC were assessed. These criterions
were evaluated to determine if pharmaceutical companies are actually adhering to their
documented practices. Given the nature of security and the inability to assess, the actual
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practices for security are beyond the scope of this research study. Therefore, security
will only be assessed within the DPPP and not the actual online practices.
Phase three of this research study included both the pre-analysis data screening
and data analysis from the data collected using the PIPVI benchmarking instrument. The
results of the data analysis were used to develop the comparison reports to address the
eight research questions and three null hypotheses. The comparison report also included
a graphical representation where appropriate.
This research study required approval from the Institutional Review Board (IRB)
because human subjects were involved for the expert panel. The PIPVI benchmarking
instrument elicited general demographics from the respondents. However, the responses
were anonymous to ensure that no PII was collected.

Instruments and Measures
Instrument Development
Two instruments were developed for this research study. The first instrument was
developed to elicit responses from the expert panel. This instrument elicited responses to
assess the validity of the content for the criteria and measures identified, provide weight
allocations of the relative importance for the criteria within DPPP, OPIS, OPCC, and the
weight allocation of the relative importance for the DPPP, OPIS, and OPCC measures
themselves that were used to develop the PIPVI. The second instrument developed was
the PIPVI benchmarking instrument that was used to collect data about the documented
and online practices of the pharmaceutical companies’ Websites. This instrument was
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developed based upon the feedback from the expert panel using the Delphi expert
methodology.
The Personal Information Privacy Violations Index Expert Panel Instrument in
Appendix B was administered using SurveyMonkey®, which is a web-based tool that
collects anonymous responses from the expert panel. The respondents of the expert panel
received a message with the details of the research study and an invitation to participate.
In an effort to elicit additional respondents, a message was also posted to LinkedIn
contacts and Information Security groups.
The PIPVI benchmarking instrument, as depicted in Appendix A, was developed
to collect data from pharmaceutical companies’ Websites to measure the contribution of
DPPP, OPIS, and OPCC on personal information privacy violations. This instrument
was also created using Microsoft Word® to facilitate data collection from the
pharmaceutical companies’ Websites. The items for measurement in the PIPVI
benchmarking instrument were a minimally modified version derived from prior pertinent
studies (Culnan, 2000; FTC, 2000; O’Connor, 2007; Schwaig et al., 2005, 2006;
Sheehan, 2005; Storey et al., 2009) along with feedback from the expert panel using the
Delphi expert methodology. The instruments used in those studies included as many as
31 items with a nominal scale, which was the approach that was adopted for this research
study. Inter-rater reliability was used by the aforementioned studies to evaluate the
reliability and validity of the instruments with estimates between .89 and 1, which is
considered to be reliable. According to Creswell (2002), inter-rater reliability means that
“two or more individuals observe an individual’s behavior and record scores, and then the
scores of the observers are compared to determine whether they are similar” (p. 182).
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Documented Practices of the Privacy Policy Measure
The DPPP construct was measured using items to assess the pharmaceutical
company’s privacy policy adherence to the FIPs. Notice, choice, security, and access are
the four principles by which the privacy policy was assessed using a nominal scale with
levels: no (0) and yes (1). The questions were structured such that a yes response
indicated a violation. The items used to measure DPPP were derived from FTC (2000),
O’Connor (2007), Schwaig et al. (2006), Sheehan (2005), and Storey et al. (2009), whose
items were structured such that a yes response indicated the presence of the item. First,
notice was measured using five items to assess the communication of the pharmaceutical
company’s Website information collection practices. Second, choice was measured using
four items to assess the pharmaceutical company’s Website practice for consumer’s
ability to control future communications and information disclosure to third parties.
Third, access was measured using three items to assess the pharmaceutical company’s
Website ability to enable consumers to retrieve and modify their information. Last,
security was measured using two items to assess the pharmaceutical company’s
information protection practices.
Online Practices of Information Sharing Measure
The OPIS construct was measured using items to assess the pharmaceutical
company’s Website actual practices for information sharing using a ratio scale to capture
the actual volume of emails and postal mail received. According to Sekaran (2003), ratio
scale is “a scale that has an absolute zero origin, and hence indicates not only magnitude,
but also the proportion of the differences” (p. 422). The items used to measure OPIS
were derived from O’Connor (2007), whose items to measure the actual online practices
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were structured such that a yes response indicated the presence of the item. To the
contrary, instead of assessing the presence of information sharing, this research study will
assess the actual volume of data received online, through postal mail, phone calls, and
text messages from the pharmaceutical company, as well as third parties. The volume of
additional communications from the pharmaceutical company unrelated to the original
request to represent internal information sharing or secondary use of information was
measured with two items. Similarly, two additional items were used to measure the
volume for actual receipt of communications from third parties.
Online Practices of Consumer Control Measure
The OPCC construct was measured using items to assess the pharmaceutical
company’s actual practices for allowing the consumer to control receipt of future
communications from the original company and third parties. Choice and access were
assessed using a nominal scale with levels: no (0) and yes (1). The questions were
structured such that a yes response indicated a violation. FTC (2000), O’Connor (2007),
Schwaig et al. (2006), Sheehan (2005), and Storey et al. (2009) included items in the
DPPP construct to measure the pharmaceutical company’s stated policies for choice and
access, which represents the consumer’s ability to control distribution and access to their
information. For this research study, the items were slightly modified to capture
responses for the actual consumer control practices of choice and access. O’Connor
(2007) measured the actual practices of choice and access of hotel Websites such that a
yes response indicated the presence of the item. This research study followed the same
approach for consumer control that was measured using four items to assess the
pharmaceutical company’s actual practice for allowing consumers to control receipt of
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future communications from original company and third parties. In addition, three items
were used to measure the consumer’s ability to access their personal information.
Documented Practices versus Actual Online Practices
The documented versus the actual OPCC was measured using items from the
DPPP to assess the pharmaceutical company’s adherence to their stated practices. Choice
and access were assessed using a nominal scale with levels: no (0) and yes (1). The
questions were structured such that a yes response indicated a violation. Choice was
measured using four items to assess the pharmaceutical company’s Website practice for
the consumer’s ability to control future communications and information disclosure to
third parties. Last, access was measured using three items to assess the pharmaceutical
company’s Website ability to enable consumers to view, modify, or delete their
information.
Pharmaceutical Company Demographics
This research study collected demographics about each pharmaceutical
company’s Website. Consistent with Sheehan (2005) and Macias and Lewis (2003), the
pharmaceutical company demographics included the pharmaceutical company name,
headquarters country/region, company size, annual revenue, years in existence. The
demographics were used for descriptive statistics, such as frequencies and measures of
central tendencies. The pharmaceutical company demographic information was used to
demonstrate that the sample is representative of the population. Furthermore, the
demographics were used as control variables for the comparison reports.
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Reliability and Validity
Creswell (2002) stated that the reliability and validity of an instrument should
provide “an accurate assessment of the variable and enable the researcher to draw
inferences to a sample or population” (p. 180). The reliability and validity of a
measurement instrument is vital and is the first line of defense against inaccurate
conclusions (Salkind, 2006). Salkind (2006) further contended that “if the instrument
fails, then everything else down the lines fails, as well” (p. 106). McFadzean et al.
(2011) noted that the Delphi expert methodology “ensures that the data collection process
is both reliable and valid because it exposes the investigation to differing, and often
divergent, opinions and seeks convergence through structured feedback” (p. 108).
Therefore, to ensure validity and reliability, this research study elicited feedback from the
expert panel to verify that the criteria used to generate the measures were appropriate to
assess the documented and online practices.
Instrument Reliability
Creswell (2002) defined reliability as, “individual scores from and instrument
should be nearly the same or stable on repeated administrations of the instrument, they
should be free from sources of measurement error, and they should be consistent” (p.
180). Sekaran (2003) contended that reliability is important because it indicates the
extent of un-bias and is an indication of stability and consistency.
Validity
Validity is described as the ability to draw significant and valuable
generalizations from the survey scores (Creswell, 2002). Similarly, Salkind (2006)
asserted that validity indicated that the test or instrument measures correspond to the
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research intentions. Creswell (2002) defined validity as the researcher’s ability to “draw
meaningful and justifiable inferences from scores about a sample or population” (p. 185).
Sekaran (2003) also noted that “validity ensures the ability of a scale to measure the
intended concept” (p. 206). Creswell (2002) further contended that five factors can
hinder validity and the ability to draw valid conclusions: “(a) poorly designed studies; (b)
participant fatigue, stress, and misunderstanding of question on the instrument; (c)
inability to make useful predictions from scores; (d) poorly designed questions or
measures of variables; and (e) information that has little use and application” (p. 185).
Using previously validated instruments with minimal changes diminished the threat to
validity for this research study. According to Creswell (2002), there are three types of
threats to validity: internal, external, and construct.
Internal Validity
According to Straub (1989), “internal validity raises the question of whether the
observed effects could have been caused by or correlated with a set of unhypothesized
and/or unmeasured variables” (p. 151). In other words, Sekaran (2003) referred to
internal validity as “the confidence we place in the cause-and-effect relationship” (p.
149). Creswell (2002) and Sekaran (2003) noted that history, maturation, regression,
selection, mortality, testing, and instrumentation are seven major threats to internal
validity. History, maturation, regression, selection, and mortality are related to
participants in the study, while testing and instrumentation are related to the procedures
of the study (Creswell, 2002).
Both the history and maturation threats involve uncontrollable changes during the
length of the study that could influence the outcome (Creswell, 2002; Sekaran, 2003).
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The limited duration of five months for this research study will alleviate history and
maturation threats that could occur during a more elongated study. Regression and
selection entail researcher bias for participant selection that could influence the outcome
(Creswell, 2002; Sekaran, 2003). Creswell (2002) and Salkind (2006) agreed that
random selection of participants would increase internal validity. Therefore, regression
and selection were prevented by randomly selecting pharmaceutical companies’ Websites
that meet specific criteria. Mortality is the attrition of participants during the research
study (Creswell, 2002; Salkind, 2006; Sekaran, 2003). Because this research study
involves an expert panel using the Delphi expert methodology, mortality is a threat.
While it was not expected that 100% participation would be maintained through the
entire process, at least 25 respondents were expected.
As previously mentioned, testing and instrumentation are threats to internal
validity related to procedures of the research study. Testing poses a threat to internal
validity when participants are exposed to a pretest that could later influence the outcome
of the posttest (Creswell, 2002; Salkind, 2006; Sekaran, 2003). Testing was not a threat
for this research study because a pretest was not administered. Next, Salkind (2006)
stated that instrumentation is a threat because “when the scoring of an instrument itself is
affected, any change in the scores might be caused by the scoring procedure, rather than
the effects of the treatment” (p. 224). Therefore, this research study used the expert panel
survey for all iterations of the Delphi expert methodology to ensure consistency in
responses and standardization. This approach is supported by Creswell (2002), who
noted that “procedures should be standardized so that the same observational scales or
instrument is used throughout the experiment” (p. 327).
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External Validity
“Threats to external validity are problems that threaten drawing correct inferences
from the sample data to other persons, settings, and past and future situations” (Creswell,
2002, p. 327). Sekaran (2003) noted that eternal validity can be maximized by ensuring
experiment conditions are compatible to the situations targeted for generalizations. The
generalization of this research study was expected to increase because the study took
place in a non-contrived setting. For instance, registrations were initiated on the actual
pharmaceutical companies’ Websites to evaluate their documented and actual online
practices, thereby reducing the threat to external validity.
Instrument Validity
Straub (1989) contended that it is important to show evidence that the instrument
is measuring what it intends to measure. Straub (1989) added that an unrepresentative
instrument would yield uncertain results. There are two types of validation used to
establish credibility of results: content and construct (Creswell, 2002; Salkind, 2006;
Sekaran, 2003; Straub, 1989). According to Creswell (2002), “content validity is the
extent to which the questions on the instrument and the scores from the questions are
representative of all the possible questions that could be asked about the content or skills”
(p. 184). Creswell (2002), Sekaran (2003), and Straub (1989) indicated that a panel of
judges or experts could be used to validate the instrument content. Hence, this research
study solicited feedback from an expert panel using the Delphi expert methodology to
validate the instrument content.
Construct validity is considered by Creswell (2002) as “a determination of the
significance, meaning, purpose, and use of scores from an instrument” (p. 184). Straub
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(1989) contended that construct validity “asks whether the measures chosen are true
constructs describing the event or merely artifacts of the methodology itself (p. 150).
Straub (1989) recommended that “researchers should use previously validated
instruments wherever possible, being careful not to make significant alterations in the
validated instrument without revalidating the instrument content, constructs, and
reliability” (p. 161). Therefore, where appropriate, this research study used previously
validated constructs from prior research (Culnan, 2000; FTC, 2000; O’Connor, 2007;
Schwaig et al., 2005, 2006; Sheehan, 2005; Storey et al., 2009).

Population and Sample
The unit of analysis for this research study was the assessment results from the
pharmaceutical companies’ Website registrations. The sample population included
pharmaceutical companies Websites headquartered in and outside of the US that provide
information about prescription drugs. The sample included Websites for prescription
medications to treat the following chronic and non-chronic conditions: allergies, birth
control, blood pressure, cholesterol, diabetes, erectile dysfunction, estrogen, frequent
urination, infertility, menopause, peyronie’s disease, prostate, and testosterone. A total of
100 Website registrations across 53 Websites of 25 pharmaceutical companies were used
for this research study using a convenience sampling. Creswell (2002) noted that “in
convenience sampling the researcher selects participants because they are willing and
available to be studied” (p. 167). In this research study, the 100 Website registrations of
pharmaceutical companies were selected based upon an extensive Internet search of
available Websites. Sekaran (2003) indicated that “ample sizes larger than 30 and less
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than 500 are appropriate for most research” (p. 295). Sekaran (2003) further noted that
“in multivariate research (including multiple regression analyses), the sample size should
be several times (preferably 10 times or more) as large as the number of variables in the
study” (p. 295). Based upon Sekaran’s (2003) recommendation, a minimum sample size
of 30 may be sufficient for a study with three independent variables.
The pharmaceutical companies Websites sample was derived from Marcias and
Lewis (2003) and Sheehan (2005) samples, supplemented with randomly selected
Websites. To be selected, the pharmaceutical company’s Website must have met the
following criteria: (a) advertise pharmaceutical drugs in the US; (b) present information
for a prescription drug; (c) have the capability to register for a newsletter, rebate, discount
card, drug sample or support program; and (d) not provide the ability to purchase the
prescription drug such as an online pharmacy. Table 8 represents the pharmaceutical
companies Website registration demographics by headquarters country/region.
Table 8
Pharmaceutical Companies Website Registrations by Headquarters Country/Region
Company

Website

Registration

Headquarters
Country/Region

n

%

N

%

n

%

Asia

2

8%

5

9%

8

8%

Europe

6

24%

17

32%

37

37%

United Kingdom

1

4%

4

8%

5

5%

United States

16

64%

27

51%

50

59%

Totals

25

100%

53

100%

100

100%
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Pharmaceutical Company Demographics
Twenty-five pharmaceutical companies were examined. The
pharmaceutical companies were headquartered in Asia, Europe, UK, and the US.
The revenue for the companies ranged from less than $1 million (2, 8%) all the
way to $51 - $100 billion (4, 16%), and ranged in employees from less than 100
(2, 8%) to over 100,000 (4, 16%). The most common headquarters
country/region was the US (16, 64%). Table 9 presents frequencies and
percentages for demographics for the pharmaceutical companies.

Table 9
Pharmaceutical Companies Demographics
Demographic

n

%

Less than 1 million

2

8%

1 - 50 million

6

24%

51 - 100 million

3

12%

101 - 500 million

2

8%

501 - 999 million

2

8%

1 - 50 billion

6

24%

51 - 100 billion
Note. n=25.

4

16%

Annual Revenue
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Table 9
Pharmaceutical Companies Demographics (continued)
Demographic

n

%

Less than 100

2

8%

100 – 1000

8

32%

1001 - 25,000

7

28%

25,001 - 50,000

2

8%

75,001 - 100,000

2

8%

4

16%

Company Size

Over 100,000
Note. n=25.

Pre-Analysis Data Screening
Mertler and Vannatta (2010) contended that pre-analysis data screening is
necessary and must be addressed prior to the statistical analysis. Levy (2006) noted that
“pre-analysis data preparation deals with the process of detecting irregularities or
problems with the collected data” (p. 150). Levy (2006) asserted that there are four
primary purposes for pre-analysis data screening: data collection accuracy, response set,
missing data, and outliers. After these issues have been addressed, “the researcher can be
confident that the main analysis will be an honest one, which will ultimately result in
valid conclusions being drawn from the data” (Mertler & Vannatta, 2010, p. 25). This
research study used SurveyMonkey®, a Web-based tool, to facilitate data collection
accuracy for the expert panel survey and Microsoft Word® for the PIPVI data collection
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form. The expert panel survey and the PIPVI data collection form elicited binary and
minimal continuous responses to prevent inconsistent responses.
Because this empirical developmental study examined several aspects of
documented and online practices, it is imperative that the data collection is accurate.
Inaccurate data collection can result from date entry or script errors (Levy, 2006).
Mertler and Vannatta (2010) noted that “the results of any statistical analysis are only as
good as the data analyzed” (p. 25). If the data collection is inaccurate, the results will be
misrepresented because it is difficult to discern if the results are invalid since results will
appear to be legitimate (Mertler & Vannatta, 2010). Therefore, the results collected were
reviewed several times to validate data collection and accuracy. In addition, to determine
the data accuracy, the data collected was examined using data frequency distributions,
and descriptive statistics using Statistical Package for the Social Sciences (SPSS®), as
recommended by Mertler and Vannatta (2010).
Another issue that may have arisen during data collection was response set. Levy
(2006) defined response set as, “cases where respondents submitted the same score for all
items” (p. 151). Because this research study involved an expert panel, response set is
valid for this research study. If response set was detected, the data was examined to
validate the responses and take the appropriate action, which may include excluding the
response set from the sample.
Missing data is another issue that must be addressed during data collection. The
data collected from the expert panel survey and PIPVI data collection form was examined
for missing responses to ensure that each question had been completed. Levy (2006)
noted that “the amount of missing data can significantly affect the validity of the data
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collected and the results drawn from it” (p. 151). Because a Web-based tool was used to
capture responses from the expert panel survey and PIPVI data collection form, missing
scores are not expected.
Identifying outliers during data collection was another issue that was addressed
during pre-analysis data screening to prevent cases that would potentially distort results
(Levy, 2006; Mertler & Vanata, 2010). Mertler and Vannatta (2010) defined outliers as
“cases with unusual or extreme values at one or both ends of a sample distribution” (p.
27). Because the responses were binary and open-ended, outliers for both the expert
panel survey and PIPVI data collection form are not expected.

Data Analysis
Data analysis was conducted on two data sets. The first data set represents data
collection from the phase one expert panel survey responses. The second data set from
the PIPVI data collection form represents scores collected from 100 Website registrations
that market chronic and non-chronic companies prescription medications. As previously
mentioned, the expert panel survey was completed using the Web-based tool
SurveyMonkey® and Microsoft Word® for the PIPVI data collection form.
Six types of analyses were conducted to assess the eight research questions and
three hypotheses: frequencies and percentages, factorial analysis of variance (ANOVA),
factorial analysis of covariance (ANCOVA), chi-square tests of independence, Pearson
correlation, and Spearman correlation. Mertler and Vannatta (2010) noted that the
purpose of factorial ANOVA is “to determine group differences when two or more
factors create these groups” (p. 90). In order to conduct a factorial ANOVA, there must
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be one dependent variable and more than one independent variable (Mertler & Vanatta,
2010; Pallant, 2010; Terrell, 2012). Terrell (2012) noted that there are four major
assumptions for using the ANOVA. First, the sample for the dependent variable should
be random. Second, “the scores must be independent of one another” (Terrell, 2012, p.
245). Third, the sample or population should be normally distributed (Terrell, 2012).
Last, there must be homogeneity of variance; Terrell (2012) qualified that “the degree of
variance within each of the samples should be about the same” (p. 245). Mertler and
Vannatta (2010) noted that ANCOVA is an extension of ANOVA in that it “adjusts the
effects of variables that are related to the dependent variables” (p. 93). With the
ANCOVA, the effects of concomitant variables can be controlled for or partialed out of
the results (Mertler & Vanatta, 2010). Mertler and Vanatta (2010) stated that
concomitant variables are variables considered to have an effect on the dependent
variable; the variable that is partialed out is called the covariate. Terrell (2012) noted that
chi-square test of independence is similar to ANOVA except that this method involves
counts of values. Pallant (2010) further noted that this test involves categorical data. The
Spearman Correlation is valid for ordinal data or ranked data (Mertler & Vanatta, 2010;
Pallant, 2010; Terrell, 2012). This method is used to “explore the strength of the
relationship between two continuous variables” (Pallant, 2010, p. 103). Moreover, the
Pearson correlation is appropriate for quantitative data, such as interval or ratio data
(Mertler & Vanatta, 2010; Terrell, 2012).
The first data set from the expert panel instrument was tabulated in the data
screening process. Those scores were placed into a table with responses from each expert
panelist that represented their opinion regarding the criteria to measure personal
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information privacy violations, as well as their weight recommendations for the criteria
and measures for DPPP, OPIS, and OPCC. Afterwards, the mean was computed for each
criteria and measure. It is important to note that the combined weights must total 100%,
as the focus of the index is to evaluate the distribution of importance across all criteria
measured.
The second data set from the PIPVI benchmarking instrument was collected from
100 Website registrations that market chronic and non-chronic prescription medications.
Those scores were placed into a table with responses for each pharmaceutical company
Website registration. Once observed scores were tabulated and divided by the total
criterion and multiplied by the Delphi expert panel mean weight for each criterion to
compute the measures DPPPM, OPISM, and OPCCM. These calculated measures were
multiplied by the mean scores for the expert panel weights and combined to derive the
PIPVI for the sample of pharmaceutical company Websites. Figure 3 depicts how the
index score was derived from the three measures and the germane criteria for each
measure. The calculated PIPVI was used to sort the data and compute the standard
deviation (SD), which was used to develop the comparison report to address the research
goals (See Eq. 1, 2, 3, & 4). In addition, the table included responses that were translated
into binary responses to represent the documented and the actual online practices of
consumer control for choice and access. Similarly, the table included responses that were
translated to a binary response to represent the pharmaceutical company’s demographics,
such as condition type (chronic or non-chronic), registration type (update or discount),
headquarters country/region (Asia, Europe, United Kingdom, & United States), PII, size,
annual revenue, and years in existence. Mertler and Vannatta (2010) noted that data
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analysis should include a more advanced technique if appropriate. Upon completion of
this data set, it was appropriate to conduct a factorial ANOVA, factorial ANCOVA, chisquare test of independence, and Spearman correlations for further comparisons of the
data based upon the pharmaceutical company’s condition type, registration type,
headquarters country/region, PII collection, size, annual revenue, and years in existence
to assess any significant differences in the DPPPM, OPISM, OPCCM, PIPVI, and the
documented OPCC versus actual OPCC practices.

Figure 3: Hierarchical View of the Index, Measures, and Criteria of PIPVI
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Eq. 3: 𝑂𝑃𝐶𝐶𝑀 = 𝑤! ∙ !"#$%  !"#$%"#& + 𝑤! ∙ !"#$%  !"#$%"#&
Eq. 4: 𝑃𝐼𝑃𝑉𝐼 = 𝑊!"""! ∙ 𝐷𝑃𝑃𝑃𝑀 + 𝑊!"#$% ∙ 𝑂𝑃𝐼𝑆𝑀 + 𝑊!"##$ ∙ 𝑂𝑃𝐶𝐶𝑀
First, to assess the fifth, sixth, and seventh research question, frequencies and
percentages were calculated for the DPPPM, OPISM, OPCCM, and PIPVI between
pharmaceutical companies that market chronic and those that market non-chronic
prescription medications. In addition, a factorial ANOVA and chi-square tests of
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independence were conducted to assess the statistical significance mean differences for
DPPPM, OPISM, OPCCM, and PIPVI between pharmaceutical companies that market
chronic and those that market non-chronic prescription medications.
RQ5: Are there any statistical significance mean differences for DPPM between
pharmaceutical companies that headquarters are based in United States
versus Asia, Europe, or United Kingdom?
RQ6: Are there any statistical significance mean differences for OPISM, OPCCM,
and PIPVI between pharmaceutical companies that: (a) market chronic
versus non-chronic prescription medications; (b) market registrations for
prescription medication discounts versus updates; (c) their headquarters are
based in United States, versus Asia, Europe, or United Kingdom?
RQ7: Are there any significant differences between the documented and the
actual online practices for choice, and access of pharmaceutical companies
that: (a) market chronic versus non-chronic prescription medications; (b)
market registrations for prescription medication discounts versus updates;
(c) their headquarters are based in United States, versus Asia, Europe, or
United Kingdom?
To assess the eighth research question, frequencies and percentages were
conducted on the types of PII that are collected by pharmaceutical companies’ Websites
over a five-month period. As previously noted, PII is represented by information such as
name, postal address, email address, phone or fax number, SSN, or credit card number
(FTC, 2000). In particular, for this research study, the capturing of name, postal address,
email address, phone number, and SSN were assessed. Frequencies and percentage were
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calculated to assess which PII are the most common among the pharmaceutical
companies. In addition, a factorial ANOVA and chi-square tests of independence were
conducted to assess the statistical significance mean differences for OPISM, OPCCM,
and PIPVI between pharmaceutical companies that collect a limited amount of PII and
those that collect a high amount of PII.
RQ8: Are there any statistical significance mean differences for OPISM,
OPCCM, and PIPVI between pharmaceutical companies that collect a
limited amount of PII and those that collect a high amount of PII?
To assess the following three null hypotheses, a factorial ANCOVA, and
Spearman correlations were conducted to assess the statistical significant difference for
DPPPM, OPISM, OPCCM, and PIPVI when controlling for companies’ size, annual
revenue, and years in existence.
H1: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will
not be significantly different when controlling for company size.
H2: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will
not be significantly different when controlling for annual revenue.
H3: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will
not be significantly different when controlling for years in existence.

Resources
The following resources were required for this research study: computer, Internet
access, Microsoft Word®, Microsoft Excel®, SPSS®, post office box, and email accounts.
Access to a computer, Internet, Microsoft Word®, Microsoft Excel®, and post office box
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are currently available. Statistical services were contracted prior to data analysis. Email
accounts were set up on a new domain that was purchased to accommodate the volume of
emails and to maintain separation from personal email accounts. Because this research
study involved an expert panel, access to human subjects was required. As a result, this
research study required approval from the Institutional Review Board (IRB).

Summary
Chapter three provided the methodology overview that was used in this research
study. This research study was considered developmental in nature and used qualitative
methods to develop and validate the reliability of the PIPVI benchmarking instrument. A
discussion of methods that were used to answer the eight research questions and three
hypotheses was presented. The PIPVI benchmarking instrument was developed to assess
the documented and online practices criteria using a literature review, in addition to
feedback by an expert panel. This process was initiated by identifying the assessment
criteria from literature. Next, an expert panel evaluated the questions used in the
instrument and the feedback was used to revise the PIPVI benchmarking instrument until
consensus was reached using the Delphi expert Methodology. According to McFadzean
et al. (2011), this methodology is acceptable to assess the reliability and validity of the
PIPVI benchmarking instrument. Issues pertaining to reliability and validity were
discussed along with how they were mitigated.
Next, the population and sample for this research study were presented, which
included the selection criteria for the Websites. Furthermore, the pre-screening data
analysis, along with the data analysis that was used to address the research questions and
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hypothesis, were discussed. Pre-screening data analysis is used to “detect irregularities or
problems with the collected data” (Levy, 2006, p. 150). Frequencies and percentages,
factorial analysis of variance (ANOVA), and factorial analysis of covariance
(ANCOVA), chi-square tests of independence, and Spearman correlations were used to
assess the statistical significance mean differences for DPPPM, OPISM, OPCCM, and
PIPVI. Last, the chapter concluded with the resources that were used to conduct this
research study.
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Chapter 4
Results

Overview
The results of this research study are presented in this chapter. The analysis of the
processes used for data collection, in addition to the method of statistical analysis used to
initiate the data analysis, is included. In phase one, the data collection for the expert
panel using the Delphi Method and results will be presented. This will be followed by
phase two – a data collection process used to attain the PIPVI data along with the preanalysis data screening of that data. The conclusion of the chapter will include phase
three, the results summary using the PIPVI benchmarking instrument, and the data
analysis processes used.

Expert Panel
The data initially collected for this research study was derived from an expert
panel survey in the area of information privacy, information security, and corporate social
responsibility. For this phase of the research study, round I was conducted using the
Delphi Method in early June 2014 and concluded late July 2014. The following sections
document the evolution of the PIPVI.
Round I - Data Collection and Analysis
During this phase of the study, the goal of the first round for the expert panel was
to corroborate the proposed measures and criteria, in addition to eliciting their
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recommendation for the weight assignments. The expert panel was comprised of 35
individuals known to the researcher, including individuals in academia and individuals
from professional society mailing lists. The individuals were selected as described in
Chapter 3. An email that contained a link to a Web-based survey tool was used to record
the opinions of the expert panel using the survey instrument shown in Appendix B and as
explained in Chapter 3. Twenty-five participants completed the survey. It is important to
note that because the survey was anonymous, it is not known how many respondents
were from the email or professional society mailing group lists. After tabulation of the
survey responses, no responses were omitted. Based upon the 35 individuals explicitly
solicited, the survey response rate was 70% and a survey completion rate of 100%. The
survey results were examined in three segments. The first segment of analysis included
the expert panel’s level of agreement regarding the proposed measures and criteria. The
second segment of analysis included the expert panel’s recommendations for the weight
allocations to support the PIPVI measures and criteria. Finally, an analysis of the
respondent’s background and opinion of future Personal Information Privacy practices
implemented on Websites are presented.
Round I - Pre-Analysis Data Screening
Prior to data analysis for the data collected from the expert panel, pre-analysis
data screening was conducted. As previously noted, the four primary purposes for preanalysis data screening are to assess the data collected for accuracy, response set, missing
data, and outliers (Levy, 2006). After the expert panel completed the first round of the
survey, pre-analysis data screening was conducted on the responses. Because the survey
was conducted using SurveyMonkey®, a Web-based tool, the responses were recorded,
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tabulated, and assessed to ensure their completeness. The survey design mitigated the
submission of incomplete responses by ensuring that all questions required a response.
Because the survey design used a Likert Scale to indicate level of agreement, there was
opportunity for response set, but none was identified for exclusion. If there were
incomplete responses, they would have been excluded for the particular measure or
criteria, instead of excluding the entire survey. Again, none were identified for
exclusion. Last, no outliers were identified or excluded. Therefore, after the four-step
assessment, all 25 responses were complete and included in the data analysis.
Expert Panel Characteristics
The expert panel was solicited by email and professional society mailing lists.
The invitation included a link to the survey. Twenty-five respondents completed all
aspects of the survey. The survey included questions about the respondents’ opinions
regarding the future of Website practices to address personal information privacy as
presented in Table 10.

Table 10
Opinion of Future Personal Information Privacy Practices Implemented on Websites
Opinion

n

%

Personal Information Privacy practices implemented on Websites are
adequate and companies will continue to adequately self-regulate over the
next 10 years

0

0%

Personal Information Privacy practices implemented on Websites are
adequate but companies need additional enforcement over the next 10
years

6

24%
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Table 10
Opinion of Future Personal Information Privacy Practices Implemented on Websites
(continued)
Opinion

n

%

Personal Information Privacy practices implemented on Websites are
inadequate and companies need additional enforcement over the next 10
years

15

60%

None of the choices adequately capture my opinion.

4

16%

Next, to obtain additional information about the expert panel, they were requested
to provide information to describe additional characteristics about their background.
They were requested to classify themselves as an academic, practitioner, or both. Table
11 represents their responses.

Table 11
Expert’s Self-Perception of Background
Self-Perception

n

%

I consider myself to be an academic

6

24%

I am both an academic and a practitioner but am mostly focused on
academics

0

0%

I consider myself to be an practitioner

12

48%

I am both a practitioner and academic, but am mostly focused on the
practitioner

4

16%

I consider myself to be evenly balanced as both a practitioner
and academic

3

12%

Based upon their responses of their perceived roles of academic or practitioner,
the respondents were questioned to acquire information regarding their experience. The
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subject matter experts who responded to the survey have taught for an average of five
years and have published an average of two peer-reviewed journal articles in the area of
information security/information privacy. The expert panel had experience supervising
students with a thesis or dissertation related to information security/information privacy.
In addition, some experts have published non-peer-reviewed journal articles, books, or
book chapters in the area of information security/information privacy. They also have an
average of six or more years of experience in multiple subject areas regarding
information security/information privacy. The mean responses are presented in Tables 12
and 13.

Table 12
Academic Information Security/Information Privacy Experience
Academic Experience
How many years have you taught undergraduate or Masters level students
in courses that have included topics in Information Security/Information
Privacy?

Mean
Years
5.36

How may Doctoral students have you supervised with Information
Security/Information Privacy-related theses or dissertations?

0.18

How many peer-reviewed journal articles have you published in the area
of Information Security/Information Privacy?

1.55

How many other periodical articles (not PRJ) have you published in the
area of Information Security/Information Privacy?

0.64

How many books or invited book chapters have you published in the area
of Information Security/Information Privacy?

0.45
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Table 13
Practitioner Information Security/Information Privacy Experience
Practitioner Experience

Mean
Years

Systems design which have involved at least some aspects of Information
Security/Information Privacy

8.47

Systems development which has involved at least some aspects of
Information Security/Information Privacy

8.42

Systems implementation which has involved at least some aspects of
Information Security/Information Privacy

10.74

Project management or supervisory management which have involved at
least some aspects of Information Security/Information Privacy

9.63

Employment or consulting engagement assignments have focused on
building or improving Information Security/Information Privacy

6.00

Employment or consulting engagement have focused on evaluating
Information Security/Information Privacy

6.17

Management assignments which have involved governance and/or policy
creation related to Information Security/Information Privacy

6.11

Round I - PIPVI Measures and Criteria Validation
The first round of the survey was for the expert panel to validate that the proposed
measures and criteria were sufficient to measure personal information privacy violations.
The expert panel was requested to specify their level of agreement for the questions
regarding each of the measures and criteria. Participants rated each question on a Likert
scale from 1 = strongly disagree to 7 = strongly agree. The highest level of agreement
was for “access is an accurate component of Consumer Control to assess” with 96% of
the respondents specifying at least somewhat agree (5) or above. Between 17 (68%) and
22 (88%) of the respondents at least somewhat agreed (5) or above to the remaining
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criteria. Hsu and Sanford (2007) recommended that the level agreement should be at
least 70%. Table 14 represents the percentage of the responses for those that specified
“somewhat agree (5)” or above.

Table 14
Round I - Level of Agreement with Criteria
Question

n

%

Notice is an accurate component of the Privacy Policy to assess

21

84%

The Privacy Policy components regarding personal information,
collected along with secondary and third party use described
above, provide an accurate assessment of notice violations

19

76%

Choice is an accurate component of the Privacy Policy to assess

19

76%

The Privacy Policy components regarding opt-in/opt-out for secondary
use and third party communications described above provide an
accurate assessment of choice violations

17

68%

Access is an accurate component of the Privacy Policy to assess

19

76%

The Privacy Policy components to review, modify, and
delete personal information collected described above provide an
accurate assessment of Access violations

18

72%

Security is an accurate component of the Privacy Policy to assess

22

88%

The Privacy Policy components regarding the steps taken to provide
security for information collected described above provide an accurate
assessment of Security violations

17

68%

DPPP-Notice

DPPP-Choice

DPPP-Access

DPPP-Security

Note. n and % refer to those that specified “somewhat agree (5)” or above.
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Table 14
Round I - Level of Agreement with Criteria (continued)
Question

n

%

Secondary Use is an accurate component of Information Sharing to
assess

21

84%

The number of emails and regular mail received described
above provide an accurate assessment of Secondary Use for
Information Sharing

18

72%

Third Party is an accurate component of Information Sharing to
assess

17

68%

The number of emails and regular mail received described
above provide an accurate assessment of Third Party Use for
Information Sharing

17

68%

Secondary Use is an accurate component of Consumer Control to
assess

22

88%

The components to opt-in/opt-out of Secondary Use described
above provide an accurate assessment of Secondary Use for
Consumer Control violations

20

80%

Third Party component is an accurate component of Consumer
Control to assess

21

84%

The components to opt-in/opt-out of Third Party described
above provide an accurate assessment of Third Party for Consumer
Control violations

20

80%

OPIS-Secondary Use

OPIS-Third Party for the Choice

OPCC-Secondary Use for the Choice

OPCC-Third Party

OPCC-Access
Access is an accurate component of Consumer Control to assess

24

96%

The components to review, modify, and delete personal information
collected described above provide an accurate assessment of Access
for consumer control violations

20

80%

Note. n and % refer to those that specified “somewhat agree (5)” or above.

102

Table 14
Round I - Level of Agreement with Criteria (continued)
Question

n

%

Name

20

80%

Postal address

18

72%

Telephone number

20

80%

Social Security Number

20

80%

Personal Identifiable Information

Note. n and % refer to those that specified “somewhat agree (5)” or above.

Round I - PIPVI Comments
All 25 respondents completed the survey with no exclusions identified. After
assessment of the data, including the comments from the expert panel, capturing the
volume of phone calls/text messages was added to the criteria for OPIS to assess
secondary and third party use. Overall, the comments were general in nature, pertaining
to the measures, criteria, and practices and did not warrant any further additions.
Round I - PIPVI Weight Elicitation for Measures and Criteria
In addition to requesting the experts to corroborate on the measures and criteria,
they were requested to allocate the relative weights for the three measures DPPP, OPIS,
and OPCC that will contribute to the PIPVI. For DPPP, the experts were requested to
allocate 100 points across the criteria of notice, choice, access, and security. For OPIS,
the experts were requested to allocate 100 points across the criteria of secondary and third
party use. For OPCC, the experts were requested to allocate 100 points across the criteria
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of choice and access. Table 15 represents the expert panel’s recommendation for the
criteria mean weight allocations.

Table 15
Round I - PIPVI Criteria and Mean Weight Allocations
Criteria

Mean
Weight

Documented Practices of the Privacy Policy Criteria - DPPP
Notice

25%

Choice

22%

Access

20%

Security

33%

Online Practices of Information Sharing criteria – OPIS
Choice: Secondary Use

55%

Choice: Third Party

45%

Online Practices of Consumer Control Criteria – OPCC
Choice

58%

Access

42%

Note. The mean weight allocations must total 100 for each criteria group.
After the expert panel was requested to assign relative weights to the criteria, they
were requested to provide relative weights to the overall measures (DPPPM, OPISM,
OPCCM) that would contribute to personal information privacy violations. Likewise, the
experts were requested to allocate 100 points across the DPPPM, OPISM, and OPCCM
measures within the PIPVI. Table 16 represents the mean weight allocations suggested
by the expert panel for the measures.
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Table 16
Round I - PIPVI Measures and Mean Weight Allocations
Measure

Mean
Weight

Personal Information Privacy Violations Index - PIPVI
Documented Practices of the Privacy Policy Measure - DPPPM

35%

Online Practices of Information Sharing Measure - OPISM

33%

Online Practices of Consumer Control Measure - OPCCM

32%

Note. The mean weight allocations must total 100.

Round II - PIPVI Measures and Criteria Weight Validation
During this phase of the study, the goal of the second round of questioning was to
obtain consensus from the expert panel regarding the mean weight assignments attained
from the first round. Twenty-three participants completed the survey. It is assumed that
these participants also participated in the first survey. After tabulation of the survey
responses, two responses regarding the weights for DPPPM were omitted because the
recommended weight distribution did not total 100. Based upon the 35 individuals
explicitly solicited, the survey response rate was 66% and a survey completion rate
between 91% and 100%. Similar to round I, all respondents cannot be assumed from the
email solicitation. Because the survey was anonymous, it is not known how many
respondents were from the professional group’s mailing lists. The data analysis for this
round was conducted on the expert panel’s opinions regarding the weight allocations for
the measures and criteria.
The data initially collected for this research study was derived from same expert
panel as round I survey. This phase of the research study was conducted using the Delphi
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Method in early August 2014 and concluded late September 2014. The following
sections presented further documents the evolution of the PIPVI.
Round II - Data Analysis and Collection
During this phase of the study, the goal of the second round of questioning was to
obtain consensus from the expert panel regarding the mean weight assignments attained
from the first round. Twenty-three participants completed the survey. This represents
92% of the respondents from the first survey. After tabulation of the survey responses,
two responses regarding the weights for DPPPM were omitted. Based upon the 35
individuals explicitly solicited, the survey response rate was 66%, but also represents a
response rate of 92% of the first respondents from the first survey. The completion rate
was between 91% and 100%. The survey results were examined to analyze the expert
panel’s opinion regarding the weight allocations for the measures and criteria. Table 17
presents the level of agreement with the criteria and measures weight allocations.

Table 17
Round II - Level of Agreement with Measure and Criteria Weight Allocations
Measures and Criteria

n

%

Notice

16

70%

Choice

11

48%

Access

15

65%

Security

12

52%

Documented Practices of the Privacy Policy Criteria - DPPP

Note. n and % refer to those that specified “somewhat agree (5)” or above.
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Table 17
Round II - Level of Agreement with Measure and Criteria Weight Allocations (continued)
Measures and Criteria

n

%

Choice: Secondary Use

17

74%

Choice: Third Party Use

17

74%

Choice

14

61%

Access

14

61%

Documented Practices of the Privacy Policy Measure - DPPPM

17

74%

Online Practices of Information Sharing Measure - OPISM

17

78%

Online Practices of Consumer Control Measure - OPCCM

17

78%

Online Practices of Information Sharing criteria - OPIS

Online Practices of Consumer Control criteria - OPCC

Personal Information Privacy Violations Index - PIPVI

Note. n and % refer to those that specified “somewhat agree (5)” or above.
Round II - Pre-Analysis Data Screening
A second survey was distributed to the subject matter experts and
professional mailing group lists to corroborate the percentage weights for each of
the criteria and measures. A total of 23 participants responded to the survey.
However, it is important to note that due to the anonymous survey, it is assumed
that the respondents participated in the first survey. For this survey, the level of
agreement ranged from 48% to 78%. For the level of agreement between 48%
and 65%, the mean weights for those who did not agree were within 5% of the
proposed weight. Therefore, the proposed weight was determined to be sufficient
as indicated in the aforementioned Table 15 and Table 16. As a result, no
additional rounds with the expert panel were required.
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PIPVI
Phase two of the study encompassed data collection from the Website
registrations using the final PIPVI benchmarking instrument. The Website registrations
occurred over a two-week period. The first group of registrations who did not require a
phone number occurred May 18 through May 23. The next group of Website
registrations occurred from June 8 through June 9 because a mobile phone was purchased
to establish a unique phone number for this research study. The data collection occurred
over a period of late June 2014 to late October 2014. The following sections will
describe the process.
Data Collection and Analysis
In phase two, the Website the PIPVI data collection was derived from several
sources to examine the documented and online practices. First, to examine the DPPP,
data was collected from the downloaded privacy policy of each pharmaceutical company
Website to provide response to the specified criteria as denoted in the final PIPVI
benchmarking instrument. The main DPPP data collection was conducted over four
weeks from mid June to mid July. Second, to examine the OPIS, the volume of emails,
postal mail, phone calls, and text messages were calculated from each Website
registration. The main OPIS data collection was conducted over one week in late
October. Third, to examine the OPCC, data from the Website registrations were
collected based upon the availability of selections to opt-in/opt-out of secondary and third
party use for both initial and after Website registration. The main OPCC data collection
was conducted over six weeks in early August 2014 to mid September 2014. In addition,
data were collected based upon the ability to review, modify, and delete personal
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information disclosed during the Website registration. Based upon the availability of
selections for opt-in/opt-out and the ability to review, modify, and delete personal
information the response was recorded. Fourth, to examine the PII required for
disclosure, data were collected from the Website registrations based upon registration
type and the response was recorded.
Pre-Analysis Data Screening
Although the data collection from phase three involved a manual effort instead of
survey respondents, pre-analysis data screening was still required. The pre-analysis data
screening was performed on the data collected from the Website registrations. First, the
recorded responses were converted to binary responses, reviewed, tabulated in a
spreadsheet, and assessed for accuracy. Afterwards, the data was evaluated for a
response set – none was identified. Then, data was evaluated for omitted responses. If
responses were omitted, they were completed using the documented sources for the
specific criteria. Last, because the data was binary, no outliers were identified or
expected. If there were outliers, the response would have been completed using the
documented sources for the specific criteria.
Data Analysis
After the pre-data analysis screening was performed, the descriptive analysis was
prepared. Descriptive statistics were calculated for the DPPPM, OPISM, OPCCM, and
PIPVI to describe any significant differences as stated in the research questions and
hypotheses. Table 18 presents the summary of Website registrations by condition type,
registration type, and headquarters country/region. The findings are presented in the
subsequent sections.
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Table 18
Pharmaceutical Company Website Registrations by Condition Type, Registration Type,
and Headquarters Country/Region
Condition Type
Headquarters
Country/Region

Registration Type

Pharmaceutical
Company

Website
Registrations

Chronic

NonChronic

Discount

Update

Asia

2

8

6

2

6

2

Europe

6

37

24

13

15

22

United Kingdom

1

5

0

5

3

2

United States

16

50

19

31

24

26

Totals

25

100

49

51

48

52

Documented Practices of the Privacy Policy (DPPP)
Twenty-five different pharmaceutical companies were examined for their
documented practices of the privacy policy (DPPP). These were the same 25
pharmaceutical companies from above. The valid range for DPPPM scores were
0.00 to 1.00, with 0.00 representing no violations and 1.00 representing
violations. The higher the score, the more DPPP violations occurred. Based upon
the assessment of DPPP, the DPPM scores ranged from 0.00 to 0.85, with a mean
of 0.39 (SD = 0.24). Both the lowest and highest score for DPPPM was for
pharmaceutical companies that headquarters country/region are in the US. A
Pearson correlation conducted between the last time their privacy policy was
updated and the measure for DPPP was not significant (r = -0.13, p = 0.687).
These scores suggest that there was no difference between how long it’s been
since the privacy policy has been updated and the DPPPM.
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Next, ANOVAs were conducted to assess if there were differences between the
DPPPM by condition type, registration type, and headquarters country/region. Results of
the ANOVA by condition type (chronic and non-chronic) were not significant, F(1, 98) =
3.11, p = 0.081, partial η2 = 0.03, suggesting there were no differences in the DPPPM by
condition type. Results were similar for registration type (update and discount), F(1, 98)
= 2.54, p = 0.114, partial η2 = 0.03, suggesting there were no differences in the DPPPM
by registration type. The ANOVA conducted for headquarters country/region was also
not significant, F(3, 21) = 1.86, p = 0.168, partial η2 = 0.21, suggesting there were no
differences in the DPPPM by headquarters country/region. Table 19 presents the
ANOVA results by condition type, registration type, and headquarters country/region.

Table 19
ANOVA Results for DPPPM by Condition Type, Registration Type, and Headquarters
Country/Region
SS

df

MS

F

p

Partial η2

Condition Type

0.02

1

0.02

3.11

0.081

0.03

Error

0.63

98

0.01

Registration Type

0.02

1

0.02

2.54

0.114

0.03

Error

0.63

98

0.01

Headquarters Country/Region

0.28

3

0.09

1.86

0.168

0.21

Error

1.06

21

0.05

Control Variable

Spearman correlations were conducted to assess the difference between company
size, annual revenue, and years in existence with DPPPM. Results of the correlations
were all not significant. Results of the correlations are presented in Table 20.
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Table 20
Spearman Correlations between Company Size, Annual Revenue, Years in Existence, and
DPPPM
Control Variable

DPPPM

Company Size

-0.28

Annual Revenue

0.03

Years in Existence
Note. All p > .050.

0.14

Because adherence with the FIPs is self-regulated, it is important to have insight
into pharmaceutical companies’ compliance. Both Europe and UK demonstrated higher
overall adherence to the FIPs than Asia or US. Table 21 presents the percentage
compliant with all aspects of the FIPs criteria by headquarters country/region.

Table 21
Pharmaceutical Company Adherence to FIPs
Headquarters
Country/Region

Notice

Choice

Access

Security

Asia

100%

0%

0%

0%

Europe

83%

17%

67%

67%

United Kingdom

100%

0%

100%

100%

United States

75%

13%

25%

38%

Online Practices of Information Sharing (OPIS)
The data collected from the 100 Website registrations examined for online
practices of information sharing (OPIS). The Website registration data was comprised of
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49 chronic and 51 non-chronic conditions and registration types of 48 as discounts and 52
as updates. The headquarters country/region for the Websites were primarily from the
US. The number of emails received from the Website registrations ranged from 0 to 36.
Surprisingly, no emails were received from 34 Website registrations across 21 unique
Websites. Pharmaceutical companies with headquarters country/region in the US and
Europe were respectively the top two that received no emails from Website registrations.
The summary of emails received from the Website registrations are presented in Table
22.

Table 22
Summary of OPIS Emails Received from Website Registrations
Emails Received

n

%

0

34

34%

1

18

18%

2–5

24

24%

6 – 10

14

14%

11 - 36

10

10%

ANOVAs were conducted to assess if there were differences in OPISM scores by
condition type, registration type, and headquarters country/region. The valid OPISM
scores range from 0.00 to 1.00, with 0.00 representing no violations and 1.00 representing
violations. The higher the score, the more OPIS violations occurred. Based upon the
assessment of OPIS, the OPISM scores ranged from 0.00 to 0.55, with a mean of 0.03
(SD = 0.12). The highest score was from a pharmaceutical company that headquarters

113

country/region is the US. Results of all the ANOVAs were not significant, p > .050 for
all, suggesting that there were no differences found. Table 23 presents the results of the
ANOVAs.

Table 23
ANOVA Results for OPISM by Condition Type, Registration Type, and Headquarters
Country/Region
SS

Df

MS

F

P

Partial η2

Condition Type

0.00

1

0.00

0.16

0.691

0.00

Error

1.32

98

0.01

Registration Type

0.00

1

0.00

0.16

0.689

0.00

Error

1.32

98

0.01

Headquarters Country/Region

0.10

3

0.03

2.55

0.600

0.07

Error

1.22

96

0.01

Control Variable

Note. p > 0.050.
Spearman correlations were also conducted to assess the differences between
emails, company size, annual revenue, and years in existence with OPISM scores.
Results of the correlations showed that emails, r = 0.37, p < .001, annual revenue, r = 0.27, p = 0.006, and years in existence were all correlated to OPISM scores. As the
volume of emails and years in existence increased, OPISM scores also tended to increase.
These scores suggest that the longer the company is in existence and the more emails are
distributed, the risk is greater for companies to share information. Additionally, as the
annual revenue of the company increased, OPISM scores tended to decrease. To the
contrary, these scores suggest that as the company’s annual revenue increases, the risk is
less for sharing information. Results of the correlations are presented in Table 24.
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Table 24
Spearman Correlations between Emails Received, Company Size, Annual Revenue, and
Years in Existence, and OPISM
Control Variable

OPISM

Emails Received

0.37**

Annual Revenue

-0.27**

Company Size

0.09

Years in Existence

0.35**

Note. * p ≤ .050. ** p ≤ .010. Otherwise p > .050.
Online Practices of Consumer Control (OPCC)
The online practices of consumer control (OPCC) scores were examined next. A
total of 60 registration types were examined. This measure was based upon the
registration types of discount and update. While there were 100 Website registrations,
each registration was initiated for a discount or update even though multiple Website
registrations occurred for a particular registration type for each Website. For example,
two Website registrations could have been initiated for a discount for the same Website,
but the difference was the selections for opt-in/opt-out. Because the criteria for consumer
control would be the same for both registrations, this was considered one registration type
for the particular Website instead of two when measuring consumer control. Details were
similar to the previous OPISM registrations. Table 25 presents the descriptive statistics
for the details for OPPCM Website registration types.
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Table 25
Summary of OPCCM by Condition Type, Registration Type, and Headquarters
Country/Region
Control Variable

n

%

Chronic

30

50%

Non-Chronic

30

50%

Discount

27

45%

Update

33

55%

Asia

5

8%

Europe

16

27%

United Kingdom

4

7%

United States

35

58%

Condition Type

Registration Type

Headquarters Country/Region

Note. n=60 for each control variable.
ANOVAs were conducted to assess if there were differences in OPCCM scores
by condition type, registration type, and headquarters country/region. The valid OPCCM
scores range from 0.00 to 1.00, with 0.00 representing no violations and 1.00 representing
violations. The higher the score, the more OPCC violations occurred. Based upon the
assessment of OPCC, the OPCCM scores ranged from 0.15 to 1.00, with a mean of 0.73
(SD = 0.25). The lowest score was from a pharmaceutical company that headquarters
country/region is Europe. Results of the ANOVAs showed significant differences in
OPCCM scores by condition type, F(1, 58) = 5.25, p = 0.026, partial η2 = 0.08. OPCCM
scores for chronic conditions tended to be significantly lower than scores for non-chronic
conditions. These scores suggest that consumers appear to have more control over their
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data for chronic conditions than for non-chronic conditions. The ANOVAs by
registration type and headquarters country/region were not significant, p > .050 for both.
Table 26 presents the results of the ANOVAs.

Table 26
ANOVA Results for OPCCM by Condition Type, Registration Type, and Headquarters
Country/Region
SS

df

MS

F

P

Partial η2

Condition Type

0.31

1

0.31

5.25

0.026

0.08

Error

3.37

58

0.06

Registration Type

0.21

1

0.21

3.45

0.068

0.06

Error

3.47

58

0.06

Headquarters Country/Region

0.44

3

0.15

2.54

0.066

0.12

Error

3.24

56

0.06

Control Variable

Spearman correlations were also conducted to assess the differences between
company size, annual revenue, and years in existence with OPCCM scores. Results of
the Spearman correlations were not significant for all correlations, p > .050 for all.
Results of the correlations are presented in Table 27.
Table 27
Spearman Correlations between Company Size, Annual Revenue, Years in Existence, and
OPCCM
Control Variable

OPCCM

Company Size
Annual Revenue
Years in Existence
Note. All p > .050.

-0.22
-0.04
-0.01
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Personal Information Privacy Violations Index (PIPVI)
The personal information privacy index (PIPVI) scores were examined next. A
total of 100 Website registrations were examined. See Table 18 above for summary by
condition type, registration type, and headquarters country/region. ANOVAs were
conducted to assess if there were differences in PIPVI scores by condition type,
registration type, and headquarters country/region. The valid PIPVI scores range from
0.00 to 1.00, with 0.00 representing no violations and 1.00 representing violations. The
higher the score, the more PIPVI violations occurred. PIPVI scores ranged from 0.06 to
0.62, with a mean of 0.34 (SD = 0.12). The lowest score was for a pharmaceutical
company that headquarters country/region is in Europe and the highest score was in the
US. Results of the ANOVAs showed significant differences in PIPVI scores by condition
type, F(1, 98) = 11.76, p = 0.001, partial η2 = 0.11. PIPVI scores for chronic conditions
tended to be significantly lower than scores for non-chronic conditions. These scores
appear to suggest that fewer personal information privacy violations occur for chronic
conditions than for non-chronic conditions. The ANOVA for PIPVI scores by registration
type was also significant, F(1, 98) = 5.12, p = 0.026, partial η2 = 0.05. PIPVI scores for
discount registration types tended to be significantly higher than update PIPVI scores.
These scores appear to suggest that more violations occur with Website registrations for
discounts than for updates. Finally, PIPVI scores were significantly different by
headquarters country/region, F(3, 96) = 6.48, p < .001, partial η2 = 0.17. Post hoc
pairwise comparisons showed that European PIPVI scores tended to be significantly
lower compared to US PIPVI scores. These results appear to suggest that European
countries might be more responsible with management and use of consumer personal
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information. Table 28 presents the results of the ANOVAs, and Table 29 represents the
mean and standard deviations. Figure 4 represents the measures contributions to PIPVI
by headquarters country/region.

Table 28
ANOVA Results for PIPVI by Condition Type, Registration Type, and Headquarters
Country/Region
SS

df

MS

F

p

Partial η2

Condition Type

0.16

1

0.16

11.76

0.001

0.11

Error

1.34

98

0.01

Registration Type

0.07

1

0.07

5.12

0.026

0.05

Error

1.42

98

0.02

Headquarters Country/Region

0.25

3

0.10

6.48

0.001

0.21

Error

1.24

96

0.01

Control Variable

Table 29
Means and Standard Deviations for PIPVI Scores by Condition Type, Registration Type,
and Headquarters Country/Region
Control Variable

M

SD

Chronic

0.30

0.13

Non-Chronic

0.38

0.10

Discount

0.37

0.12

Update

0.32

0.12

Condition Type

Registration Type
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Table 29
Means and Standard Deviations for PIPVI Scores by Condition Type, Registration Type,
and Headquarters Country/Region (continued)
Control Variable

M

SD

Asia

0.40

0.07

Europe

0.28

0.14

United Kingdom

0.29

0.07

United States

0.38

0.10

0.34

0.12

Headquarters Country/Region

Total

Figure 4: Measures Contributions to PIPVI by Headquarters Country/Region
Spearman correlations were also conducted to assess the differences between
company size, annual revenue, and years in existence with PIPVI scores. Results showed
significance for annual revenue, r = -0.21, p = 0.036, and for company size, r = -0.29, p <
.001. These scores suggest that as the pharmaceutical company size and annual revenue
increased, PIPVI scores tended to decrease. This implies that as companies’ revenue and
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employees increase, they are more responsible with managing consumer information.
Table 30 presents the results of the Spearman correlations.

Table 30
Spearman Correlations between Company Size, Annual Revenue, Years in Existence, and
PIPVI
Control Variable

PIPVI

Company Size

-0.29**

Annual Revenue

-0.21*

Years in Existence

0.02

Note. * p ≤ .050. ** p ≤ .010. Otherwise p > .050.
Documented and Actual OPCC Practices for Choice and Access
To determine if companies are adhering to their documented practices, the OPCC
of choice and access criteria were selected for assessment. A series of chi-square tests of
independence were conducted to examine the differences in documented versus actual
opt-in/opt-out practices for Website registrations by condition type, registration type, and
headquarters country or region. The differences were examined for the consumer’s
ability to opt-in/opt-out of secondary and third party use during and after initial
registration and the ability to review, modify or delete personal information. Differences
in the ability to opt-in/opt-out of secondary use during initial Website registration were
examined first. Results of the chi-squares showed no difference between the documented
and actual practices by condition type, registration type, or headquarters country/region
(p > .050 for all). Table 31 presents the chi-squares for differences in the documented
and actual practices to opt-in/opt-out of secondary use during initial Website registration.
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Table 31
Chi-squares for Documented versus Actual Practices for Opt-in/Opt-out of Secondary
Use During Initial Website Registration
Difference
Control Variable

DV/ANV

D/A

DNV/AV

Condition Type
Chronic

10

13

7

Non-Chronic

12

14

4

Registration Type
Discount

9

12

6

Update

13

15

5

χ2

df

p

1.04

2

0.595

0.56

2

0.757

11.56

Headquarters Country/Region
Asia

4

0

1

Europe

5

11

5

United Kingdom

0

2

2

United States

13

14

3

6

0.073

Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and
Actual in agreement for Violation or No Violation; DNV/AV = Documented No
Violation/Actual Violation.
Second, differences in the ability to opt-in/opt-out of secondary user after initial
Website registration were examined. Results of the chi-squares showed a significant
difference between documented versus actual practices to opt-in/opt-out of secondary use
and headquarters country/region, χ2(6) = 20.20, p = 0.003. Further examination showed
that Europe had a higher level of agreement between the documented and actual
practices, with the US close behind. This confirms that the documented/undocumented
practices (violations) and actual practices are in agreement. No other large differences
between the actual and documented practices were found in the chi-square. The chisquares for condition type and registration type were both not significant (p > .050 for
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both). Table 32 presents the chi-squares for the differences in the documented versus
actual practices for the consumer to opt-in/opt-out of secondary use after initial Website
registration.

Table 32
Chi-squares for Documented versus Actual Opt-in/Opt-Out of Secondary Use after Initial
Website Registration
Difference
Control Variable

DV/ANV

D/A

DNV/AV

Condition Type
Chronic

7

17

6

Non-Chronic

8

12

10

Registration Type
Discount

3

14

10

Update

12

15

6

Headquarters Country/Region
Asia

3

2

0

Europe

3

15

3

United Kingdom

0

0

4

United States

9

12

9

χ2

df

p

1.93

2

0.381

5.89

2

0.053

20.20

6

0.003

Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and
Actual in agreement for Violation or No Violation; DNV/AV = Documented No
Violation/Actual Violation.
Third, differences in the ability to opt-in/opt-out of third party use during initial
Website registration were examined. Results of the chi-squares showed a significant
difference between documented versus actual practices to opt-in/opt-out of third party use
during initial Website registration and headquarters country/region, χ2(6) = 14.19, p =
0.028. However, the documented values were found to be below 1.00, and thus caution
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should be taken in the interpretation and generalization of the chi-square results.
Although significance was found, no large differences between the actual and
documented practices were found in the chi-square. This suggests that there were slight
differences between documented and actual practices for all headquarters
countries/regions, but no major differences. Thus, no definite interpretation could be
made for the chi-square. The chi-squares for condition type and registration type were
both not significant (p > .050 for both). Table 33 presents the chi-squares for
documented versus actual practices for the consumer to opt-in/opt-out of third party use
after initial Website registration.
Table 33
Chi-squares for Documented versus Actual Practices for Opt-in/Opt-out of Third Party
Use During Initial Website Registration
Difference
Control Variable

DV/ANV

D/A

DNV/AV

Condition Type
Chronic

5

21

4

Non-chronic

2

25

3

Registration Type
Discount

1

23

3

Update

6

23

4

Headquarters Country/region
Asia

3

2

0

Europe

2

17

2

United Kingdom

0

4

0

United States

2

23

5

χ2

df

P

1.78

2

0.411

3.15

2

0.207

14.19

6

0.028

Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and
Actual in agreement for Violation or No Violation; DNV/AV = Documented No
Violation/Actual Violation.
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Fourth, differences in the ability to opt-in/opt-out of third party use after initial
Website registration were examined. Results of the chi-squares showed no difference
between the documented and actual practices to opt-in/opt-out of third party use after
initial Website registration by condition type, registration type, or headquarters
country/region (p > .050 for all). Table 34 presents the chi-squares for differences in the
documented versus actual practices to opt-in/opt-out of third party use after initial
Website registration.

Table 34
Chi-squares for Documented versus Actual Practices for Opt-in/Opt-out of Third Party
Use After Initial Website Registration
Difference
Control Variable

DV/ANV

D/A

DNV/AV

Condition Type
Chronic

1

26

3

Non-chronic

0

27

3

Registration Type
Discount

0

25

2

Update

1

28

4

Headquarters Country/Region
Asia

0

5

0

Europe

0

20

1

United Kingdom

0

4

0

United States

1

24

5

χ2

Df

p

1.02

2

0.601

1.25

2

0.536

4.30

6

0.636

Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and
Actual in agreement for Violation or No Violation; DNV/AV = Documented No
Violation/Actual Violation.
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Fifth, differences in the ability to review personal information disclosed during
the Website registrations were examined. Results of the chi-squares showed a significant
difference between the documented versus actual practices to review personal
information and headquarters country/region, χ2(6) = 17.84, p = 0.007. However, the
documented practices were found to be below 1.00, and thus caution should be taken in
the interpretation and generalization of the chi-square results. Although significance was
found, no large differences between actual and documented practices were found in the
chi-square. This suggests that there were slight differences between documented and
actual practices for all headquarters countries/regions, but no major differences. Thus, no
definite interpretation could be made for the chi-square. The chi-squares for condition
type and registration type were both not significant (p > .050 for both). Table 35 presents
the chi-squares for the differences in the documented versus actual practices for the
ability to review personal information.

Table 35
Chi-squares for Documented versus Actual Practices for the Ability to Review Personal
Information
Difference
Control Variable

DV/ANV

D/A

DNV/AV

Condition Type
Chronic

3

13

14

Non-Chronic

3

16

11

Registration Type
Discount

1

14

12

Update

5

15

13

χ2

df

p

0.67

2

0.715

2.16

2

0.339
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Table 35
Chi-squares for Documented versus Actual Practices for the Ability to Review Personal
Information (continued)
Difference
Control Variable

DV/ANV

D/A

DNV/AV

Headquarters Country/Region
Asia

3

2

0

Europe

1

10

10

United Kingdom

0

1

3

United States

2

16

12

χ2

df

p

17.84

6

0.007

Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and
Actual in agreement for Violation or No Violation; DNV/AV = Documented No
Violation/Actual Violation.
Sixth, differences in the ability to modify personal information disclosed during
the Website registration were examined. Results of the chi-squares showed a significant
difference between the documented versus actual practices for the ability to modify
personal information disclosed during the Website registration and headquarters
country/region, χ2(6) = 20.46, p = 0.002. However, documented practices were found to
be below 1.00, and thus caution should be taken in the interpretation and generalization
of the chi-square results. There were more European companies with agreement between
the documented and actual practices for the ability to modify personal information
disclosed during the Website registration. Finally, there were more US pharmaceutical
companies with differences between the documented and actual practices, particularly for
the actual practices not in accordance with the documented practices for the ability to
modify personal information disclosed during the Website registration. The chi-squares
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for condition type and registration type were both not significant (p > .050 for both).
Table 36 presents the chi-squares for the differences in the documented versus actual
practices for the ability to modify personal information disclosed during the Website
registration.

Table 36
Chi-squares for Documented versus Actual Practices for the Ability to Modify Personal
Information
Difference
Control Variable

DV/ANV

D/A

DNV/AV

Condition Type
Chronic

3

11

16

Non-Chronic

3

9

18

Registration Type
Discount

1

9

17

Update

5

11

17

Headquarters Country/Region
Asia

3

2

0

Europe

1

10

10

United Kingdom

0

1

3

United States

2

7

21

χ2

df

p

0.32

2

0.853

2.29

2

0.318

20.46

6

0.002

Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and
Actual in agreement for Violation or No Violation; DNV/AV = Documented No
Violation/Actual Violation.
Last, differences in the ability to delete personal information disclosed during the
Website registration were examined. Results of the chi-squares analysis showed a
significant difference between the documented versus actual practices for the ability to
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delete personal information disclosed during the Website registration and headquarters
country/region, χ2(3) = 9.35, p = 0.025. The Asian pharmaceutical companies in this
research study did not have documented practices to delete nor did they provide the
ability to delete personal information. Therefore, there were more Asian pharmaceutical
companies with agreement between documented and actual PIPV to delete, while there
were fewer undocumented violations for the ability to delete personal information
disclosed during the Website registration. The chi-squares analysis for condition type
and registration type were both not significant (p > .050 for both). Table 37 presents the
chi-squares for the differences in the documented versus actual practices for the ability to
delete personal information disclosed during the Website registration.
Table 37
Chi-squares for Documented versus Actual Practices for the Ability to Delete Personal
Information
Difference
Control Variable

DV/ANV

D/A

DNV/AV

Condition Type
Chronic

-

18

12

Non-Chronic

-

16

14

Registration Type
Discount

-

14

13

Update

-

20

13

Headquarters Country/Region
Asia

-

5

0

Europe

-

11

10

United Kingdom

-

0

4

United States

-

18

12

χ2

df

p

0.27

1

0.602

0.46

1

0.496

9.35

3

0.025
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Note. DV/ANV = Documented Violation/Actual No Violation; D/A = Documented and
Actual in agreement for Violation or No Violation; DNV/AV = Documented No
Violation/Actual Violation.
Personal Identifiable Information (PII)
The data to support the transactions for the 60 Website registration types
previously mentioned to measure the online practices of consumer control were also used
to examine the personal identifiable information (PII) scores. For instance, the data
collection for an update or discount are the same regardless of other selections used to
differentiate the particular Website registration. Table 38 presents the PII characteristics
of the Website registrations.
Table 38
Summary of PII Data Collection
PII Level

n

%

Low (1 – 2)

11

18%

Medium (3)

19

32%

High (4 -6)

30

50%

Note. n=60.
Chi-square tests of independence were conducted to assess if there was a
difference between company size, annual revenue, condition type, registration type, and
headquarters country/region with total PII level. The results of the chi-squares showed
significance for annual revenue, χ2(4) = 15.95, p = 0.003, employees, χ2(4) = 11.09, p
= 0.026, and for headquarters country/region, χ2(6) = 12.65, p = 0.049. However, the
expected values for headquarters country/region were below 1.00 in some cases, and thus
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caution should be taken in the interpretation and generalization of the results. There were
a larger number of high PII level Website registrations from pharmaceutical companies
with greater than $1 billion in revenue. Next, there were a larger number of high PII
level Website registrations from companies with 1,001 to 50,000 employees. Last, there
were fewer high PII level Website registrations from US pharmaceutical companies.
Table 39 presents the results for the chi-squares.

Table 39
Chi-squares between Company Size, Annual Revenue, Condition Type, Registration Type,
Headquarters Country/Region, and Total PII Level
Total PII Level
Control Variable

Low

Medium

High

Company Size
Less than 1,000

3

8

6

1,001 to 50,000

6

1

13

Greater than 50,000

2

10

11

Annual Revenue
Less than 50 million

2

10

5

51 – 999 million

5

3

3

Greater than 1 billion

4

6

22

Condition Type
Chronic

4

6

19

Non-Chronic

7

13

11

Registration Type
Discount

4

5

18

Update

7

14

12

χ2

df

P

11.09

4

0.026

15.95

4

0.003

5.47

2

0.065

5.74

2

0.057
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Table 39
Chi-squares between Company Size, Annual Revenue, Condition Type, Registration Type,
Headquarters Country/Region, and Total PII Level (continued)
Total PII Level
Control Variable

Low

Medium

High

Headquarters Country/Region
Asia

1

0

4

Europe

1

6

14

United Kingdom

2

0

2

United States

7

13

10

χ2

df

P

12.65

6

0.049

Additional ANOVAs were conducted to assess if there were differences in
OPISM, OPCCM, and PIPVI by PII (low versus high). Results of the ANOVA for
OPISM by PII were not significant, F(1, 58) = 0.42, p = 0.517, partial η2 = 0.01.
Results of the ANOVA for OPCCM by PII were also not significant, F(1, 58) = 0.68, p =
0.412, partial η2 = 0.01. Finally, results of the ANOVA for PIPVI by PII were not
significant, F(1, 58) = 0.05, p = 0.819, partial η2 = 0.00. This suggests that no
significant differences were found in OPISM, OPCCM, and PIPVI by PII. Results of the
ANOVAs are presented in Table 40.
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Table 40
ANOVAs for OPISM, OPCCM, and PIPVI by PII
SS

df

MS

F

p

Partial η 2

OPISM

0.00

1

0.00

0.42

0.517

0.01

Error

0.02

58

0.00

OCCM

0.01

1

0.01

0.68

0.412

0.01

Error

0.43

58

0.01

PIPVI

0.00

1

0.00

0.05

0.819

0.00

Error

0.74

58

0.01

Measure

Controlling for Company Size, Annual Revenue, and Years in Existence
The Spearman correlations and non-parametric measures were used to examine
the differences between DPPM, OPISM, OPCCM, and PIPVI with company size, annual
revenue, and years in existence. OPISM scores were significantly negatively related to
annual revenue and positively related to years in existence (see Table 24). PIPVI scores
were significantly negatively related to company size and annual revenue (see Table 30).
No other significant differences were found. Based upon the results, hypothesis one can
be accepted, because no significance was found with company size. However, because of
the significant differences with annual revenue and years in existence, the ANOVAs for
OPISM and PIPVI were re-conducted as ANCOVAs to assess if controlling for annual
revenue and years in existence affects the outcome of the comparisons.
The results of the ANCOVA for OPISM scores by condition type after controlling
for annual revenue and years in existence were significant, F(1, 96) = 5.74, p = 0.019,
partial η2 = 0.06. This is a change from the original ANOVA conducted. Based upon
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the results, hypotheses two and three were rejected, because significance was found with
annual revenue and years in existence. In addition, the mean for chronic conditions was
significantly higher than the mean for non-chronic conditions. The results of the
ANCOVA for OPISM scores by registration type were not significant, F(1, 96) = 0.26, p
= 0.611, partial η2 = 0.00, which is similar to the previous results. The results for the
ANCOVA for OPISM scores by headquarters country/region were not significant, F(3,
94) = 0.24, p = 0.865, partial η2 = 0.01, mirroring what was previously found. Results
of the new ANCOVAs for OPISM scores are presented in Table 41.

Table 41
ANCOVA Results for OPISM Scores by Condition Type, Registration Type, and
Headquarters Country/Region Controlling for Annual Revenue and Years in Existence
SS

df

MS

F

p

Partial η 2

Condition Type

0.01

1

0.01

5.74

0.019

0.06

Annual Revenue

0.02

1

0.02

17.37

0.001

0.15

Years in Existence

0.03

1

0.03

25.11

0.001

0.21

Error

0.10

96

0.00

Registration Type

0.00

1

0.00

0.26

0.611

0.00

Annual Revenue

0.01

1

0.01

11.47

0.001

0.11

Years in Existence

0.02

1

0.02

21.32

0.001

0.18

Error

0.11

96

0.00

Headquarters
Country/Region

0.00

3

0.00

0.24

0.865

0.01

Annual Revenue

0.01

1

0.01

10.77

0.001

0.10

Years in Existence

0.02

1

0.02

18.86

0.001

0.17

Error

0.11

94

0.00

Source
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The results of the ANCOVA for PIPVI scores by condition type while controlling
for annual revenue showed significance, F(1, 97) = 7.79, p = 0.006, partial η2 = 0.07,
suggesting that the PIPVI scores for chronic conditions were significantly lower than the
PIPVI scores for non-chronic conditions. The results suggest that fewer violations occur
with chronic conditions than for non-chronic. This is similar to the results found in the
original ANOVA. Significance was also found by registration type, F(1, 97) = 4.64, p =
0.034, partial η2 = 0.05, also mirroring the results found in the previous ANOVA.
Finally, the results for differences by headquarters country/region were also similar to the
previous ANOVA, F(3, 95) = 6.87, p < .001, partial η2 = 0.18. Results of the new
ANCOVAs for PIPVI scores are presented in Table 42.

Table 42
ANCOVA Results for PIPVI Scores by Condition Type, Registration Type, and
Headquarters Country/Region Controlling for Annual Revenue
SS

df

MS

F

p

Partial η 2

Condition Type

0.11

1

0.11

7.79

0.006

0.07

Annual Revenue

0.02

1

0.02

1.21

0.275

0.01

Error

1.32

97

0.01

Registration Type

0.07

1

0.07

4.64

0.034

0.05

Annual Revenue

0.06

1

0.06

4.39

0.039

0.04

Error

1.36

97

0.01

Headquarters Country/Region

0.25

3

0.09

6.87

0.000

0.18

Annual Revenue

0.01

1

0.01

1.12

0.293

0.01

Error

1.17

95

0.01

Control Variable
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Thus, from the results of the ANCOVAs, the only change that was made by
controlling for the relevant covariates was the ANCOVA for OPISM scores by condition
type. Previously, the ANOVA results were not significant, but after controlling for
registration type and annual revenue, significant differences in OPISM scores were found
by condition type.
Validity Analysis
According to Pallant (2010), “the validity of a scale refers to the degree to which
it measures what it is suppose to measure” (p. 7). She further noted that because there is
no clear indicator of a scale’s validity, the validation encompasses a “collection of
empirical evidence concerning its use” (p. 7). The two main threats to validity in this
research were construct and content. To ensure constructs of this research were valid, this
research study used previously validated constructs from prior research. Another main
threat to validity was the content validity. Once the constructs were gleaned from the
literature review and the draft instrument was developed, an anonymous expert panel was
solicited to elicit feedback on the proposed criteria and measures. The expert panel was
solicited based upon their experience and knowledge of information privacy or
information security from both the academic and corporate sectors to establish a qualified
group of subject matter experts. The expert panel was requested to review the proposed
criteria and indicate their level of agreement and provide additional comments if they
disagreed. Once the first round of the Delphi Method was completed, responses were
reviewed for applicable revisions to the benchmarking instrument.
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Reliability Analysis
Pallant (2010) noted that “the reliability of a scale indicates how free it is from
random error” (p. 6). To ensure reliability, this research used the aforementioned expert
panel to validate the proposed criteria and measures. In addition, another researcher
reviewed the data to ensure accuracy. Special attentiveness and concentration was taken
during the data collection phases to ensure responses were complete and correct to
achieve an accurate assessment of the practices for the Website registrations. The
Cronbach alpha values are noted in Table 43. While it is recommended that the alpha
values be above .7 (Pallant, 2010; Sekaran, 2003), Pallant (2010) noted that the alpha
value could be fairly low if there are fewer than 10 scales. Therefore, because the PIPVI
instrument meets this criterion, the alpha values were expected to be low.

Table 43
Reliability of Scales
Scale

Item

α

DPPP

Notice, Choice, Access, Security

.59

OPIS

Secondary Use, Third Party Use*

-.04

OPCC

Choice, Access

.46

PIPVI

DPPPM, OPISM, OPCCM

.00

Note. * Measurement was constant except for one company.

Summary of the Results
This chapter presented the results of the study. First, the chapter began with
phase one of the research study, which involved engaging the expert panel. The
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demographics of the expert panel and the results of both surveys using the Delphi Method
were discussed. The discussion encompassed the elicitation of an expert panel to confirm
the criteria and measures that contribute to personal information privacy violations, along
with the weight allocations that were used to calculate the PIPVI. Next, phase two of the
study was discussed that described the data collection for the 100 Website registrations.
The chapter concluded with phase three that presented the data analysis and results of the
PIPVI.
The nine goals of this research study were achieved using a three-phased
approach: the first specific goal of this research study was to develop and assess the
experts’ approved components and weights for the DPPP implemented by pharmaceutical
companies using the Delphi expert methodology. The second specific goal of this
research study was to develop and assess the experts’ approved components and weights
for the OPIS implemented by pharmaceutical companies using the Delphi expert
methodology. The third specific goal of this research study was to develop and assess the
experts’ approved components and weights for the OPCC implemented by
pharmaceutical companies using the Delphi expert methodology. The fourth specific
goal of this research study was to develop the components of the single, integrated
measure of PIPVI and assess the DPPP, OPIS, and the OPCC implemented by
pharmaceutical companies using the Delphi expert methodology. The first four goals
were met with the development of the DPPPM, OPISM, OPCCM, PIPVI, which included
the criteria and weight allocations. The fifth specific goal was to assess and compare the
DPPPM of pharmaceutical companies that headquarters are based in United States versus
Europe, Asia, or United Kingdom. This goal was met as presented in Table 19. The
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sixth specific goal was to assess and compare the OPISM, OPCCM, and PIPVI for 100
Website registrations of pharmaceutical companies that a) market chronic versus nonchronic prescription medications, b) market registrations for prescription medication
discounts versus updates, c) their headquarters are based in United States versus Europe,
Asia, or United Kingdom. This goal was met as presented in Table 22, Table 25, and
Table 27. The seventh specific goal was to assess and compare the differences for 100
Website registrations between the documented and actual online practices of consumer
control for choice and access of pharmaceutical companies that a) market chronic versus
non-chronic prescription medications, b) market registrations for prescription medication
discounts versus updates, c) their headquarters are based in United States, versus Europe,
Asia, or United Kingdom. This goal was met as presented in Table 33, Table 34, Table
35, Table 36, Table 37 and Table 38. The eighth specific goal of this research study was
to assess and compare the OPISM, OPCCM, and PIPVI between pharmaceutical
companies that collect a limited amount of PII and those that collect a high amount of
PII. This goal was met as presented in Table 31. The last and ninth goal was to measure
if there were any significant differences in the pharmaceutical companies’ DPPPM,
OPISM, OPCCM, and PIPVI based on their size, reported annual revenues, and years in
existence. This goal was met as presented in Table 32.
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Chapter 5
Conclusions, Implications, Recommendations, and Summary

Conclusions
Because incidents continue to rise due to companies’ misuse of consumer
information (Anton et al., 2010; Lanier & Saini, 2008; Pollach, 2007), this research study
attempted to address the proliferation of online privacy violations by companies. This
was conducted by developing a PIPVI benchmarking instrument, including its essential
hierarchical components, to assess documented and online practices implemented on
Websites. This research study achieved the nine goals with a three-phased approach.
First, an expert panel using the Delphi expert methodology was used to develop relative
weights for the criteria, documented practices of the privacy policy measure (DPPPM),
online practices of information sharing measure (OPISM), online practices of consumer
control measure (OPCCM), and the Personal Information Privacy Violations Index
(PIPVI). Second, the PIPVI benchmarking instrument was used to assess the
documented and online practices implemented for 100 pharmaceutical companies’
Website registrations. Last, a comparison report was developed for 100 Website
registrations of pharmaceutical companies.

Discussion
Overall, the results indicated that pharmaceutical companies with headquarters in
Europe had fewer personal information privacy violations than the US. In addition, the
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results suggested that as the annual revenue of the pharmaceutical company increased,
fewer OPIS violations occurred. Second, as years in existence increased, the more OPIS
personal information privacy violations occurred. Third, the results suggested
pharmaceutical companies were more responsible with managing personal information
for chronic conditions than for non-chronic conditions. Fourth, fewer violations occurred
with Website registrations for updates than for discounts. Fifth, as company size and
annual revenue increased, the PIPVI scores tended to decrease, which insinuates
companies are more responsible when they have higher revenue and a larger volume of
employees. Finally, both Europe and UK demonstrated more overall adherence to FIPs
than the US and Asia. This suggests that self-regulation may not be sufficient, while
more enforcement may be necessary to decrease personal information privacy violations.

Implications
This research study has some implications for the existing body of knowledge in
the area of information privacy and information security. Companies are continuing to
use the Internet as a source for engaging customers. This research study demonstrated
that the PIPVI benchmarking instrument could be used to assess the documented and
actual practices implemented on Websites. Because companies can revise their privacy
policies or Website registrations at any time, there is risk of revisions that can alter the
results. Therefore, it is important to ensure that when assessing documented Website
practices, the researcher must be very meticulous and organized to capture data at that
point in time for comparison to validate any changes. During this research study, there
were no updates to any of the documented practices of the privacy policy. In addition to
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revisions to the documented practices of the privacy policy, there is also risk to revisions
for registration types. For example, the information required for disclosure to register for
updates or discounts could be revised or no longer available. During this research study,
this was also not experienced.
In this research study, the expert panel phase occurred over approximately16
weeks. This time period was required to allow for sufficient participation. Hsu and
Sanford (2007) recommended a minimum of 45 days for administering a Delphi study. It
is important to note that the survey method is one of the drawbacks of using the Delphi
method because it could delay other processes. They further noted that it is crucial for
the researcher to encourage the expert panel to respond to ensure a sufficient response
rate. Because phase two for the Website registrations could be initiated simultaneously
with phase one, the expert panel phase did not cause a delay in the other proceeding
phases.
This research study provides a PIPVI benchmarking instrument that can be used
to assess the documented and actual Website practices of companies. This benchmarking
instrument could assist companies with assessing their practices to provide insight into
what the company can do to further encourage adherence with the FIPs.

Study Limitations
As with any research study, this one also had some limitations. One of the main
significant limitations of our study is the generalizable of the specific index values (not
the weights) due to the sample used. It is expected that the Delphi compositions of the
hierarchical weights will indeed be generalized in the future, but as time progresses, the
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use of the benchmarking index on different companies may yield different values. While
the sample size of 100 Website registrations is valid, further studies can use a larger
sample size to increase validation of the results and generalizability. Next, there was not
an equal distribution of pharmaceutical company Website registrations across each
headquarters country/region. Furthermore, because some of the Website registrations did
not receive any emails, OPIS could not be truly assessed for all pharmaceutical
companies Website registrations. Finally, because most pharmaceutical companies
documented practices specified to submit request to delete personal information through
email, phone, or mail, the delete practices could not be assessed.

Recommendations and Future Research
This research study outlined the research plan to develop a set of measures and a
single composite index based upon hierarchical criteria identified by current US laws and
regulations recommended for ethical business practices for online transactions. The
weights of the hierarchical criteria and composite index were developed using a Delphi
approach. Followed by the development of the PIPVI, along with the data collection and
analysis using the research outline plan discussed here. The findings and the results of
the statistical analyses were reported.
Future studies are warranted to increase the validity of the instrument. In
addition, more research will be needed to expand the sample size and the use of other
industries to increase the generalizability. While our work concentrated on the
pharmaceutical market, future research could include assessing other industries.
Moreover, future work can assess the opt-out practices against the Controlling the
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Assault of Non-Solicited Pornography and Marketing Act (CAN-SPAM Act). An
extension of assessing the opt-out practices could include examining the differences
based upon the type of request such as Website or email. Another area of future research
includes selection of a population with criteria specifically for males and females or age
to determine if the documented and online practices of companies differ by gender or
age. Another area of future research includes having an equal distribution of Website
registrations across each headquarters country/region. Finally, because the privacy
policies stated that requests to delete information must be submitted by phone, email, or
mail, future research could include assessing the delete practices of pharmaceutical
companies or other industries.

Summary
This research study addressed the proliferation of online privacy violations by
companies (Anton, Earp, & Young, 2010; Kim & Byramjee, 2014; Li, Sarathy, & Xu,
2011; Nam et al., 2006; Nhan, Kinkade, & Burns, 2009; Peltier et al., 2009). Personal
information privacy violations using the Internet continue to receive media attention and
continue to be a growing concern for consumers (K. Kim & Kim, 2011; Koorzaan &
Boswell, 2008; Li et al., 2011). Because of the consistent occurrence of personal
information violations, the growth of e-commerce is at risk (Kim & Byramjee, 2014; K.
Kim & Kim, 2011; Li et al., 2011). The information privacy and information security
literature present substantial evidence that consumers continue to be concerned about
how their information is managed, used, and distributed by companies, especially if
accessed via the Web. While the advancement of technology has provided significant

144

benefits to companies and consumers, the proliferation of personal information privacy
violations demonstrates that it has also had an adverse effect. Because of technological
advancements of the Internet, companies are able to collect, store, transfer, sell, and
analyze consumer information (Kim & Byramjee, 2014). Companies leverage the
Internet as a source of communication to engage and establish relationships with
customers. However, in order to establish the relationship, the consumer voluntarily and
involuntarily discloses information. Through both voluntary and involuntary methods,
companies are able to collect and aggregate consumer information. As a result of the
continued proliferation of personal information privacy violations, consumers continue to
be concerned how companies manage their information. As previously noted, consumers
expect companies to have an ethical responsibility to engage in practices that maintain
information integrity and protect consumer information from unauthorized disclosure,
access, use, or loss (Kelly & Rowland, 2000; Peltier, Milne, & Phelps, 2009).
Consumers have an even greater expectation for financial, medical, and health
information (Gupta, Iyer, & Weisskirch, 2010; Yang & Wang 2009). Literature
presented significant evidence that the documented practices of the privacy policy
(DPPP), online practices of information sharing (OPIS), and online practices of consumer
control (OPCC) are three practices that contribute to personal information privacy
violations by companies. The literature further noted that there is little research in studies
that assesses both the documented and online practices contributing to the proliferation of
personal information privacy violations. Given the significant rise in the use of
healthcare Websites (Davis, 2012; Kim & King, 2009) and the sensitivity of consumers
to information privacy, pharmaceutical companies’ Websites are the focus of this
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research study. Therefore, the main goal of this research study was to develop the
Personal PIPVI benchmarking instrument that can be used to assess the DPPP, OPIS,
OPCC, and compute PIPVI while using it to compare 100 registrations initiated through
53 Websites of 25 pharmaceutical companies that market chronic and non-chronic
prescription medications. This was achieved using three phases to answer eight research
questions and three hypotheses.
In phase one, an expert panel from academia and practitioners in the field of
information security and privacy, as well as corporate social responsibility were engaged
to answer the first four research questions. The expert panel survey was conducted using
the Delphi Method. The survey requested the expert panel to indicate their level of
agreement with the criteria, measures, along with their recommendation for the relative
weight allocations. The outcome of the two survey rounds was the development of and
the relative weight allocations for the documented practice of the privacy policy measure
(DPPPM), online practices of information sharing (OPISM), online practices of consumer
control (OPCCM), and the personal information privacy violations index (PIPVI).
RQ1a: What are the experts’ approved components of the DPPP implemented by
pharmaceutical companies using a Delphi expert methodology?
RQ1b: What are the experts’ approved weights of the DPPP’s components
implemented by pharmaceutical companies using a Delphi expert
methodology?
RQ2a: What are the experts’ approved components of the OPIS implemented by
pharmaceutical companies using a Delphi expert methodology?
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RQ2b: What are the experts’ approved weights of the OPIS’s components
implemented by pharmaceutical companies using a Delphi expert
methodology?
RQ3a: What are the experts’ approved components of the OPCC implemented by
pharmaceutical companies using a Delphi expert methodology?
RQ3b: What are the experts’ approved weights of the OPCC’s components
implemented by pharmaceutical companies using a Delphi expert
methodology?
RQ4: What are the experts’ approved weights of the single, integrated measure of
PIPVI’s components of DPPP, OPIS, and the OPCC implemented by
pharmaceutical companies using a Delphi expert methodology?
In phase two, the privacy policy of the pharmaceutical companies was
downloaded to assess the documented practices of the privacy policy (DPPP). In
addition, 100 Website registrations were initiated across 53 Websites of 25
pharmaceutical companies. The pharmaceutical companies were headquartered in Asia,
Europe, UK, and the US. The Website registrations were initiated for prescription
medications that marketed chronic and non-chronic conditions with registration types of
update and discount. It is important to note that Websites that sold prescription
medications were excluded from the sample. Data was collected, analyzed, and
calculated to derive the values for the DPPPM, OPISM, OPCCM, and PIPVI.
The remaining research questions and hypotheses were achieved in phase three.
First, there were no significant differences for DPPM, OPISM, and OPCCM between
pharmaceutical companies that a) market chronic versus non-chronic prescription
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medications, b) market registrations for prescription medication discounts versus updates,
c) their headquarters are based in United States, versus Europe, Asia, or United Kingdom.
Second, there were no significant differences for OPCCM between pharmaceutical
companies that a) market registrations for prescription medication discounts versus
updates and b) their headquarters country/region are based in US, Europe, Asia, or UK.
Differing from DPPPM and OPISM, there was a significant difference for OPCCM
between pharmaceutical companies that market chronic versus non-chronic prescription
medications. The results suggest that consumers had more control over their data for
chronic conditions than for non-chronic conditions. Third, there was a significant
difference for PIPVI between pharmaceutical companies that a) market chronic versus
non-chronic prescription medications, b) market registrations for prescription medication
discounts versus updates, c) their headquarters are based in United States, versus Europe,
Asia, or United Kingdom. The results suggest that fewer personal information privacy
violations occur for chronic conditions, update registrations, and for pharmaceutical
companies that are headquartered in Europe. Overall, Europe was more responsible with
managing consumer information compared to the US, Asia, or UK. Finally, both Europe
and UK demonstrated a higher adherence to the FIPs than the US and Asia.
RQ5: Are there any statistical significance mean differences for DPPM between
pharmaceutical companies that headquarters are based in United States
versus Europe, Asia, or United Kingdom?
RQ6: Are there any statistical significance mean differences for OPISM, OPCCM,
and PIPVI between pharmaceutical companies that a) market chronic versus
non-chronic prescription medications, b) market registrations for
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prescription medication discounts versus updates, c) their headquarters are
based in United States, versus Europe, Asia, or United Kingdom?
Fourth, there were no significant differences in the documented versus actual
practices for choice (opt-in/opt-out) between pharmaceutical companies that a) market
chronic versus non-chronic prescription medications, b) market registrations for
prescription medication discounts versus updates. However, for pharmaceutical
companies headquarters country/region, there was a significant difference for opt-in/optout of secondary use after initial Website registration and opt-in/opt-out of third party use
during initial Website registration. Once again Europe had a higher level of agreement
for the ability to opt-in/opt-out of secondary use after initial Website registration. Fifth,
there were no significant differences in the documented versus actual practices for access
(review, modify, delete) between pharmaceutical companies that a) market chronic versus
non-chronic prescription medications or b) market registrations for prescription
medication discounts versus updates. On the other hand, there was a significant
difference for access between pharmaceutical companies that their headquarters are based
in United States, versus Europe, Asia, or United Kingdom. The results suggest that the
US pharmaceutical companies had a higher disagreement between the documented and
actual practices for the ability to modify personal information.
RQ7: Are there any significant differences between the documented and the
actual online practices for choice, and access of pharmaceutical companies
that a) market chronic versus non-chronic prescription medications, b)
market registrations for prescription medication discounts versus updates, c)
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their headquarters are based in United States, versus Europe, Asia, or United
Kingdom?
Sixth, there were no significant mean differences for OPISM, OPCCM, and
PIPVI between pharmaceutical companies that collect a limited amount of PII and those
that collect a high amount of PII. Pharmaceutical companies with annual revenue greater
than 1 billion dollars and pharmaceutical companies with a company size of 1,001 to
50,000 employees had a higher volume of Website registrations that collected a high
level of PII. However, the US had fewer Website registrations that collected a high level
of PII.
RQ8: Are there any statistical significance mean differences for OPISM, OPCCM
and PIPVI between pharmaceutical companies that collect a limited amount
of PII and those that collect a high amount of PII?
Last, unlike OPISM and PIPVI, there were no significant mean differences for the
pharmaceutical company’s DPPPM and OPCCM when controlling for company size,
annual revenue, and years in existence. Because there was no significant difference
found for DPPPM, IPOSM, OPCC, or PIPVI, hypothesis one was accepted. A significant
difference was found for OPISM and PIPVI when controlling for annual revenue and
years in existence. Therefore, both hypotheses two and three were rejected.
H1: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will
not be significantly different when controlling for company size.
H2: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will
not be significantly different when controlling for annual revenue.
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H3: The pharmaceutical company’s DPPPM, OPISM, OPCCM, and PIPVI will
not be significantly different when controlling for years in existence.
Like any study, this research study had four main limitations. The first limitation
was the set of measures combined to form the PIPVI. The second limitation was that the
reliability and validation of the instrument relied on an expert panel. The expert panel,
the relative weights, criteria, and measures may not be representative of the broader
population. For these reasons, generalization of the results from this research study was
cautioned. Future studies are required with other populations to increase generalizability
of the results and improve the validity of the instrument. The third limitation was the
inability to assess certain practices, such as security and the ability to delete personal
information disclosed during the Website registration. In addition, because some of the
Website registrations did not produce any emails, the OPIS measure could not be fully
assessed for all Website registrations. The last limitation is that the results represent data
at a point in time.
This research study made several contributions to the information privacy domain
and body of knowledge. The study provided empirical evidence regarding the magnitude
of voluntary adherence to the Fair Information Practices by pharmaceutical companies.
This evidence is important to regulators and associations to assist with understanding the
effectiveness of self-regulation. This research study provided insight into the
documented and actual online practices of pharmaceutical companies that contribute to
personal information privacy violations. Given the heightened concerns of consumers
regarding personal information privacy, the results of this research study provided
consumers with empirical evidence of how their information is managed and used by
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pharmaceutical companies. A high magnitude of personal information privacy violations
could negatively impact consumers’ trust, concerns, and interactions with the Websites,
which could continue to constrain the growth of e-commerce.
In conclusion, other researchers can use the PIPVI benchmarking instrument to
assess Websites for new populations. The PIPVI benchmarking instrument can be used
as a tool by researchers and corporations to assess and provide awareness regarding the
documented and actual online practices of Websites. In addition, regulators and
advocacy groups can use this type of evidence to assess and aide in determining if
companies can be trusted with self-regulation and if more stringent laws and regulations
or enforcement are necessary.
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Appendix A
PIPVI Data Collection Form
PHARMACEUTICAL COMPANY DEMOGRAPHICS
Pharmaceutical Company
Website URL
Headquarters Country/Region
Company Size
Annual Revenue
Years in Existence
Condition Type
Registration Type
Name
Email Address
The questions below are represented such that a response of YES will be an
indication of a violation. An “X” will be placed in the space to indicate a response of
YES or NO for each question. A response will be indicated for all questions.
PART 1 – DOCUMENTED PRACTICES OF THE PRIVACY POLICY
NOTICE
YES
DPPP-N1 The Privacy Policy contains a declaration that the Website
does NOT collect any personal information from
consumers
DPPP-N2 The Privacy Policy does NOT contain a declaration about
the specific personal information the Website collects from
consumers
DPPP-N3 The Privacy Policy does NOT contain a declaration that the
Website may use personal information it collects for
internal purposes
DPPP-N4 The Privacy Policy does NOT contain a declaration about
whether the Website uses personal information it collects to
send communications to the consumer
DPPP-N5 The Privacy Policy does NOT contain a declaration about
whether the Website discloses personal information it
collects to third parties

NO
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CHOICE
YES

NO

YES

NO

YES

NO

DPPP-C1 The Privacy Policy does NOT contain a declaration that
the Website provides the choice to opt-in/opt-out of
future communications from the company other than
those directly related to a transaction originated by the
consumer
DPPP-C2 The Privacy Policy does NOT contain a declaration that
the Website provides the choice to opt-out of future
communications at a later date after receipt of
communications
DPPP-C3 The Privacy Policy does NOT contain a declaration that
the Website provides the choice to opt-in/opt-out of
information disclosure to third parties
DPPP-C4 The Privacy Policy does NOT contain a declaration that
the Website provides the choice to opt-out of future
communications from third parties at a later date after
receipt of communications
ACCESS
DPPP-A1 The Privacy Policy does NOT contain a declaration that
the Website allows consumers to review personal
information previously collected
DPPP-A2 The Privacy Policy does NOT contain a declaration that
the Website allows consumers to modify personal
information previously collected
DPPP-A3 The Privacy Policy does NOT contain a declaration that
the Website allows consumers to delete personal
information previously collected
SECURITY
DPPP-S1 The Privacy Policy does NOT contain a declaration that
the Website takes any steps to provide security of the
personal information collected
DPPP-S2 The Privacy Policy does NOT contain a declaration that
the Website takes steps to provide security for personal
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information the Website collects, during transmission of
the information from the consumer to the Website
PART 2 – ONLINE PRACTICES OF INFORMATION SHARING
SECONDARY USE
YES
OPIS-SU1

NO

Received emails or regular mail, text, or phone calls for
other purposes from the pharmaceutical company
Total

OPIS-SU2 How many emails, text, or phone calls were received for
other purposes from the pharmaceutical company
OPIS-SU3 How many pieces of regular mail, text, or phone calls
were received for other purposes from the
pharmaceutical company
THIRD PARTY
YES
OPIS-TP1

NO

Received emails or regular mail, text, or phone calls for
other purposes from the third parties
Total

OPIS-TP2 How many emails were received from third parties
OPIS-TP3 How many pieces of regular mail, text, or phone calls
were received for other purposes from third parties
PART 3 – ONLINE PRACTICES OF CONSUMER CONTROL
CHOICE: SECONDARY USE
YES
OPCC-SU1 Consumers do NOT have the option to opt-in/opt-out to
receive future communications from the Website (other
than those directly related to processing an order or
responding to a consumer’s question)
OPCC-SU2 Consumers do NOT have the option to opt-out of
receiving future communications from the Website at a
later date after receipt of communications (other than
those directly related to processing an order or
responding to a consumer’s question)

NO
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CHOICE: THIRD PARTY
YES

NO

YES

NO

OPCC-TP3 Consumers do NOT have the option to opt-in/opt-out of
disclosure of personal identifying information to third
parties
OPCC-TP4 Consumers do NOT have the option to opt-out of
disclosure of personal identifying information to third
parties at a later date after receipt of communications
ACCESS
OPCC-A1 The Website does NOT allow consumers to review
personal information previously collected about them
OPCC-A2 The Website does NOT allow consumers to modify
personal information previously collected about them
OPCC-A3 The Website does NOT allow consumers to delete
personal information previously collected about them
PART 4 – DOCUMENTED VERSUS ACTUAL PRACTICES
Compare the documented practices against the actual online practices of consumer
control for choice and access.
CHOICE: SECONDARY USE
Documented Actual
OPCC-SU1 Consumers do NOT have the option to opt-in/optout to receive future communications from the
Website (other than those directly related to
processing an order or responding to a consumer’s
question)
OPCC-SU2 Consumers do NOT have the option to opt-out of
receiving future communications from the Website
at a later date after receipt of communications
(other than those directly related to processing an
order or responding to a consumer’s question)
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CHOICE: THIRD PARTY
Documented

Actual

Documented

Actual

OPCC-TP3 Consumers do NOT have the option to opt-in/optout of disclosure of personal identifying
information to third parties
OPCC-TP4 Consumers do NOT have the option to opt-out of
disclosure of personal identifying information to
third parties at a later date after receipt of
communications
ACCESS
OPCC-A1 The Website does NOT allow consumers to review
personal information previously collected about
them
OPCC-A2 The Website does NOT allow consumers to modify
personal information previously collected about
them
OPCC-A3 The Website does NOT allow consumers to delete
personal information previously collected about
them
PART 5 – PERSONAL IDENTIFYING INFORMATION
The Website collects the following personal identifying information
YES
PII1

Name

PII2

Postal Address

PII3

Telephone Number

PII4

Social Security Number

NO
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Appendix B
Round I Expert Panel Survey
Thank you for taking the time to participate in this expert panel survey on the
documented and online practices of Websites. I need your help to review the proposed
measurement criteria and provide your expert opinion regarding their relative importance.
Finally, you will be asked a few questions about your background and experience.
This expert panel survey is part of a PhD doctoral dissertation research study, which
seeks to develop the Personal Information Privacy Violation Index (PIPVI)
benchmarking instrument that can be used to assess the documented and actual online
practices of Websites. Your assistance and expertise as an expert is being solicited to
review the initial instrument and perform a qualitative evaluation of the instrument's
validity by answering questions pertaining to the criteria being measured, which are as
follows:
1. Document Practices of the Privacy Policy (Notice, Choice, Access, Security)
2. Online Practices of Information Sharing (Choice, Access)
3. Online Practices of Consumer Control (Choice, Access)
PART 1 – DOCUMENTED PRACTICES OF THE PRIVACY POLICY
Personal Information Privacy Violations will be assessed by the Documented
Practices of the Privacy Policy (DPPP) of Websites. The criteria are written such
that a yes response will indicate a violation. Please read the criteria for assessment
and provide response to the questions below.
NOTICE
DPPP-N1 The Privacy Policy contains a declaration that the Website does NOT collect
any personal information from consumers
DPPP-N2 The Privacy Policy does NOT contain a declaration about the specific personal
information the Website collects from consumers
DPPP-N3 The Privacy Policy does NOT contain a declaration that the Website may use
personal information it collects for secondary purposes
DPPP-N4 The Privacy Policy does NOT contain a declaration about whether the Website
uses personal information it collects to send communications to the consumer
DPPP-N5 The Privacy Policy does NOT contain a declaration about whether the Website
discloses personal information it collects to third parties
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1. Violation of the Notice component of the Documented Practices of the Privacy
Policy will be assessed using the data collected from the questions above. Please
evaluate the following statements.
Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

Notice is an accurate
component of the
Privacy Policy to
assess

¢

¢

¢

The Privacy Policy
components
regarding personal
information
collected along with
secondary and third
party use described
above provide an
accurate assessment
of Notice violations

¢

¢

¢

Neither
Agree or
Disagree
(4)
¢

¢

Somewhat
Agree (5)

Agree
(6)

Strongly
Agree
(7)

¢

¢

¢

¢

¢

¢

Additional Comments

CHOICE
DPPP-C1 The Privacy Policy does NOT contain a declaration that the Website
provides the choice to opt-in/opt-out of future communications from the company other
than those directly related to a transaction originated by the consumer
DPPP-C2 The Privacy Policy does NOT contain a declaration that the Website
provides the choice to opt-out of future communications at a later date after receipt of
communications
DPPP-C3 The Privacy Policy does NOT contain a declaration that the Website
provides the choice to opt-in/opt-out of information disclosure to third parties
DPPP-C4 The Privacy Policy does NOT contain a declaration that the Website
provides the choice to opt-out of future communications from third parties at a later date
after receipt of communications
2. Violation of the Choice component of the Documented Practices of the Privacy
Policy will be assessed using the data collected from the questions above. Please
evaluate the following statements.
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Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

Choice is an
accurate component
of the Privacy
Policy to assess

¢

¢

¢

The Privacy Policy
components
regarding personal
information
collected along with
secondary and third
party use described
above provide an
accurate assessment
of Choice violations

¢

¢

¢

Neither
Agree or
Disagree
(4)
¢

¢

Somewhat
Agree (5)

Agree
(6)

Strongly
Agree
(7)

¢

¢

¢

¢

¢

¢

Additional Comments

ACCESS
DPPP-A1 The Privacy Policy does NOT contain a declaration that the Website allows
consumers to review personal information previously collected
DPPP-A2 The Privacy Policy does NOT contain a declaration that the Website allows
consumers to modify personal information previously collected
DPPP-A3 The Privacy Policy does NOT contain a declaration that the Website allows
consumers to delete personal information previously collected
3. Violation of the Access component of the Documented Practices of the Privacy
Policy will be assessed using the data collected from the questions above. Please
evaluate the following statements.
Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

Access is an
accurate component
of the Privacy
Policy to assess

¢

¢

¢

The Privacy Policy
components to
review, modify, and
delete personal
information
collected described

¢

¢

¢

Neither
Agree or
Disagree
(4)
¢

¢

Somewhat
Agree (5)

Agree
(6)

Strongly
Agree
(7)

¢

¢

¢

¢

¢

¢
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above provide an
accurate assessment
of Access violations

Additional Comments

SECURITY
DPPP-S1 The Privacy Policy does NOT contain a declaration that the Website takes any
steps to provide security of the personal information collected
DPPP-S2 The Privacy Policy does NOT contain a declaration that the Website takes
steps to provide security for personal information the Website collects during
transmission of the information from the consumer to the Website
4. Violation of the Security component of the Documented Practices of the Privacy
Policy will be assessed using the data collected from the questions above. Please
evaluate the following statements.
Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

Security is an
accurate component
of the Privacy
Policy to assess

¢

¢

¢

The Privacy Policy
components
regarding the steps
taken to provide
security for
information
collected described
above provide an
accurate assessment
of Security
violations

¢

¢

¢

Neither
Agree or
Disagree
(4)
¢

¢

Somewhat
Agree (5)

Agree
(6)

Strongly
Agree
(7)

¢

¢

¢

¢

¢

¢

Additional Comments

PART 2 – ONLINE PRACTICES OF INFORMATION SHARING
Personal Information Privacy Violations will be assessed by the Online Practices of the
Information Sharing (OPIS) of Websites. Please read the criteria for assessment and
provide response to the questions below.
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SECONDARY USE
OPIS-SU1 How many emails were received for other purposes from the company
OPIS-SU2 How many pieces of regular mail were received for other purposes from the
company
Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

Secondary Use is an
accurate component
of the Information
Sharing to assess

¢

¢

¢

The number of
emails and
regular mail
received described
above provide an
accurate assessment
of Secondary Use
for Information
Sharing violations

¢

¢

¢

Neither
Agree or
Disagree
(4)
¢

¢

Somewhat
Agree (5)

Agree
(6)

Strongly
Agree
(7)

¢

¢

¢

¢

¢

¢

Additional Comments

THIRD PARTY
OPIS-TP1 How many emails were received from third parties
OPIS-TP2 How many pieces of regular mail were received for other purposes from third
parties
Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

Third Party Use is
an accurate
component of the
Information Sharing
to assess

¢

¢

¢

The number of
emails and
regular mail
received described
above provide an
accurate assessment
of Third Party Use
for Information

¢

¢

¢

Neither
Agree or
Disagree
(4)
¢

¢

Somewhat
Agree (5)

Agree
(6)

Strongly
Agree
(7)

¢

¢

¢

¢

¢

¢
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Sharing violations

Additional Comments

PART 3 - ONLINE PRACTICES OF CONSUMER CONTROL
Personal Information Privacy Violations will be assessed by the Online Practices of
Consumer Control (OPCC) by Websites. The criteria are written such that a yes response
will indicate a violation. Please read the criteria to allow consumers to opt-in/out of
Secondary Use and information disclosure to Third Parties along with the ability to
Access their information and provide response to the questions below.
CHOICE: SECONDARY USE
OPCC-SU1 Consumers do NOT have the option to opt-in/opt-out to receive future
communications from the Website (other than those directly related to processing an
order or responding to a consumer’s question)
OPCC-SU2 Consumers do NOT have the option to opt-out of receiving future
communications from the Website at a later date after receipt of communications (other
than those directly related to processing an order or responding to a consumer’s question)
7. Violation of Secondary Use for the Choice component of Online Practices of
Consumer Control will be assessed using the data collected from the questions
above. Please evaluate the following statements.
Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

Secondary Use is an
accurate component
of Consumer
Control to assess

¢

¢

¢

The number of
emails and
regular mail
received described
above provide an
accurate assessment
of Secondary Use
for Consumer
Control violations

¢

¢

¢

Additional Comments

Neither
Agree or
Disagree
(4)
¢

¢

Somewhat
Agree (5)

Agree
(6)

Strongly
Agree
(7)

¢

¢

¢

¢

¢

¢
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CHOICE: THIRD PARTY
OPCC-TP1 Consumers do NOT have the option to opt-in/opt-out of disclosure of
personal identifying information to third parties
OPCC-TP2 Consumers do NOT have the option to opt-out of disclosure of personal
identifying information to third parties at a later date after receipt of communications
8. Violation of the Third Party component of Online Practices of Consumer Control
will be assessed using the data collected from the questions above. Please evaluate
the following statements.
Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

Third Party Use is
an accurate
component of
Consumer Control
to assess

¢

¢

¢

The number of
emails and
regular mail
received described
above provide an
accurate assessment
of Third Party Use
for Consumer
Control violations

¢

¢

¢

Neither
Agree or
Disagree
(4)
¢

¢

Somewhat
Agree (5)

Agree
(6)

Strongly
Agree
(7)

¢

¢

¢

¢

¢

¢

Additional Comments

ACCESS
OPCC-A1 The Website does NOT allow consumers to review personal information
previously collected about them
OPCC-A2 The Website does NOT allow consumers to modify personal information
previously collected about them
OPCC-A3 The Website does NOT allow consumers to delete personal information
previously collected about them
9. Violation of the Access component of Online Practices of Consumer Control will
be assessed using the data collected from the questions above. Please evaluate the
following statements.
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Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

¢

¢

¢

Access is an
accurate component
of Consumer
Control to assess

¢

The Privacy Policy
components to
review, modify, and
delete personal
information
collected described
above provide an
accurate assessment
of Access for
Consumer Control
violations

¢

¢

Neither
Agree or
Disagree
(4)
¢

¢

Somewhat
Agree (5)
¢

¢

Agree
(6)

Strongly
Agree
(7)
¢

¢

¢

¢

Additional Comments

PART 4 - PERSONAL INDENTIFYING INFORMATION
10. Some Websites collect Personal Identifying Information (PII). Please review the
suggested PII information for assessment and provide response if they represent
PII.

Name
Postal Address
Telephone Number
Social Security
Number

Strongly
Disagree
(1)

Somewhat
Disagree
(2)

Disagree
(3)

¢
¢
¢
¢

¢
¢
¢
¢

¢
¢
¢
¢

Neither
Agree or
Disagree
(4)
¢
¢
¢
¢

Somewhat
Agree (5)

Agree
(6)

Strongly
Agree
(7)

¢
¢
¢
¢

¢
¢
¢
¢

¢
¢
¢
¢

Additional Comments

PART 5 - WEIGHT ASSSIGNMENT
11. Each of these criteria will be assessed against a consensus of documented
industry practices. If each measured criteria is assumed to meet industry practice
guidance, what should the relative importance of each of the Documented Practices
of the Privacy Policy (DPPP) criteria be relative to one another?
Please allocate 100 points among the Documented Practices of the Privacy Policy
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criteria listed.
[DPPP-N] Notice
[DPPP-C] Choice
DPPP-A] Access
[DPPP-S] Security

12. Each of these criteria will be assessed against a consensus of documented
industry practices. If each measured criteria is assumed to meet industry practice
guidance, what should the relative importance of each of the Online Practices of
Information Sharing (OPIS) criteria be relative to one another?
Please allocate 100 points among the Online Practices of Information Sharing
criteria listed
[OPIS-SU] Secondary Use
[OPIS-TP] Third Party
13. Each of these criteria will be assessed against a consensus of documented
industry practices. If each measured criteria is assumed to meet industry practice
guidance, what should the relative importance of each of the Online Practices of
Consumer Control (OPCC) criteria be relative to one another?
[OPCC-C] Choice
[OPCC-A] Access
14. The three proposed measures described above will be assessed based on the
clusters of criteria described above. These are to be combined into a single index.
Please indicate the relative importance of each of the Personal Information Privacy
Violations Index (PIPVI) criteria by assigning weights.
Please allocate 100 points among the Personal Information Privacy Violations Index
(PIPVI) criteria listed.
DPPP - Documented
Practices of the Privacy
Policy
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OPIS - Online Practices of
Information Sharing
OPCC - Online Practices of
Consumer Control
PART 6 - DEMOGRAPHICS
15. Which of the following statements best describes your opinion about the future
of Personal Information Privacy practices implemented on Websites?
¢ Personal Information Privacy practices implemented on Websites are adequate and
companies will continue to adequately self regulate over the next 10 years
¢ Personal Information Privacy practices implemented on Websites are adequate but
companies need additional enforcement over the next 10 years
¢ Personal Information Privacy practices implemented on Websites are inadequate and
companies need additional enforcement over the next 10 years
¢ None of the choices adequately capture my opinion. My opinion is:

16. Please provide a general estimate of your background to the following questions:
Would you classify yourself as an ‘academic’ or ‘practitioner’ in regards to your
involvement with Information Security/Information Privacy?
¢ I consider myself to be an academic
¢ I am both an academic and a practitioner but am mostly focused on academics n
¢ I consider myself to be a practitioner
¢ I am both a practitioner and academic, but am mostly focused on the practitioner
¢ I consider myself to be evenly balanced as both a practitioner and academic
17. If you consider yourself an academic, what is your experience with the subject
area of Information Security/Information Privacy?
How many years have you taught undergraduate or Masters
level students in courses that have included topics in
Information Security/Information Privacy?

168

How may Doctoral students have you supervised with
Information Security/Information Privacy related thesis or
dissertations?
How many peer-reviewed journal articles have you published
in the area of Information Security/Information Privacy?
How many other periodical articles (not PRJ) have you
published in the area of Information Security/Information
Privacy?
How many books or invited book chapters have you published
in the area of Information Security/Information Privacy?
18. If you consider yourself to be a practitioner, what is your experience with the
subject area of Information Security/Information Privacy (years in each answer
need not be mutually exclusive)?
How many years of systems design which have involved at
least some aspects of Information Security/Information
Privacy?
How many years of systems development which have involved
at least some aspects of Information Security/Information
Privacy?
How many years of systems implementation which has
involved at least some aspects of Information
Security/Information Privacy?
How many years of project management or supervisory
management which have involved at least some aspects of
Information Security/Information Privacy?
How many years of employment or consulting engagement
assignments have focused on building or improving
Information Security/Information Privacy?
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Appendix C
Round I Email to Expert Panel
Dear Privacy, Security, HR, Medical, and Pharmaceutical Experts,
We need your help in providing expert feedback on a framework for an upcoming
doctoral research study. I am a PhD Candidate in Information Systems with a
concentration in Information Security at the Graduate School of Computer and
Information Sciences, Nova Southeastern University. My research is seeking to develop
an index to measure if there are (or to what extent the magnitude exists) personal
information privacy violations by companies' Websites. To develop the index, I need
assistance from those that have knowledge in Information Security/Information
Privacy/Human Resources/Medical/Pharmaceutical to review the proposed measurement
criteria for the documented and online practices of Websites and provide your expert
opinion regarding their relative importance by assigning weights to help me develop the
novel benchmarking instrument of the Personal Information Privacy Violations Index
(PIPVI).
This survey response will be used to develop the Personal Information Privacy Violation
Index (PIPVI) benchmarking instrument that will help organizations as well as industry
entities to assess the documented and actual online practices of Websites, especially in
the medical and/or pharmaceutical field. Your assistance and expertise is being solicited
to review the initial instrument and perform an evaluation of the criteria's validity by
answering questions pertaining to the criteria being measured, which are as follows;
1. Document Practices of the Privacy Policy (Notice, Choice, Access, Security)
2. Online Practices of Information Sharing (Choice, Access)
3. Online Practices of Consumer Control (Choice, Access)
The information provided will be used only for this research study and in aggregated
form. No personal identifiable information (PII) will be collected. If you are willing to
participate, please click on the link below for access and completion by Friday, June 13.
https://www.surveymonkey.com/s/PIPVI_ExpertPanelSurvey
Thank you in advance for your consideration. I appreciate your assistance and
contribution to this research study.
Should you wish to receive the findings of the study, please send me an email and I will
be happy to provide you with information about the academic research publication(s)
resulting from this study.
Regards,
Shonda Brown, PhD Candidate
E-mail: bshonda@nova.edu
Information Systems with a concentration in Information Security
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Graduate School of Computer and Information Sciences
Nova Southeastern University
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Appendix D
Round II Expert Panel Survey
Thank you for taking the time to participate in this final phase of the expert panel survey
on the documented and online practices of Websites. I need your help to review the
aggregated results from the first phase that represent the percentages for the proposed
measurement criteria and provide your expert opinion regarding their relative importance.
The survey has four questions that should take approximately less than 10 minutes to
complete. Finally, you will be asked a few questions about your background and
experience if you did not participate in the first phase of the survey.
This expert panel survey is part of a PhD doctoral dissertation research study which seeks
to develop the Personal Information Privacy Violation Index (PIPVI) benchmarking
instrument that can be used to assess the documented and actual online practices of
Websites. Your assistance and expertise is being solicited as an expert to review the
aggregated results by answering questions pertaining to the percentages assigned to the
criteria being measured, which are as follows;
1. Document Practices of the Privacy Policy (Notice, Choice, Access, and Security)
2. Online Practices of Information Sharing (Choice and Access)
3. Online Practices of Consumer Control (Choice and Access)
PART 1 – CONCEPTUAL MODEL
The conceptual model is displayed to provide insight into the research study and the
criteria that will contribute to the development of the Personal Information
Privacy Violation Index.
PART 2 - WEIGHT ASSIGNMENT
1. DOCUMENTED PRACTICES OF THE PRIVACY POLICY
Each of these criteria will be assessed against a consensus of documented industry
practices. The aggregated responses from the first phase of the survey are indicated below
as percentages in red that represents the relative importance of each of the Documented
Practices of the Privacy Policy (DPPP) criteria. Please indicate your opinion regarding
the validity of the aggregated results. If new weights are provided, the allocation must
equal 100 points.
DOCUMENTED PRACTICES OF THE PRIVACY POLICY are the documented
practices of the company that is represented in the Privacy Policy. The criteria for the
Privacy Policy represent the following.
Notice provides consumers clear and conspicuous notice of the company's information
practices, including what information they collect, how they collect it, how it is used,

172

how they provide Choice, Access, and Security to consumers, and whether they disclose
the information collected to other entities
Choice - documented practices on whether the company allows customers to opt-in/optout of information sharing within and outside of the company
Access - documented practices on whether the company allows customers to access and
modify information provided during the transaction
Security - documented practices about the company's security of the information they
collect from consumers
YES the % appears valid
as the relative weight

NO the % does not appear valid
as the relative weight

[DPPP-N] Notice
25%

¢

¢

[DPPP-C] Choice
22%

¢

¢

DPPP-A] Access
20%

¢

¢

[DPPP-S] Security
33%

¢

¢

Other Percentage (please specify)

2. ONLINE PRACTICES OF INFORMATION SHARING
Each of these criteria will be assessed against a consensus of documented industry
practices. The aggregated responses from the first phase of the survey are indicated below
as percentages in red that represent the relative importance of each of the Online
Practices of Information Sharing (OPIS) criteria. Please indicate your opinion regarding
the validity of the aggregated results. If new weights are provided, the allocation must
equal 100 points.
ONLINE PRACTICES OF INFORMATION SHARING are the actual practices of
the company regarding sharing information within or outside of the company
Secondary Use is information shared within the company and used for purposes other
than original transaction
Third Party Use is information shared outside of the company
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YES the % appears valid
as the relative weight

NO the % does not appear valid
as the relative weight

[OPIS-SU]
SECONDARY
USE
55%

¢

¢

[OPIS-TP] THIRD
PARTY
45%

¢

¢

Other Percentage (please specify

3. ONLINE PRACTICES OF CONSUMER CONTROL
Each of these criteria will be assessed against a consensus of documented industry
practices. The aggregated responses from the first phase of the survey are indicated below
as percentages in red that represent the relative importance of each of Consumer Control
(OPCC) criteria. Please indicate your opinion regarding the validity of the aggregated
results. If new weights are provided, the allocation must equal 100 points.
ONLINE PRACTICES OF CONSUMER CONTROL are the actual practices of the
company regarding the consumer's ability to control their information
Choice is the ability to opt-in/opt-out of information sharing within and outside of the
company
Access is the ability to access and modify information provided during the transaction
YES the % appears valid
as the relative weight

NO the % does not appears
valid as the relative weight

[OPCC] CHOICE
58%

¢

¢

[OPCC] ACCESS
42%

¢

¢

Other Percentage (please specify
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4. PERSONAL INFORMATION PRIVACY VIOATIONS INDEX
The three proposed measures described below will be combined to create the Personal
Information Privacy Violations Index (PIPVI). The aggregated responses from the first
phase of the survey are indicated below as percentages in red that represent the relative
importance of each of measure. Please indicate your opinion regarding the validity of the
aggregated results. If new weights are provided, the allocation must equal 100 points.
DOCUMENTED PRACTICES OF THE PRIVACY POLICY are the documented
practices of the company that are represented in the Privacy Policy
ONLINE PRACTICES OF INFORMATION SHARING are the actual practices of
the company for sharing information within or outside of the company
ONLINE PRACTICES OF CONSUMER CONTROL are the actual practices of the
company regarding the consumers' ability to control their information

[DPPP] DOCUMENTED
PRACTICES OF THE
PRIVACY POLICY
35%

YES the % appears valid
as the relative weight

NO the % does not appear valid
as the relative weight

¢

¢

¢

¢

¢

¢

Other Percentage (please specify)

[OPIS] ONLINE PRACTICES
OF INFORMATION SHARING
33%
Other Percentage (please specify)

[OPCC] PRACTICES OF
CONSUMER CONTROL
32%

Other Percentage (please specify)
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PART 3 - DEMOGRAPHICS
Please complete if you didn't participate in the first phase of the survey
15. Which of the following statements best describes your opinion about the future
of Personal Information Privacy practices implemented on Websites?
¢ Personal Information Privacy practices implemented on Websites are adequate and
companies will continue to adequately self regulate over the next 10 years
¢ Personal Information Privacy practices implemented on Websites are adequate but
companies need additional enforcement over the next 10 years
¢ Personal Information Privacy practices implemented on Websites are inadequate and
companies need additional enforcement over the next 10 years
¢ None of the choices adequately capture my opinion. My opinion is:

16. Please provide a general estimate of your background to the following questions:
Would you classify yourself as an ‘academic’ or ‘practitioner’ in regards to your
involvement with Information Security/Information Privacy?
¢ I consider myself to be an academic
¢ I am both an academic and a practitioner but am mostly focused on academics
¢ I consider myself to be a practitioner
¢ I am both a practitioner and academic, but am mostly focused on the practitioner
¢ I consider myself to be evenly balanced as both a practitioner and academic
17. If you consider yourself an academic, what is your experience with the subject
area of Information Security/Information Privacy?
How many years have you taught undergraduate or Masters
level students in courses that have included topics in
Information Security/Information Privacy?
How may Doctoral students have you supervised with
Information Security/Information Privacy related thesis or
dissertations?
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How many peer-reviewed journal articles have you published
in the area of Information Security/Information Privacy?
How many other periodical articles (not PRJ) have you
published in the area of Information Security/Information
Privacy?
How many books or invited book chapters have you published
in the area of Information Security/Information Privacy?
18. If you consider yourself a practitioner, what is your experience with the subject
area of Information Security/Information Privacy (years in each answer need not be
mutually exclusive)?
How many years of systems design which have involved at
least some aspects of Information Security/Information
Privacy?
How many years of systems development which have involved
at least some aspects of Information Security/Information
Privacy?
How many years of systems implementation which has
involved at least some aspects of Information
Security/Information Privacy?
How many years of project management or supervisory
management which have involved at least some aspects of
Information Security/Information Privacy?
How many years of employment or consulting engagement
assignments have focused on building or improving
Information Security/Information Privacy?
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Appendix E
Round II Email to Expert Panel
Dear Privacy, Security, HR, Medical, and Pharmaceutical Experts,
Thank you again for the previous feedback. The responses from the first phase of the
survey have been aggregated and we need your help for the last time to validate the
weight assignments for the criteria that will be used to develop the Personal Information
Privacy Violations Index (PIPVI). The survey contains four questions soliciting your
expert opinion regarding the relative importance of the criteria and four questions
regarding your background if you did not participate in the first phase of the survey.
Please help me by providing your expert opinion in this final phase by clicking on the
link below to access the survey.
https://www.surveymonkey.com/s/PIPVI_ExpertPanelSurvey2
I need your help in providing expert feedback on a framework for an upcoming doctoral
research study. I am a PhD Candidate in Information Systems with a concentration in
Information Security at the Graduate School of Computer and Information Sciences,
Nova Southeastern University. My research is seeking to develop an index to measure if
there are (or to what extent the magnitude exist) personal information privacy violations
by companies' Websites. To develop the index, I need assistance from those that have
knowledge in Information Security/Information Privacy/Human
Resources/Medical/Pharmaceutical industries.
That's where I need your help!
The survey responses will be used to develop the Personal Information Privacy Violation
Index (PIPVI) to assess the magnitude of personal information privacy violations of
Websites, especially in the medical and/or pharmaceutical field. Your assistance and
expertise is being solicited for the last time to perform an evaluation of the aggregated
weight assignments based upon the responses from the first phase of the survey to the
following criteria;
1. Document Practices of the Privacy Policy (Notice, Choice, Access, and Security)
2. Online Practices of Information Sharing (Choice and Access)
3. Online Practices of Consumer Control (Choice and Access)
The information provided will be used only for this research study and in aggregated
form. No personal identifiable information (PII) will be collected.
Thank you in advance for your consideration. I appreciate your assistance and
contribution to this research study.
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Should you wish to receive the findings of the study, please send me an email and I will
be happy to provide you with information about the academic research publication(s)
resulting from this study.
Regards,
Shonda Brown, PhD Candidate
E-mail: bshonda@nova.edu
Information Systems with a concentration in Information Security
Graduate School of Computer and Information Sciences
Nova Southeastern University
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